Molecular characterisation and immunological analysis of clinical and environmental isolates of Mycobacterium kansasii from South African gold mines by Kwenda, Geoffrey
  
 
 
 
Molecular Characterisation and Immunological 
Analysis of Clinical and Environmental  
Isolates of Mycobacterium kansasii from  
South African Gold Mines 
 
 
Geoffrey Kwenda 
 
 
A thesis submitted to the Faculty of Health Sciences, University 
of the Witwatersrand, Johannesburg, in fulfilment of the 
requirements for the degree  
of 
Doctor of Philosophy 
 
 
 
Johannesburg 
 
June 2010
ii 
 
DECLARATION 
 
I, Geoffrey Kwenda, declare that this is my own work. It is being submitted for the Degree 
of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not 
been submitted for any degree at this or other university. 
 
 
 
 
                25th day of June, 2010 
              Geoffrey Kwenda 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
DEDICATION 
This thesis is dedicated to my mother who taught me that the best kind of knowledge to 
have is that which is learnt for its own sake. 
iv 
 
PUBLICATIONS AND PRESENTATIONS 
 
The following manuscripts, based on this thesis, have been prepared for publication: 
• Kwenda, G, Churchyard, G. J, Stevenson, K, Heron, I, Thorrold, C, Duse, A. G and 
Marais, E (2010). Molecular characterisation of clinical and environmental isolates of 
Mycobacterium kansasii from a South African gold-mining region. (Manuscript I). 
 
• Kwenda, G, Duse, A. G and Marais, E (2010). Genetic differences between clinical 
and environmental isolates of Mycobacterium kansasii. (Manuscript II). 
 
• Kwenda, G, Duse, A. G, Marais, E, Wadee, A.A and van Dixhoorn-Smit, M (2010). 
Mycobacterium kansasii modulates the expression of cytokines by human lymphocytes 
in vitro. (Manuscript III). 
 
 
Part of this work has been presented at the following scientific meetings: 
• Kwenda, G, Duse, A. G and Marais, E (2008). Use of Hybridisation-Monitored 
Genome Differential Analysis to identify differences between a clinical and an 
environmental strain of Mycobacterium kansasii. Poster Presentation at the Wits 
University Research Day, September 20, 2008. Awarded Best Poster Prize in the 
category of Molecular and Comparative Biosciences. 
 
• Kwenda, G, Poswa, X, Churchyard, G. J, Calver, A. D, Duse, A. G and Marais, E 
(2007). Molecular Analysis of Mycobacterium kansasii Isolates from South African 
Gold Mines. Poster Presentation at the Federation of Infectious Diseases Societies of 
Southern Africa (FIDSSA) Second Joint Congress held in Cape Town, 28 to 31 
October 2007. 
 
 
 
 
 
v 
 
ABSTRACT 
The South African gold-mining workforce has an unusually high incidence of 
Mycobacterium kansasii disease, yet little is known about the possible sources of M. 
kansasii infection, genetic diversity and the basis for this organism’s pathogenicity. The 
purpose of this study was to investigate these issues in a gold-mining environment. Five 
M. kansasii isolates and 10 other potentially pathogenic mycobacteria were cultured 
mainly from showerhead biofilms. PCR-restriction analysis (PRA) of the hsp65 gene on 
191 clinical and on the 5 environmental M. kansasii isolates revealed 160 subtype I (157 
clinical and 3 environmental), 8 subtype II (clinical) and 6 subtype IV (5 clinical and 1 
environmental) strains. Twenty-two isolates (21 clinical and 1 environmental) did not 
show the typical M. kansasii PRA patterns. After confirmation by DNA sequencing as 
belonging to the M. kansasii species, the results suggested that these isolates were 
probably new subtypes of M. kansasii. In contrast to the clonal population structure found 
amongst the subtype I isolates from studies in other countries, DNA fingerprinting of 114 
subtype I clinical and environmental isolates showed genetic diversity amongst the 
isolates. One of the environmental isolates showed 100% identity with a clinical isolate, 
suggesting that water distribution systems are possible sources of M. kansasii infection for 
the miners. An investigation into the genetic differences between clinical (subtype I) and 
environmental (III, IV and V) isolates, using Hybridisation Monitored Differential 
Analysis (HMDA), identified 45 open reading frames (ORFs) encoding predominantly 
membrane-associated proteins that include six potential virulence factors, two family 
members of transcription regulators for drug and xenobiotic metabolism, three family 
members of multidrug efflux systems, a number of proteins associated with lipid and 
carbohydrate metabolism and transport, and a number of hypothetical proteins with 
unknown function. Immunological analysis of M. kansasii isolates, using the Lymphocyte 
Transformation and Cytometric Bead Array assays, showed that M. kansasii modulates 
immune responses through suppression of lymphocyte blastogenesis and by altering the 
expression of Th1/Th2/Th17 cytokines by human lymphocytes in vivo for its own survival. 
This study demonstrated for the first time that water distribution systems in South Africa 
are possible sources of M. kansasii infection, and showed that subtype I strains of M. 
kansasii from the study region display genetic diversity and have unique or divergent 
genes not found in other subtypes. It also demonstrated that immunosuppression is one of 
the pathogenic mechanisms employed by M. kansasii. 
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CHAPTER 1 
General Introduction 
 
1.0 Introduction 
1.1 Background 
The genus Mycobacterium comprises more than 130 species, including pathogens and 
saprophytes (Gutierrez et al, 2009). Based on their clinical significance, these species can 
be divided into three groups. The first group includes obligate pathogens for humans and 
animals, i.e, the Mycobacterium tuberculosis complex (M. tuberculosis, M. bovis, M. 
africanum, M. microti, M. canettii, M. pinnipedii and M. caprae), M. leprae and M. 
lepraemurium, which are generally not found in the environment. M. tuberculosis complex 
(MTBC), the causative agent for tuberculosis, is by far the most important of the genus 
Mycobacterium from a clinical perspective (Primm et al, 2004). The second group 
comprises mycobacteria that are potentially pathogenic to humans or animals. The 
majority of these species have been isolated from various terrestrial and aquatic 
environments and are capable of causing disease in individuals with predisposing 
conditions. Examples include M. kansasii, M. avium and the other members of the so-
called “M. avium complex” (MAC). The third group consists of saprophytic species that 
are non-pathogenic or only exceptionally pathogenic, e.g, M. gordonae, M. goodii and M. 
smegmatis. The second and third group are alternatively referred to as Environmental 
Mycobacteria (EM), Atypical Mycobacteria (ATM), Mycobacteria Other Than M. 
tuberculosis (MOTT) or Non-Tuberculous Mycobacteria (NTM). However, the latter two 
terminologies are rather confusing because some members of these groups, e.g. M. 
kansasii, can also cause tuberculosis-like lesions (Griffith, 2002; Smith et al, 2003; Shitrit 
et al, 2007). 
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Recently there has been increasing awareness of NTM disease. This may be attributed to 
the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) 
epidemic, the high incidence of tuberculosis (TB) and other respiratory diseases, and the 
greater awareness on the part of clinical and laboratory personnel of the impact of NTM 
on human health (Horsburgh, 1996, Bloch et al, 1998; Cattamanchi et al, 2008). 
Furthermore, NTMs are often involved in nosocomial outbreaks (Phillips and von Reyn, 
2001), but there is little or no evidence for person-to-person transmission of these 
organisms. Although the reservoir of infection in most cases remains unclear, there is a 
general notion that NTM infections derive mainly from the environment (Engel et al, 
1980, Chang et al, 2002, Vaerewijck et al, 2005, Falkinham et al, 2008; Narang et al, 
2009). However, the significance of isolation of these organisms in clinical samples 
remains unclear since the number of diseases they cause is difficult to assess and no 
system for notification exists as in the case of M. tuberculosis.  
 
In South Africa, the gold-mining workforce has been reported to have an unusually high 
incidence of M. kansasii disease (Corbett et al, 2000). This high incidence of disease has 
been attributed to the susceptibility of the miners to a number of risk factors for NTM 
disease (Corbett et al, 1999a; Corbett et al, 1999c; Churchyard, 2000; Corbett et al, 2000). 
However, little is known about its natural reservoir, mode of transmission and 
pathogenicity. Reports on M. kansasii from the South African gold mines have mainly 
focused on its clinical features (Corbett et al, 1999a; Corbett et al, 1999b; Churchyard et 
al, 1999; Corbett et al, 2000). No laboratory studies on M. kansasii have been conducted 
to complement the clinical findings. 
 
 
4 
 
1.2 General Characteristics of M. kansasii 
M. kansasii is an environmental opportunistic pathogen that causes tuberculosis-like 
disease and is often associated with immunocompromised persons or those who have had 
lung disease previously (Bloch et al, 1998; Razavi and Cleveland, 2000; Griffith, 2002; 
Smith et al, 2003; Arend et al, 2004; Yim et al, 2005; Griffith et al, 2007). It is considered 
to be the most virulent NTM species and the second most important NTM species, after M. 
avium isolated from patients with AIDS (Wolinsky, 1992; Bloch et al, 1998). Unlike other 
NTM species, most isolates from clinical specimens are considered to be clinically 
significant, but the sources of infection are difficult to identify (Bloch et al, 1998; Griffith, 
2002).  
 
M. kansasii is a slow-growing aerobic, photochromogenic, long, beaded, acid-fast bacillus 
with bent or folded ends arranged in a haphazard fashion that produces predominantly 
rough or smooth colonies with irregular edges, which develop intense yellow pigmentation 
on exposure to light (Jenkins et al, 1982; Wayne and Kubica, 1986). It requires 2 to 3 
weeks’ growth over a temperature range of 32 to 42oC, but grows better at 37oC. The 
biochemical characteristics that form the basis for its identification include production of 
catalase, nitrate reductase, pyrazinamidase and its ability to hydrolyse Tween 80 (Jenkins 
et al, 1982; Wayne and Kubica, 1986). 
 
Phylogenetic and molecular analyses have demonstrated that M. kansasii is a 
heterogeneous species, with 7 subtypes to date. Subtype I represents the most common 
isolate from humans (Ross et al, 1992; Alcaide et al, 1997; Picardeau et al, 1997; Richter 
et al, 1999; Taillard et al, 2003; Santin et al, 2004). This heterogeneity has raised 
questions as to whether M. kansasii is a single species or a complex (Tortoli, 2003a).  
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1.3 Taxonomic and Phylogenetic Status 
Taxonomically, M. kansasii belongs to the genus Mycobacterium, which is a single genus 
within the family Mycobacteriaceae, under the order Actinomycetales, class Actinomycetes 
and phylum Actinobacteria (Wayne and Kubica, 1986). The order Actinomycetales 
includes a diverse group of microorganisms, but mycobacteria and allied taxa are easily 
distinguished on the basis of their ability to synthesise mycolic acids, acid-alcohol fastness 
and a high GC content (61-71%) in their genomic deoxyribonucleic acid (DNA). M. 
kansasii has a GC content of 66% (Veyrier et al, 2009). The only exception is M. leprae, 
which has a low GC content of 54 to 57% (Wayne and Kubica, 1986; Levy-Frebault and 
Portaels, 1992). The acid-fastness that these organisms exhibit is attributed to the high 
lipid content in their cell walls that prevent penetration of dyes, which requires the 
organism first to be heated to allow the dye to penetrate the bacteria. The subsequent 
destaining process, with an acid or alcohol, removes the dyes from most other bacteria but 
mycobacteria retain the dye and are thus referred to as acid-fast bacilli (Wayne and 
Kubica, 1986; Leão et al, 2004). 
  
Over the last few decades, a number of tests and techniques have been developed for 
identifying, characterising and classifying mycobacteria, leading to the generation of a 
huge amount of information. Thus, there was a great need for consolidating and 
standardising this information, especially that pertaining to classification. This led to the 
formation of the International Working Group on Mycobacterial Taxonomy (IWGMT) in 
1967, which played a vital role in harmonising approaches to the taxonomy of 
mycobacteria (Wayne and Kubica, 1986; Wayne et al, 1989). Technologies for analysis of 
semantides are being developed and improved all the time and this has allowed 
comparisons to be made between phenotypic and genotypic relationships of mycobacteria. 
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A variety of approaches have been used to characterise the systematics and taxonomy of 
mycobacteria. The early classification of NTMs was based on the growth rate, 
pigmentation and clinical significance (Runyon, 1959). A fundamental taxonomic division 
was tied to growth rate: members of the mycobacteria were defined as either slow or rapid 
growers. The rapid growers show visible growth within 7 days and the slow growers 
require more than 7 days for visible growth (Wayne and Kubica, 1986). By these criteria, 
the genus was divided into the 4 Runyon groups: Group I, slow-growing 
photochromogens (bacterial colonies produce pigment only with light, e.g M. kansasii, M. 
marinum, M. simiae); Group II, slow-growing scotochromogens (bacterial colonies 
produce pigment even in darkness, e.g., M. scrofulaceum, M. szulgai, M. gordonae); 
Group III, slow-growing non-photochromogens (bacterial colonies produce weak to no 
pigment in both darkness and light, e.g., M. malmoense, M. xenopi, M. avium-
intracellulare); and Group IV, the rapid growers (bacterial colonies grow within 7 days 
with little to no pigment, e.g. M. fortuitum, M. chelonae, M. abscessus).  
 
Results from cultural and biochemical tests have been analysed by numerical taxonomic 
techniques to identify clusters of related mycobacteria (Wayne and Diaz, 1982; Wayne et 
al, 1983; Wayne et al, 1991), but these have not provided precise boundaries between 
some species such as between M. avium and M. intracellulare (Wayne and Kubica, 1986). 
More recently, other methods have been used to complement the numerical studies and to 
confer natural relationships among the mycobacteria. These studies include 
immunological techniques (Shivannavar et al, 1996), comparison of cell wall components 
(Tsang et al, 1983; Ausina et al, 1992; Ridell, 1993), comparison of homologous enzyme 
sequences (Ridell, 1993), DNA-DNA hybridisation (Lévy-Fébaulty et al, 1986), plasmid 
profiles (Meissner and Falkinham, 1986) and restriction endonuclease analyses (Ferdinand 
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et al, 2004). These too have so far failed to provide a unified and unambiguous 
classification of the genus. 
 
In recent years there has been an emphasis on the development of molecular tools which 
have led to the profound modifications in the classification and methods of identification 
of mycobacteria. These methods, utilising one or several appropriate genes, are gaining 
importance due to the fact that they yield quick and, in most cases, unequivocal results 
(Ferdinand et al, 2004). These methods allow different laboratories to compare their 
results. Different phylogenies for the genus have been developed using sequence analysis 
of the 16S rRNA gene (Rogall et al, 1990b; Stahl and Urbance, 1990; Harmsen et al, 
2002). For instance, the number of genes encoding the 16S rRNA has been used to 
separate slow and rapid growers, with rapid most growers having two copies of the gene 
and slow growers only having one (Helguera-Repette et al, 2004). The 16S rRNA is an 
approximately 1500bp sequence encoded by the 16S ribosomal DNA (rDNA). The rDNA 
gene is a highly conserved gene in which regions common to all bacteria exist while 
nucleotide variations are concentrated in certain areas. In mycobacterial 16S rDNA, the 
nucleotide stretches are shared by all members of the genus Mycobacterium and also 
contain the hypervariable regions characterised by species-specific variability 
(Boddinghaus et al, 1990). The 16S rRNA-based genetic investigation of mycobacterial 
taxonomy and phylogeny focuses on two hypervariable sequences, known as region A and 
region B, which correspond to the Escherichia coli positions around 130 to 210 and 430 to 
500, respectively (Böttger, 1996).  
 
However, within the genus Mycobacterium, the interspecies similarity is relatively high, 
from 94.3 to 100% (Rogall et al, 1990a). Some species have a very high degree of 
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similarity or have exactly identical sequences such as M. kansasii and M. gastri, M. 
senegalense and M. farcinogenes, M. marinum and M. ulcerans, M. malmoense and M. 
szulgai and members of the Mycobacterium tuberculosis complex (Rogall et al, 1990a). 
This suggests that these organisms are phylogenetically related and might be considered 
subspecies of each other. The use of the 16S rRNA gene has led to problems related to 
cross-reactivity when oligonucleotide probes are used and makes the design of probes 
directed towards a broad panel of all clinically important species difficult (Emler et al, 
1995; Kox et al, 1995). The distinction between two species, whether at species or 
subspecies level, is very important since, for instance, M. kansasii is usually significant 
when isolated from a clinical specimen, whereas M. gastri is rarely significant (Turenne et 
al, 2001). 
 
In view of the foregoing problems, a study of more variable sequences in the RNA operon 
of phylogenetically and closely related species was sought. The genes coding for rRNA 
are arranged in the order 5’-16S-23S-5S-3’ and are separated by two non-coding spacer 
regions (Klappenbach et al, 2000; van der Giessen et al, 1994). The 16S-23S rDNA 
internal transcribed spacer (ITS) has been suggested to represent a potential target within 
the bacterial genome to find suitable sites for probes and from which to derive additional 
phylogenic information. This locus is flanked by well-conserved regions of the rRNA 
operon, containing both conserved and highly variable sequences (van der Giessen et al, 
1994). The 16S-23S ITS region is considered a useful genomic marker for the subtyping 
of M. kansasii strains (Roth et al, 2000; Iwamoto and Saito, 2006). 
 
Apart from the rRNA gene sequences, other genes have been targeted for the identification 
or classification of mycobacteria. These include hsp65 (Telenti et al, 1993; Ringuet et al, 
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1999; Brunello et al, 2001), sodA (Zolg and Philippi-Schulz, 1994; Gingeras et al, 1998), 
rpoB (Gingeras et al, 1998; Kim et al, 1999), recA (Blackwood et al, 2000), gyrA (Sander 
et al, 1998), gyrB (Kasai et al, 2000) and secA1 (Zelazny et al, 2005). The hsp65 gene is a 
member of the family of heat-shock protein genes that is highly conserved amongst 
mycobacterial species. It also presents hypervariable regions (positions 624 to 664 and 683 
to 725 of the M. tuberculosis gene), whose sequences are used for identification purposes 
(Ringuet et al, 1999). The gene products are highly immunogenic, with an exceptional 
degree of evolutionary conservation. They function in intracellular protein folding, 
assembly and transport and their expression is up-regulated under cellular stress. The sodA 
gene encodes superoxide dismutase (SOD), a metalloenzyme that constitutes one of the 
major defence mechanisms against oxidative stress (Zhang et al, 1991; Kang et al, 2006) 
and may play a role in the development of protective immunity against mycobacteria as it 
has been shown to possess immunogenic properties (Pal and Horwitz, 1992; Orme et al, 
1993). SOD belongs to a family of proteins which has been conserved throughout 
evolution, from bacteria to humans (Zhang et al, 1995). The rpoB gene encodes for the β-
subunit of RNA polymerase, an oligomeric enzyme responsible for RNA synthesis (Lesley 
et al, 1987) and its mutation is associated with drug resistance to rifampicin (Klein et al, 
2001).  The product of the recA gene plays an essential role in genetic recombination, 
repair of stalled replication forks, double strand break repairs, induction of SOS response 
and SOS mutagenesis (Cox, 2003). The gyrA and gyrB genes code for type II DNA 
topoisomerases, termed DNA gyrases, responsible for controlling supercoiling of DNA in 
cells. The A subunit of DNA gyrase, GyrA, is well conserved amongst bacteria and is 
responsible for mediating double-strand breakage and reunion of DNA, while the other 
subunit, GyrB, is responsible for energy transduction through ATP hydrolysis (Wigley, 
1995). The secA1 gene is a house-keeping gene that encodes the essential protein, SecA1, 
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a key component of the major pathway of protein secretion across the cytoplasmic 
membrane of mycobacterial and other bacterial species (Mori and Ito, 2001). 
  
The use of a single gene for the identification and classification of mycobacteria does not 
show good discrimination of the bacteria (Kim et al, 1999; Stackebrandt et al, 2002). In 
order to increase the discriminatory power of these molecular methods in the identification 
and phylogenetic studies of bacteria, the combined use of several gene sequences has been 
recommended (Stackebrandt et al, 2002). In addition to the 16S rRNA gene, four to five 
house-keeping genes are recommended, especially for the description of novel bacterial 
species. Devulder and colleagues developed a multigene sequence database dedicated to 
the identification of species within the genus Mycobacterium by targeting four genes, 16S 
rRNA, hsp65, rpoB and sod (Devulder et al, 2005). In this study, they were able to show 
that the studied genes, which are located in different parts of the genome, evolved in the 
same manner, and that the use of several genes makes it possible to refine the phylogenetic 
approach and provides the molecular basis for accurate species identification. Recently, 
this multigene approach has been used to test the discriminatory power and robustness of 
the hsp65, 16S-23S ITS, gryB and 16S rRNA genes in the phylogenetic analysis of M. 
kansasii strains. The results revealed that an intermediate M. kansasii type I strain exists, 
and suggested that type I strains evolved from type II strains and that there is a possible 
evolutionary link between the two strains (Iwamoto and Saito, 2006). Type I strains have 
been mainly isolated from humans, while type II strains have been isolated from both 
humans and the environment, and the other subtypes have been isolated mainly from the 
environment (Tortoli, 2003a). 
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1.4 Epidemiology 
The epidemiology of M. kansasii is predominantly urban and has been associated with 
high density and low income communities, especially in highly industrialised areas (Penny 
et al, 1982; Chobot et al, 1997; Iinuma et al, 1997; Bloch et al, 1998; Churchyard, 2000; 
Santin et al, 2004). The organism has been isolated from water distribution systems in the 
same communities where patients with M. kansasii disease have been identified 
(Steadham, 1980; Chobot et al, 1997). Large regional differences have been detected in 
the incidence of M. kansasii infection. Geographical areas reported to have high 
incidences of M. kansasii disease include the Czech Republic (Kubin et al, 1980), the 
United Kingdom (Lamden et al, 1996), South Africa (Churchyard, 2000),  Spain (Santin et 
al, 2004) and Central and Southern United States (Steadham, 1980; Zhang et al, 2004) 
where it is the major cause of NTM pulmonary disease. There is no evidence for human-
to-human transmission of this organism. Although the reservoir of infection in most cases 
remains unclear, there is a general notion that M. kansasii infections may be acquired from 
the environment, but a definitive link between the environment and human disease has not 
yet been established. Drinking water distribution systems, tap water and shower heads 
have been reported to be the major sources of M. kansasii (Engel et al, 1980; Picardeau et 
al, 1997). Infection probably occurs via an aerosol route (Griffith, 2002). 
 
Recognised risk factors for M. kansasii infection include male sex, older age, smoking, 
malignancy, alcoholism, diabetes, previous mycobacterial disease, chronic obstructive 
lung disease (COPD), immunosuppression and pre-existing lung disease such as silicosis 
(Wolinsky, 1992; Bloch et al, 1998; Corbett et al, 1999c; Corbett et al, 2000; Jacobson et 
al, 2000). In South African gold miners, there is an unusually high incidence of M. 
kansasii infection and this has been estimated to be about 320 per 100 000 (Corbett et al, 
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2000). These miners have several risk factors for NTM disease, including HIV infection, 
high incidence of tuberculosis, silicosis, the extensive use of aerosolised water for dust 
control by the gold mines and an unusually high occupational exposure to NTM organisms 
(Corbett et al, 1999c; Corbett et al, 2000; Churchyard and Corbett, 2001). In Spain and the 
United Kingdom reported rates were 73 per 100 000 (Pintado et al, 1999) and 92 per 100 
000 (Klein et al, 1998), respectively, while in the United States the rates ranged from 100 
to 2667 per 100 000 (Carpenter and Parks, 1991; Bamberger et al, 1994; Witzig et al, 
1995; Bloch et al, 1998).  
 
1.5 Comparative Genomics 
Advances in molecular biology have revolutionised the field of mycobacterial research. 
They are providing us with valuable insights into the relationships between genotype and 
phenotype in mycobacteria and have paved a way for the development of the field of 
genomics, which refers to the study of all genes that are present in a genome (Brosch et al, 
2001).  
 
Comparative genomics is the analysis and comparison of genomes from different species. 
Its purpose is to gain a better understanding of how species have evolved and to determine 
the function of genes and non-coding regions of the genome. It involves the use of 
computer programs that can align multiple genomes and look for regions of similarity 
among them (Brosch et al, 2001). The increasing availability of complete bacterial 
genome sequences is leading to the widespread use of comparative and functional 
genomics methods for the better understanding of metabolism, identification of unique 
virulence factors (Brosch et al, 2001; Gordon et al, 2002), diagnostic and therapeutic 
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targets (Fitzgerald and Musser, 2001; Randhawa and Bishai, 2002), and evolution of 
mycobacteria (Brosch et al, 2001; Kato-Maeda et al, 2001; Cole, 2002; Behr, 2008).  
 
One of the first applications of comparative mycobacterial genomics involved the 
comparison of macrorestriction profiles using low frequency restriction enzymes and 
Pulsed-Field Gel Electrophoresis (PFGE). These studies revealed differences amongst the 
mycobacterial isolates studied (Zhang et al, 1995; Iinuma et al, 1997; Legrand et al, 2001) 
and contributed significantly to the construction of physical maps that were essential for 
the generation of the first mycobacterial genome sequence, M. tuberculosis H37Rv 
(Philipp et al, 1996; Cole et al, 1998). These studies also confirmed the extensive 
relatedness and sequence variation amongst genomes of mycobacteria (Zhang et al, 1995; 
Alcaide et al, 1997; Legrand et al, 2001). PFGE has also been used as a molecular typing 
tool for M. kansasii in a number of studies (Alcaide et al, 1997; Iinuma et al, 1997; 
Picardeau et al, 1997; Zhang et al, 2004).  
 
The next major step in the development of comparative genomics involved the use of 
genomic subtractive hybridisation, which led to the identification of Regions of Difference 
(RD) amongst some mycobacterial strains (Mahairas et al, 1996; Gordon et al, 1999). 
Using subtractive hybridisation, Gordon and co-workers were able to identify three 
regions of difference (RD1-RD3) in the genome of M. tuberculosis H37Rv that were 
absent from M. bovis BCG (Gordon et al, 1999). RD1 was found to be present in all 
virulent laboratory and clinical strains of M. bovis and M. tuberculosis (Mahairas et al, 
1996). This region comprises 9 genes (Rv3871 – Rv3879) and spans a 9.5kb region. In M. 
bovis BCG, RD1 completely removes 7 genes (Rv3872 – Rv3878) and truncates two 
others (Rv3871 – Rv3879c) (Lewis et al, 2003). Two of the genes in this region are 
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involved in the secretion of two highly antigenic proteins, ESAT-6 and CFP-10, and 
deletion mutants of M. tuberculosis have been found to be less virulent than the wild type 
strains (Lewis et al, 2003). Recently, RD1 has also been found to present in M. kansasii 
and other slow-growing mycobacteria, and may play a vital role in their virulence (Arend 
et al, 2005; van Ingen et al, 2009). 
 
In recent years a number of subtractive hybridisation approaches for the identification of 
genetic differences between genetically-related bacteria have been developed. One of its 
first applications in mycobacteriology involved the detection of mRNA either from an 
organism grown under different growth conditions or from two strains of the same or 
closely related species. In a recent approach, Selective Capture of Transcribed Sequences 
(SCOTS), a PCR-based method that directly identifies bacterial genes specifically 
expressed in different environments, mRNA was isolated from an experimental condition, 
in this case, from infected human macrophages. After converting it to complementary 
DNA (cDNA), the collection of molecules was prehybridised to itself to remove highly 
abundant sequences, after which it was hybridised to biotinylated bacterial genomic DNA. 
The captured DNA molecules were then isolated via streptavidin-coated magnetic beads, 
eluted and subjected to a series of SCOTS to enrich for the targeted sequences (Graham 
and Clark-Curtiss, 1999). The approach has provided insights into several important 
microbial pathogens and allowed the first global characterisation of bacterial gene 
expression patterns in naturally infected human tissues. SCOTS has been used to identify 
potentially important genes in M. tuberculosis (Graham and Clark-Curtiss, 1999), 
Salmonella typhimurium (Morrow et al, 1999), Helicobacter pylori (Graham et al, 2002), 
Listeria monocytogenes (Liu et al, 2002) and M. avium (Hou et al, 2002). Although 
SCOTS has the advantage of identifying low abundance mRNA, it cannot be used to 
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quantify in vivo gene expression levels because of the cDNA normalisation step included 
in the protocol. Additionally, it does not detect global genetic variations amongst bacterial 
strains or species but targets cDNA derived from differentially expressed genes. 
 
To facilitate the detection of genetic variations amongst phylogenetically-related bacteria, 
a variation of the SCOTS method that does not rely on mRNA expression, termed Genome 
Fragment Enrichment (GFE) was recently developed (Shanks et al, 2006a). Like SCOTS, 
GFE is a positive selection strategy that utilises competitive solution hybridisation to 
obtain DNA fragments present in one pool of fragments but not another. Biotinylated, 
sheared genomic DNA from one bacterial strain or species (tester) was prehybridised with 
sheared genomic DNA from a second strain or species (driver) prior to being self-
hybridised with PCR amplified DNA sequences from the first bacterium containing 
defined terminal sequence tags. This step blocked complementary sequences between the 
two populations. The desired DNA hybrids consisting of original biotinylated strands not 
blocked by this step were then isolated by streptavidin binding and, the captured genomic 
fragments containing defined terminal tags were selectively amplified by PCR. GFE has 
been successfully applied to the identification of Enterococcus faecalis genome-specific 
sequences (Shanks et al, 2006a), bovine faeces-specific DNA sequences (Shanks et al, 
2006b) and bacterial DNA markers for the detection of chicken and human faecal 
pollution in water (Lu et al, 2007; Shanks et al, 2007). 
 
Another recent and simplified alternative to the identification of chromosomal variations 
in closely related organisms is Hybridisation-Monitored Genome Differential Analysis 
(HMDA). This is a PCR-based solid subtractive hybridisation method that utilises a 
ribosomal DNA (rDNA) monitoring system to track the entire subtraction process 
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(Yueqing et al, 2006). In the original approach, tester DNA was enzymatically digested, 
tagged with adaptors for PCR amplification and exposed to randomly sheared driver DNA 
immobilised on a nylon membrane disc to eliminate homologous fragments. Several 
rounds of the hybridisation process were carried out with the replacement of the driver 
discs after each round. The end-point of the hybridisation process was determined when 
the conserved 18S rDNA sequence in the tester DNA population was no longer detectable 
by PCR. The resulting unbound tester DNA fragments were then PCR-amplified and 
directly cloned for further analysis (Yueqing et al, 2006). HMDA has been successfully 
used to identify unique sequences found in Saccharomyces cerevisiae but absent in 
Schizosaccharomyces pombe (Yueqing et al, 2006).  
 
However, there is very little information available regarding genetic studies on M. 
kansasii. Efforts are currently underway by the McGill University Sequencing Centre in 
Canada to determine the complete genome sequence of its type strain, M. kansasii ATCC 
12478. Preliminary data generated from the draft genomic sequence, completed on 
December 16, 2008, shows that the genome of M. kansasii is about 6.4 Mb and contains 
approximately 5961 genes and 5913 proteins from 299 DNA contiguous sequences 
(contigs) http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome&cmd=Retrieve&dopt= 
Overview&list_uids=6107 [last accessed June 1, 2010]). The data being generated from 
this sequence will shed some light on its genetic characteristics, such as those related to 
virulence and its evolution (Behr, 2008). 
 
1.6 Mode of Infection and Immune Response 
Unlike M. tuberculosis, there is very little information available on how infection by M. 
kansasii is acquired. Infection is probably achieved through inhalation of M. kansasii-
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containing aerosols into pulmonary alveoli or implantation through broken skin. 
Generally, there is interplay between the mycobacteria and the host to determine the 
outcome of infection. M. kansasii, like other mycobacteria, is an intracellular pathogen, 
infecting and surviving in macrophages and re-directing host responses to make a safe 
haven for itself (Smith et al, 2003). Following infection, the mycobacteria bind to 
phagocytic receptors and are taken up by resident macrophages, dendritic cells and 
monocytes recruited from the blood stream. The mycobacteria can also be trafficked to 
other sites, especially in immunocompromised patients, where they generally persist and 
multiply (McGeady and Murphey, 1981; Paniker, 2007). 
 
1.6.1 Innate Immune Response 
Endocytosis of mycobacteria involves different receptors on phagocytic cells, which bind 
either to non-opsonised mycobacteria or recognise opsonins on the surface of 
mycobacteria. In vitro studies have implicated several surface receptors on phagocytic 
cells involved in the recognition and binding of mycobacteria. These include complement 
receptors (CR) 1, 2, 3, and 4, mannose receptors (MR), CD14, pulmonary surfactant 
protein A (Sp-A) and Toll-like receptors (TLR) and scavenger receptors (Schlesinger et al, 
1996; Means et al, 1999; Le Cabec et al, 2000; Peyron et al, 2000). The CR3 receptor has 
been shown to play a key role in the phagocytosis of M. kansasii, both by macrophages 
and neutrophils (Le Cabec et al, 2000; Peyron et al, 2000). Cholesterol seems to play an 
essential role in the internalisation of the mycobacteria by accumulating around 
phagocytic receptors prior to the uptake of the mycobacteria (Gatfield and Pieters, 2000; 
Peyron et al, 2000). 
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Immune cells are able to recognise the mycobacteria via molecules present on the surface 
of the bacteria termed pathogenic-associated molecular patterns (PAMPs), molecules 
expressed invariably by several related pathogens but not by normal host cells (Medzhitov 
and Janeway, 2002). PAMPs are ligands for innate pattern recognition receptors that are 
expressed on myeloid antigen presenting cells (APC), macrophages and dendritic cells. 
APCs utilise PAMP receptors to recognise pathogens, initiate and orchestrate 
inflammatory responses to trigger mechanisms of pathogen killing via innate immunity. 
Antigens derived from engulfed pathogens are subsequently presented to lymphocytes, 
which initiate adaptive immune responses. The human pattern receptors include a family 
of 11 Toll-like receptors (TLRs), among which TLR2 and TLR4 are cell surface proteins 
specialised in binding to lipid-based components of mycobacterial cell walls and initiate 
an inflammatory signalling cascade that is critical to the innate immune response (O'Neill 
and Bowie, 2007). Recognition of M. kansasii has been reported to engage TLR2 (Vignal 
et al, 2003; Quesniaux et al, 2004), while that of M. tuberculosis involves both TLR2 and 
TLR4 (Means et al, 1999). TLR2 binds mycobacterial lipomannans (LM), while the 
ligands for TLR4 remain unknown (Jo et al, 2007). Other molecules such as the mannose-
capped lipoarabinomannans (ManLAM) do not act via TLR but bind to the MR and 
dendritic cell-specific intracellular adhesion molecule-grabbing non-integrin (DC-SIGN) 
(Jo et al, 2007). 
 
The host defence mechanism against mycobacterial infection mainly employs TLR2 and 
TLR4 (Jo et al, 2007). The activation of these two receptors affects the type 1 helper (Th1) 
and type 2 helper (Th2) lymphocytes differently. One of the key signalling pathways 
activated by these receptors is through the nuclear factor-κB (NF-κB), which leads to the 
expression of cytokines, chemokines and inducible nitric synthase (iNOS) (Jo et al, 2007). 
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iNOS generates nitric oxide (NO), a key mediator in reactive nitrogen intermediates 
mediated by microbicidal mechanisms of macrophages (Fang, 2004). Activation of NF-κB 
by both TLR2 and TLR4 requires the adaptor protein, myeloid differentiation primary 
response gene 88 (MyD88), which is important for the induction of Tumour Necrosis 
Factor-α (TNF-α), interleukin-10 (IL-10), IL-18, interferon-γ (IFN-γ) and IL-1β (Ryffel et 
al, 2006; O'Neill and Bowie, 2007; Fang et al, 2010). Stimulation of TLR4 by 
mycobacteria has also been shown to induce production of IL-32, a cell-associated pro-
inflammatory cytokine produced through a caspase-1 and IL-18 dependent production of 
IFN-γ and its main sources are Natural Killer (NK) cells, epithelial cells and blood 
monocytes (Netea et al, 2006). Additional studies have demonstrated that in human 
monocytes and macrophages TLR2 also triggers the expression of vitamin D receptor and 
vitamin D-1-hydroxylase genes, leading to the induction of an antimicrobial peptide, 
cathelicidin, which results in the killing of mycobacteria (Liu et al, 2007). 
 
CCR5, a chemokine receptor found on dendritic cells, is another important host molecule 
that could act as a pattern recognition receptor and has been shown to recognise 
mycobacterial heat shock protein 70 (hsp70), leading to diverse cellular immune responses 
(Floto et al, 2006).  
 
Apart from macrophages and dendritic cells, other leukocytes also participate in the innate 
immune responses, including neutrophils and NK cells. Neutrophils are amongst the 
earliest cells to be recruited to sites of inflammation. They have well-characterised 
antimicrobial mechanisms (Urban et al, 2006). Using whole blood assays, neutrophils 
were shown to contribute significantly to innate resistance to mycobacterial infection and 
this resistance was attributed to the presence of antimicrobial peptides in these cells 
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(Martineau et al, 2007). Conversely, neutrophils have also been associated with the 
development of disease rather than protection of the host. Eruslanov and co-workers, using 
a mouse model, demonstrated that M. tuberculosis-susceptible mice had larger and longer 
accumulation of neutrophils in tuberculous lesions as compared to M. tuberculosis-
resistant mice (Eruslanov et al, 2005). This may have been influenced by the differential 
expression of chemoattractant molecules to neutrophils (Keller et al, 2006). 
 
NK cells are also very important effector cells of the innate immune system 
(Vankayalapati and Barnes, 2009). They act by directly lysing pathogens or infected cells 
by the production of perforins and are amongst the first cells to produce IFN-γ during 
immune response. In TB, NK cells have also been shown to contribute to the clearance of 
M. tuberculosis through production of IL-22, which inhibits intracellular mycobacterial 
growth by enhancing phagolysosomal fusion (Dhiman et al, 2009) and to optimise the 
ability of CD8+ cells to produce IFN-γ and lyse M. tuberculosis-infected cells 
(Vankayalapati and Barnes, 2009). 
 
1.6.2 Adaptive Immune Response 
Unlike the innate immune mechanisms, the adaptive immune responses require specific 
recognition of foreign antigens. After the innate system recognises an invading pathogen 
and attempts to control its early spread, the adaptive immune response is activated to deal 
with the pathogen in a specific manner and is effected through the humoral and cell-
mediated immune responses.  
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1.6.2.1 Humoral Immune Response 
Since mycobacteria are intracellular pathogens, antibodies may not gain access to the 
pathogens and may not play a protective role. However, during the initial stages of 
infection, antibodies seem to have an opsonising role by improving phagocytosis by 
macrophages or the cytotoxic actions of NK cells. In a recent study De Vallière and co-
workers demonstrated that lipoarabimannan (LAM)-specific antibodies increased the 
internalisation and killing of M. bovis BCG. Furthermore, the M. bovis BCG-induced 
antibodies were shown to significantly enhance the cell-mediated immune response with 
increased T cell proliferation and IFN-γ production in mycobacterium-specific CD4+ T 
lymphocytes (CD4+ T cells) and CD8+ T cells (de Valliere et al, 2005). This is a good 
example through which mycobacterium-specific antibodies have been shown to have the 
potential of enhancing both innate and cell-mediated immune responses to mycobacteria. 
 
Recently, the use of passive immunisation with immunoglobulin A (IgA) antibodies and 
IFN-γ was attempted in order to induce protection against TB using an experimental 
mouse model of TB lung infection. IgA and IFN-γ were administered three days prior to 
infection and a further co-inoculation with IgA after 2 hrs, 2 days and 7 days after an 
aerosol infection with M. tuberculosis H37Rv. A 17-fold reduction in colony-forming 
units (CFU), as wells as a lowering of granulomatous infiltration of the lungs, were 
observed (Reljic et al, 2006). 
 
1.6.2.2 Cell-Mediated Immune Response 
Control of mycobacterial infection by the host depends on a functional cell-mediated 
immune response through the CD4+ T cells. In essence, the initiation of the adaptive 
immune responses is influenced by antigen presentation, co-stimulation signals from 
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mycobacteria and cytokine production. Since mycobacteria reside inside a compartment 
within macrophages, their antigens are presented in association with Major 
Histocompatibility Complex (MHC) class II molecules to specific CD4+ T cells (Reith and 
Mach, 2001). MHC class I molecules, expressed on all nucleated cells, present 
mycobacterial antigens that escape from phagosomes to CD8+ T cells and non-
polymorphic MHC class I molecules such as type CD1 molecules, expressed on 
macrophages and dendritic cells, are capable of presenting mycobacterial lipoproteins to 
CD1-restricted T cells (Munk and Emoto, 1995). The expression of these antigen 
presenting molecules is regulated by cytokines. IFN-γ stimulates the expression of MHC 
(Reith and Mach, 2001) while anti-inflammatory cytokines inhibit its expression. 
Macrophages infected with mycobacteria are capable of down-regulating the expression of 
MHC molecules through production of anti-inflammatory cytokines (Weiss et al, 2001). 
 
Macrophages play a role in the initial defence against mycobacteria by producing 
cytokines that have a regulatory role on macrophages themselves and T cells, which are 
important in specific cell-mediated immune responses (Flynn and Chan, 2001). They 
produce IL-12, IL-10 and IL-18, which strongly influence the T cell cytokine responses 
(Oppmann et al, 2000; Luo et al, 2004). IL-12 is a potent stimulus for T cells to secrete 
IFNγ, whereas IL-10 inhibits the production of IL-12 and favours the development of cells 
that produce T helper 2 (Th2) cytokines. IL-18 acts synergistically with IL-12 to enhance 
T cell production of IFNγ (Luo et al, 2004).   
 
CD4+ T cells contribute to defence against infectious agents by producing specific patterns 
of cytokines. Based on their functions, pattern of cytokine secretion and their expression 
of specific transcription factors, four CD4+ T cell effector lineages have been described: 
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Th1, Th2, Th17 and T regulatory (T reg) cells (Murphy and Reiner, 2002; Sakaguchi, 
2004; Harrington et al, 2005; Bettelli et al, 2007; Bluestone et al, 2009). Other Th lineages 
may exist (Szabo et al, 2003; Bluestone et al, 2009). Th1 cells mainly produce IFNγ 
(important for macrophage activation and clearance of intracellular pathogens) and IL-2, 
whereas Th2 cells produce IL-4, IL-5, IL-10 and IL-13, which are important for the 
production of IgE, eosinophil recruitment and clearance of extracellular parasites (Szabo 
et al, 2003; Ansel et al, 2006).  
 
Although it is well recognised that Th1 cytokines are critical in cell-mediated responses to 
mycobacteria, it is also clear that this immunity alone is not enough (Flynn, 2004). Recent 
data seem to indicate that Th1 cells and IFN-γ play a limited role in murine lung infection 
with M. kansasii (Wieland et al, 2006a). Both wild-type mice and knock-out mice were 
shown to display normal resistance against pulmonary infection with M. kansasii. This 
was in sharp contrast to previous findings that showed that Th1 cells were important for 
protection against M. tuberculosis (Flynn and Chan, 2001). In a follow-up study, IL-1 was 
shown to positively contribute to an effective clearance of M. kansasii from the respiratory 
tract by an unidentified mechanism (Wieland et al, 2006b). It is thought that TLRs, 
complement and antibodies could be involved in the activation of IL-1 and that TNF-α 
could have augmented this protective mechanism since it is one of the key mediators of 
host defence mechanisms against mycobacterial infection (Flynn and Chan, 2001). TNF-α 
is important for walling off infection and prevention of dissemination (Flynn and Chan, 
2001).  
 
Th17 cells belong to a CD4+ T cell subset that is distinct from Th1 and Th2 subsets. They 
have significant pro-inflammatory functions via the production of cytokines IL-17A, IL-
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17F, IL-21 and IL-22 (Harrington et al, 2005; Park et al, 2005; Liang et al, 2006).   
Through the production of these pro-inflammatory cytokines, Th17 cells also trigger the 
production of other cytokines such as IL-6, Granulocyte-Macrophage Colony-Stimulating 
Factor (GM-CSF), Granulocyte Colony-Stimulating Factor (G-CSF), chemokines (CXCL-
1, CXCL-2, CXCL-5, CXCL-8) and metalloproteins (Liang et al, 2006; Chen et al, 2010). 
Th17 cells play a significant role not only in the development of autoimmune and 
inflammatory diseases, but also in protection against extracellular bacteria and fungi, 
particularly at epithelial surfaces (Weaver et al, 2007).  Recent studies have also indicated 
that Th17 cells are the major IL-17-producing cells and participate in the protective 
immunity against M. tuberculosis (Wozniak et al, 2006; Khader et al, 2007). Khader and 
colleagues reported an indirect role for the Th17 response in protective immunity in mouse 
models of M. tuberculosis infection (Khader et al, 2005, Khader et al, 2007; Khader and 
Cooper, 2008). Human Th17 response is inducible by M. tuberculosis infection and a 
reduced M. tuberculosis antigen-specific Th17 response, which may be due to suppression 
of Th1 cytokine, has been observed in patients with active disease compared to healthy 
subjects (Scriba et al, 2008).  
 
Regulatory T cells (T regs) are characterised by expression of the transcription factor 
forkhead box P3 (FOXP3) and IL-2 and Transforming Growth Factor-β (TGF-β), and 
CD28 co-stimulation seem to be important for their generation (Chen et al, 2003). These 
cells may be involved in self-tolerance, immune regulation and promotion of immune 
responses under certain circumstances (Curotto de Lafaille and Lafaille, 2009). 
 
The destruction of intracellular pathogens primarily relies on cytotoxic lymphocytes such 
as NK cells and CD8+ T cells. CD8+ T cells require an antigen to be presented in 
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association with MHC class I molecules but it is not clear how the activation of these cells 
occurs as bacterial antigen presentation is not likely to occur via MHC class I proteins. 
One hypothesis states that mycobacterial antigens either leak out from, or are actively 
transported out of, the phagosome into the cytosol where they are processed for MHC 
class I presentation (Hartmann and Plum, 1999). A second hypothesis assumes that the 
presentation of mycobacterial antigens is done in the context of MHC molecule Ib, which 
does not require processing of antigens through the endoplasmic reticulum (Munk and 
Emoto, 1995). Whatever the mechanism may be, cytotoxic CD8+ T cells have been shown 
to secrete IFN-γ and TNF-α, and are capable of directly killing mycobacteria-containing 
macrophages through the production of perforins and granzymes that punch holes in the 
cell membranes (Stenger et al, 1997). Additionally, they may also produce granulysin 
which enter infected macrophages through holes and directly kill intracellular 
mycobacteria (Serbina and Flynn, 1999). 
 
In additional to T cells discussed above, large granular lymphocytes, referred to as γδ T 
cells, play a key role in adaptive immune response. These cells do not require interaction 
with MHC molecules for activation and function as cytotoxic cells, and may act as antigen 
presenting cells (Kabelitz et al, 2000; Brandes et al, 2005). Stimulation of human γδ T 
cells has been shown to result in aggressive production of IFN-γ and TNF-α, which are 
potent activators of phagosome-lysosome fusion (Boom, 1999). In both human and mouse, 
γδ T cells have been shown to contribute to the elimination of M. tuberculosis and to have 
an anti-inflammatory effect (D'Souza et al, 1997; De La Barrera et al, 2003). However, the 
role of these cells in M. kansasii infection is unknown. 
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1.6.2.3 Granulomas 
One of the major outcomes of mycobacterial infection in vivo is the formation of 
granulomas. Granulomas are sites for containment of mycobacteria consisting of a central 
necrotic core surrounded by concentric layers of macrophages, Langerhans giant cells and 
lymphocytes (Flynn and Chan, 2001). Mature granulomas are characterised by high levels 
of immunological activity mediated by macrophages and T cells resulting in the 
production of a variety of cytokines and chemokines (Flynn and Chan, 2001). However, 
mycobacteria have evolved strategies to evade complete eradication in the granulomas. 
When the immune response is weakened due to immunosuppression, the bacilli within the 
granulomas can escape from the containment area to cause active disease and 
dissemination to other sites (Smith et al, 2003). Only limited work has been done to 
understand immune responses elicited by M. kansasii. 
 
1.7 Pathogenesis 
Despite the clinical importance of M. kansasii, little is known about its pathogenicity. 
Most of the literature to date has mainly dealt with clinical aspects of M. kansasii-induced 
disease. Once inside the host cell, pathogenic mycobacteria are capable of evading 
destruction by the immune system. An important key to the success of these organisms is 
likely to be due to their unusual cell wall structure, comprising a highly complex array of 
lipids, glycolipids and proteins, and its interaction with the immune system. Two of the 
predominant glycolipids, lipoarabinomannans (LAM) and their biosynthetic precursors, 
lipomannans (LM) are believed to play important roles in the physiology of the bacterium 
as well as in the modulation of the host response during infection. LAMs have been 
reported to be secreted from macrophages and, therefore, may also affect the functioning 
of uninfected neighbouring cells in a paracrine manner (Beatty et al, 2000). Using the 
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THP-1 human monocytic cell line, it was shown that M. kansasii LM (kanLM) was a 
potent inducer of apoptosis and pro-inflammatory cytokines, highlighting the importance 
of kanLM in the pathogenesis of M. kansasii. Assessment of the role of M. kansasii LAM 
(kanLAM) showed that it did not induce apoptosis, but only did so after the removal of the 
arabimannan domain (Guerardel et al, 2003; Vignal et al, 2003). The presence of 
oligomannoside caps on LAM is considered to be one of the strategies that pathogenic 
mycobacteria like M. kansasii and M. tuberculosis utilise to mimic endogenous host 
components in order to evade host defence mechanisms (Jozefowski et al, 2008). In fact, it 
has been shown that the presence of ManLAM on M. tuberculosis stimulates antigen 
presenting cells (APC) to induce regulatory T cells to start producing IL-10 and TGF-β, 
two of the cytokines that significantly contribute to the inhibition of Th1 responses (Garg 
et al, 2008). 
 
In immunocompetent patients, pulmonary disease has been reported to generally resemble 
that of TB and this includes formation of cavitary lesions, which mostly involve upper 
lobes (Shitrit et al, 2007). Using BALB/c mice, Fujita and co-workers were able to 
demonstrate that trehalose 6,6’-dimycolate (TDM), the cord factor, from both M. kansasii 
and M. tuberculosis induced marked toxicity, thymic atrophy and granulomatogenicity in 
lungs and spleens of the mice as compared to TDMs from other mycobacterial strains. 
This was mainly attributed to the existence of longer chain and abundance of α-mycolic 
acids in TDMs of these two mycobacterial species (Fujita et al, 2007). In some instances 
M. kansasii infection has been shown to mimic other disease conditions. Chen and co-
workers, in a recent case report, showed that two immunocompetent patients with 
systemic M. kansasii infection presented with disease resembling a peripheral T cell 
lymphoma. These patients presented with nodules infiltrated with lymphocytes and small 
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aggregates of epithelioid histiocytes. In both cases, granulomas were poorly formed, 
mimicking peripheral T cell lymphomas, but were negative for T cell receptor (TCR) gene 
rearrangement (Chen et al, 2008). Without the isolation and identification of M. kansasii, 
diagnosis of this M. kansasii-induced disease would have been complicated. 
 
In patients with HIV infection, M. kansasii disease presents with diverse features which 
may make diagnosis difficult (Smith et al, 2003; Cattamanchi et al, 2008). A recent review 
of pathological features associated with M. kansasii infection in patients with AIDS 
showed that M. kansasii infection induced predominantly pulmonary disease with a wide 
range of inflammatory reactions. This included granulomas with or without necrosis, 
neutrophilic abscesses, spindle cell proliferations and foci of granular eosinophilic 
necrosis. A high incidence of thoracic lymph node involvement and a lower incidence of 
disseminated disease were also reported (Smith et al, 2003). This is probably the only 
study that documents detailed pathological features associated with M. kansasii-induced 
disease. 
 
1.8 Clinical Presentations 
M. kansasii infections are more common in males than in females, especially in the older 
population, and age shifts correlate with the population infected with HIV  (Churchyard, 
2000; Churchyard and Grant, 2000; Yim et al, 2005). The high frequency of infection 
observed in males may be attributed to their occupation, which may predispose them to 
high risk factors for M. kansasii infection (Wolinsky, 1992; Bloch et al, 1998; Corbett et 
al, 1999; Jacobson et al, 2000; Churchyard and Corbett, 2001). 
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1.8.1 Disease in Immunocompetent Patients  
In immunocompetent patients, pulmonary disease is the most frequent clinical 
manifestation but in some patients there is no associated illness (Wolinsky, 1992; Bloch et 
al, 1998; Griffith, 2002; Arend et al, 2004; Yim et al, 2005; Shitrit et al, 2006). The 
antigenic and clinical characteristics of M. kansasii make it the mycobacterium most 
similar to M. tuberculosis, but the symptoms it causes may be less severe and more 
chronic as compared to that induced by M. tuberculosis (Bloch et al, 1998; Koh et al, 
2002; Marras and Daley, 2004; Shitrit et al, 2008). In the years preceding the emergence 
of the HIV/AIDS pandemic, M. kansasii was the NTM agent mostly responsible for 
pulmonary infections in patients with previous pulmonary disease, but disseminated 
disease was extremely rare (Horsburgh, 1996).  
 
Lung disease affects more than 50% of patients and, if untreated, can lead to death 
(Griffith, 2002; Shitrit et al, 2007). Symptoms closely resemble those of pulmonary 
tuberculosis. Commonly reported symptoms include fever, chills, night sweats, productive 
or non-productive cough, weight loss, fatigue, dyspnoea and chest pain (Bloch et al, 1998; 
Koh et al, 2002). Chest radiography abnormalities in the majority of patients show 
cavitary disease mainly in the right lung with an upper lobe predilection, usually with 
evidence of cavitation and scarring (Griffith, 2002; Shitrit et al, 2008). Extrapulmonary 
infections, including lymphadenitis, skin and soft tissue infection and joint infection, have 
been reported occasionally (Horsburgh, 1996; Bloch et al, 1998; Razavi and Cleveland, 
2000; Koh et al, 2002; Benton et al, 2004). Disseminated infections are rare in 
immunocompetent patients (Wolinsky, 1992; Griffith, 2002).  
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1.8.2 Disease in HIV-infected patients  
M. kansasii infection usually manifests late in the course of HIV disease (Klein et al, 
1998; Manfredi et al, 2004). In patients infected with HIV, any organ can be affected, 
making the clinical presentation non-specific. Commonly reported symptoms include 
fever, night sweats, weight loss, fatigue, cough and chest pain (Witzig et al, 1995; 
Cattamanchi et al, 2008). Chest radiographs mainly show lack of cavitations. The most 
common features are consolidations and nodules in the mid and lower lung zones 
(Cattamanchi et al, 2008). In the same study of radiographical presentations of M. kansasii 
lung disease in patients with HIV, Cattamanchi and co-workers found that patients with 
HIV infection and M. kansasii lung disease present with diverse chest radiological 
patterns, most commonly consolidations and nodules mostly located in the mid and lower 
lung zones. This is in contrast to the findings in patients without HIV in whom upper-lobe 
radiographic abnormalities are normally seen (Griffith, 2002; Shitrit et al, 2007).  
 
In predicting the mortality of pulmonary M. kansasii infection in patients with HIV, 
Marras and colleagues studied 127 patients with pulmonary M. kansasii and found that 
33% fulfilled the American Thoracic Society criteria for the disease (Griffith et al, 2007). 
Twenty-one percent of these received at least one antimycobacterial drug for at least 3 
months and 53% died. Mortality was associated with a lower CD4 cell count and positive 
smear microscopy. Antiretroviral therapy and M. kansasii treatment were associated with 
survival (Marras et al, 2004).  
 
1.9 Diagnosis 
It is generally accepted that the isolation of NTMs from sputum of individual patients is 
not proof of disease, as this may represent colonisation of the respiratory tract or specimen 
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contamination. This has led to the establishment of the diagnostic criteria for NTM by the 
American Thoracic Society (ATS) (Griffith et al, 2007). These globally adopted criteria 
have also been applied to M. kansasii and are based the isolation of NTM from two or 
more sputum specimens taken at different times in addition to clinical and chest 
radiographical abnormalities.  
 
However, these criteria are not considered appropriate for the diagnosis of NTM disease in 
the South African mining industry as they have demonstrated under-diagnosis of M. 
kansasii disease due to the logistical barriers associated with the requirement for multiple 
sputum isolates (Churchyard and Corbett, 2001). To address this problem, the Safety In 
Mines Research Advisory Committee (SIMRAC) in South Africa has suggested a number 
of modification to the ATS diagnostic criteria for pulmonary NTM disease in the South 
African mining industry (Churchyard and Corbett, 2001).  The following are the suggested 
adaptations of the ATS diagnostic criteria:  
• compatible signs and symptoms and reasonable exclusion of other disease to 
explain the condition (including M. tuberculosis disease) 
• pulmonary changes compatible with pulmonary NTM disease 
• two NTM isolates from separate sputum or broncho-alveolar lavage (BAL) 
specimens. The ATS recommends at least 3 isolates to confirm smear negative 
disease 
• heavy growth and numerous acid-fast bacilli (AFB) isolated for a single available 
BAL specimen 
• single NTM isolate from lung biopsy tissue; single available sputum isolate 
identified as M. kansasii. The ATS recommendations do not distinguish between 
species with different intrinsic pathogenesis and do not recommend treating a 
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single sputum or BAL NTM isolate unless the diagnosis is supported by 
granulomas or AFB on lung biopsy tissue 
• single available sputum isolate identified as an NTM species associated with a 
previous episode of mycobacterial disease (potential relapse). 
 
Generally, diagnosis of NTM disease, including that of M. kansasii is based on clinical, 
radiological and laboratory findings. The confirmation of clinical and radiological 
suspicions of M. kansasii-associated disease involves the use of both phenotypic and 
genotypic methods. Phenotypic methods are used to detect visible characteristics of the 
organism such as acid-fastness, colonial morphology and biochemical reactions. By 
contrast, genotypic methods detect the genetic characteristics of the organism.  
 
1.9.1 Phenotypic Methods 
On culture M. kansasii exhibits slow growth and photochromogenicity by producing a 
yellow pigment upon exposure to light, grows optimally at 37oC and produces either rough 
or smooth colonies with irregular edges on solid media (Wayne and Kubica, 1986). Its 
isolation involves the use of media such as Löwenstein-Jensen (LJ), Middlebrook 7H10 
(M7H10) and M7H9 broth. Optimised automated techniques such as the BACTEC MGIT 
960 (Becton Dickinson Laboratories, Sparks, MD, USA) are also used and these systems 
have reduced the time taken for detecting mycobacteria. The main biochemical tests used 
for its identification include production of catalase, urease, pyrazinamidase, nitrate 
reductase production and its ability to hydrolyse Tween 80 (Kent and Kubica, 1985; Leão 
et al, 2004). Chromatographic methods such as High Performance Liquid 
Chromatography (HPLC) have also been shown to be useful for the definitive 
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identification of M. kansasii (Riviere et al, 1987; Butler and Kilburn, 1988; Butler and 
Guthertz, 2001). 
 
1.9.2 Genotypic Methods 
A number of molecular techniques have been developed for the detection and 
identification of mycobacteria and are now providing rapid and accurate results. These 
techniques are mainly based on the amplification or hybridisation of nucleic acids. 
 
1.9.2.1 PCR Restriction-Enzyme Analysis 
PCR Restriction-Enzyme Analysis (PRA) is a rapid PCR method, based on the 
amplification of a 441bp DNA fragment of the hsp65 gene, followed by digestion with 
two restriction enzymes, BstEII and HaeIII (Telenti et al, 1993). The products of the 
digestion are analysed by agarose gel electrophoresis, evaluated with the help of a 
published algorithm (Devallois et al, 1997; Chimara et al, 2008) and compared to 
PRASITE (http://app.chuv.ch/parasite/index.html), an internet database maintained by the 
Swiss National Centre for Mycobacteria. PRA analysis of M. kansasii results in seven 
subtypes. Other genes, such as rpoB and gyrB, have also been used with PRA for the 
identification of mycobacteria (Lee et al, 2000; Goh et al, 2006). A number of studies 
have reported the successful application of this assay in clinical settings (de Magalhaes et 
al, 2002; Leão et al, 2005, Martin et al, 2007). 
 
1.9.2.2 Commercial Assays 
A number of molecular assays for identifying M. kansasii and other mycobacteria are 
available commercially and are widely acknowledged in literature. These include 
AccuProbe (Gen-Probe, San Diego, CA, USA [Drake et al, 1987; Reisner et al, 1994; 
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Tortoli et al, 1996; Richter et al, 1999]), Inno LiPA Mycobacteria (Innogenetic, Ghent, 
Belgium [Scarparo et al, 2001; Mijs et al, 2002; Tortoli et al, 2003b]) and GenoType 
Mycobacterium (Hain Life Science, Nehren, Germany [Richter et al, 2006; Franco-
Alvarez de Luna et al, 2006; Gitti et al, 2006; Russo et al, 2006; Neonakis et al, 2007; 
Seagar et al, 2008]).  
 
1.9.2.3 DNA Sequencing 
DNA Sequencing is regarded as the “gold” standard for the identification of all 
microorganisms, including mycobacteria. The rationale behind this methodology is that 
highly conserved target regions, but variable genes within the Mycobacterium genus, are 
first amplified by PCR, followed by sequencing of the amplicons on an automated 
sequencer. Once the sequences have been determined, they are compared with a library of 
known sequences in databases available on the internet. Genes commonly targeted for 
sequencing include the 16S rDNA gene (Rogall et al, 1990a; Stahl and Urbance, 1990; 
Kox et al, 1995; Harmsen et al, 2002) the 16S-23S rDNA internal transcribed spacer (ITS) 
(Roth et al, 2000; Iwamoto and Saito, 2006), the rpoB gene (Gingeras et al, 1998; Kim et 
al, 1999), the gyrB gene (Kasai et al, 2000), the hsp65 gene (Telenti et al, 1993; Ringuet 
et al, 1999; Brunello et al, 2001), the  recA gene (Blackwood et al, 2000), the gyrA gene 
(Sander et al, 1998), the sodA gene (Zolg and Philippi-Schulz, 1994) and the secA1 gene 
(Zelazny et al, 2005). This methodology, generally, offers microbiology laboratories the 
ability to identify newly described mycobacterial species. 
 
1.10 Treatment 
M. kansasii isolated from lungs or elsewhere almost always warrants treatment, especially 
in patients with AIDS and in other immunocompromised groups, as it is more likely to be 
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associated with disease (Bloch et al, 1998, Corbett et al, 1999a; Churchyard and Corbett, 
2001; Griffith, 2002; Marras and Daley, 2004; Cattamanchi et al, 2008). Unfortunately, 
there is no standardised treatment for M. kansasii, although it seems to be sensitive to a 
number of anti-tuberculosis medications (Griffith, 2002). The current ATS 
recommendation for treatment of pulmonary M. kansasii disease in non-HIV infected 
patients includes rifampicin, isoniazid and ethambutol administered daily for 18 months 
plus 12 months of negative sputum cultures (Griffith et al, 2007). This is longer than the 
usual treatment for tuberculosis, which usually takes about 6 to 9 months. Clarithromycin 
has been suggested as a reasonable alternative in patients who cannot tolerate one of these 
three drugs (Griffith et al, 2003). Other agents with useful activity against M. kansasii 
include sulphamethoxazole, amikacin, streptomycin, fluoroquinolones and rifabutin. It is 
recommended that patients with rifampicin-resistant M. kansasii strains should be treated 
with clarithromycin, or azithromycin, moxifloxaxin, ethambutol, sulphamethoxazole, or 
streptomycin (Griffith, 2007).  
 
The recommended treatment regimen for disseminated M. kansasii disease is the same as 
for pulmonary disease but rifampicin is contra-indicated in patients with AIDS taking 
protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors NNRT)  
(Graybill and Bocanegra, 2001; Griffith et al, 2007). Rifampicin is a potent inducer of 
hepatic P-450 cytochrome enzymes, resulting in significantly enhanced metabolism of 
these two classes of drugs, rendering them potentially ineffective (Graybill and Bocanegra, 
2001). In place of rifampicin, rifabutin has been recommended (Griffith et al, 2007).  
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1.11 Statement of the Problem and Study Justification 
The incidence of M. kansasii disease in the South African gold-mining workforce appears 
to be very high, and M. kansasii has been reported to the most common cause of NTM 
lung disease in both HIV-positive and non-HIV-negative patients in this population 
(Churchyard et al, 1999; Corbett et al, 1999b; Churchyard, 2000; Corbett et al, 2000). 
Despite the clinical importance of M. kansasii, there has been no report from South Africa 
on the identification of its sources of infection or on any molecular or immunological 
analysis that would contribute to the understanding of its pathogenicity.  
 
Such studies would contribute to the development of intervention strategies to be used in 
the prevention of transmission of M. kansasii-associated or other NTM diseases. They 
would also lead to the identification of genes that would be potential targets for drugs, and 
assist future vaccine studies. 
 
37 
 
1.12 Objectives of the Study 
The primary goal of this study was to determine the molecular and immunological 
characteristics of clinical and environmental isolates of M. kansasii from a South African 
gold-mining region. More specifically, the objectives of the study were:  
1. To identify the potential environmental sources of M. kansasii infection in the Vaal 
River gold-mining region.  
2. To determine the genetic diversity amongst clinical and environmental isolates of M. 
kansasii. 
3. To identify genetic differences between the predominant clinical isolate of M. kansasii 
and other environmental isolates of M. kansasii. 
4. To determine whether M. kansasii has the ability to induce immunomodulation on 
human lymphocyte activity in vitro. 
 
1.13 Thesis Layout 
This thesis is divided into 7 chapters: Chapter 1 deals with the introduction and background to 
the Study; Chapter 2 deals with the methods used in the Study; Chapter 3 deals with aspects 
concerning the examination of environmental samples collected from two mining regions for 
the presence of mycobacteria; Chapter 4 focuses on the assessment of the genetic diversity 
amongst the clinical and environmental isolates of M. kansasii; Chapter 5 deals with the 
investigation of genetic differences between the clinical and environmental isolates of M. 
kansasii; Chapter 6 involves the immunological assessment of the ability of M. kansasii to 
induce immunomodulation on human lymphocyte activity in vitro; and Chapter 7 discusses 
and summarises all the major findings for the Study and suggestions for future work. The 
thesis layout is schematically shown in the flow chart below (Figure 1.1).  
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Figure 1.1:  Thesis layout. 
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CHAPTER 2 
Materials and Methods 
 
2.0 Introduction 
This chapter is divided into four main sections that describe all the methods used in this 
study. The first two sections describe the bacteria, culture and DNA preparation methods 
used. The remaining sections describe methods used for specific chapters. 
 
2.1 Study Sites 
Water and biofilm samples were collected from a number of sites in the Vaal River gold-
mining region of the North-West Province, South Africa from 31st July to 1st August 2006 
and from 28th February to 2nd March 2007, and from the Secunda coal-mining complex in 
Mpumalanga Province from 16th April to 18th April 18 2008. Clinical isolates of M. 
kansasii were obtained through the West Vaal Hospital Tuberculosis Laboratory at Orkney 
situated in the Vaal River gold-mining region at the same time as the environmental 
samples. These isolates were obtained from the West Vaal Hospital or Leslie Williams 
Hospital in Cartonville. These two hospitals are the major sources of tertiary care in these 
regions for gold miners, who are mostly black African migrants, employed by one of the 
largest mining companies in South Africa. The Vaal River gold-mining region is situated 
at a latitude of approximately 26o30’S and longitude 26o45’E, some 175 km south-west of 
Johannesburg (Figure 2.1). The region typically experiences warm to hot summers, 22 to 
34oC, and cool to cold winter temperatures, with the average being about 15.5oC. The 
topography of the region is generally flat, with some undulating hills. The Vaal River 
passes through this region (Figure 2.1). The second region, the Secunda coal-mining 
complex, is situated at a latitude of approximately 26o33’S and longitude 29o10’E and is 
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about 154 km north-east of Johannesburg. The region is situated at approximately latitude 
26o33’S and longitude 29o10’E and is about 154 km north-east of Johannesburg. The 
region has summer temperatures ranging from 19 to 33oC and winter temperatures ranging 
from 6 to 26oC.  
 
Figure 2.1: The Vaal River gold-mining region, North-West Province, South Africa, where M. kansasii 
clinical isolates, some of the water and biofilm samples were obtained. Water and biofilm samples were 
collected randomly from water distributing systems in mine hostels, change rooms, kitchens, boreholes, 
showerheads and piped underground water around a number of mine shafts shown above (Map courtesy of 
the Orkney Municipal Council, North-West Province). 
 
The Vaal River gold-mining region was the main region of interest as this was the 
environment where a high incidence of M. kansasii infection had previously been reported 
in the gold-mining workforce (Corbett et al. 1999; Churchyard & Corbett 2001). The 
Secunda coal-mining complex was included in order to assess whether M. kansasii was 
also prevalent in a coal-mining environment. Reports from Europe have reported high 
incidences of M. kansasii infections from coal-mining regions (Kubin et al. 1980; Lamden 
et al. 1996; Chobot et al. 1997).  
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2.2 Bacterial Strains and Culture Conditions 
Bacterial strains used in this study included clinical and environmental isolates of M. 
kansasii and Escherichia coli DH5α. Control strains of M. kansasii were kindly provided 
by Veroniqué Vincent and Cristina Gutierrez of the National Reference Centre for 
Mycobacteria, Pasteur Institute, Paris, France and Petra de Haas of the National Institute 
of Public Health and the Environment, Bilthoven, The Netherlands. The control strains 
included three isolates each for genotypes I, II, III, IV, V, one for genotype VI and ATCC 
12478, obtained from the National Health Laboratory Service (NHLS) Central TB 
Laboratory in Johannesburg. E. coli DH5α (F-Ø80dlacZM15[lacZYA-argF]U169 
RecA1endA1hsdR17[rk,mk+]phoAsupE44thi-1gyrA96recA1tonA (Hanahan, 1983), 
Invitrogen Life Technologies, Paisley, UK) was used in cloning experiments (Chapter 5).  
 
Clinical isolates were all single patient isolates collected retrospectively and were obtained 
in the course of routine patient care. They were isolated from sputum samples after 
digestion and decontamination with the sodium hydroxide N-acetyl-L-cystein (NaOH-
NALC) method (Leão et al, 2004). All mycobacterial strains were grown in Middlebrook 
7H9 (M7H9) broth supplemented with OADC (oleic acid albumin dextrose catalase) 
(Difco-BD, Sparks, MD, USA), 0.5% glycerol and 0.05% Tween 80 with agitation, or on 
M7H10 plates supplemented with 10% OADC (Merck Chemicals, Darmstadt, Germany), 
0.5% glycerol and 0.05% Tween 80, or on Löwenstein-Jensen (LJ) slopes (Diagnostic 
Media Products, Johannesburg). Mycobacterial strains were stored at -80oC in Dubos 
medium (BD-Difco Laboratories, Sparks, MD, USA) (800µl Dubos stock [1.3g Dubos 
broth base, 30ml glycerol, 170ml distilled water] plus 800µl culture medium) until they 
were required for testing. E. coli DH5α  strains were grown in Luria-Bertani (LB) broth 
with agitation or on LB agar plates (Sigma-Aldrich, Steinheim, Germany) supplemented 
43 
 
with 100µg/ml of ampicillin (Sigma-Aldrich, Steinheim, Germany). The bacteria were 
grown at 25, 30 or 37oC. 
 
2.3 DNA Preparation 
Genomic DNA used in this study was primarily prepared either by the thermolysis of 
bacteria cells in TE buffer (as described under Section 2.4.3.1) or by the CTAB method. 
The main method utilised for genomic DNA preparation was the modified CTAB 
(cetyltrimethylammonium bromide) method (Ausubel et al, 2001). Briefly, a loopful of 
mycobacterial cells from the LJ slopes were transferred into a microcentrifuge tube 
containing 400µl of 1x TE buffer (10mM Tris-HCl [pH 8.0], 0.mM EDTA [pH 8.0]). The 
cells were first heat-killed at 80oC for 20min and cooled at room temperature. Lysozyme 
(Sigma-Aldrich, Steinheim, Germany) was added at the final concentration of 2mg/ml and 
the tube was incubated overnight at 37oC. Seventy microlitres of sodium dodecyl sulphate 
(SDS) and 5µl of 10mg/ml proteinase K (Sigma-Aldrich, Steinheim, Germany) were 
added, and the mixture was incubated for 10min at 65oC. One hundred microlitres of 5M 
sodium chloride and 100µl CTAB/sodium chloride (4.1g sodium chloride, 10g CTAB up 
to 100ml distilled water) were added and incubated for 10min at 65oC. Seven hundred and 
fifty microlitres of chloroform/isoamyl alcohol (24:1) (Merck Chemicals, Darmstadt, 
Germany) were then added, vortexed and centrifuged for 5min at 14 000rpm. The aqueous 
supernatant was transferred to a fresh tube and 0.6 volume of isopropanol were added to 
precipitate the DNA. After 30min at -20oC and centrifuging for 15min at 14 000rpm, the 
pellet was washed once for 5min with 1ml of cold 70% ethanol, air-dried and dissolved in 
50µl of  1x TE buffer. The concentration of DNA was estimated by ultraviolet 
spectroscopy at 260nm. A DNA sample with an optical density (OD) of 1 at 260nm 
corresponded to a DNA concentration of 50µg/ml of double-stranded DNA. The purity of 
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the DNA was determined by a DNA/protein absorbance ratio of 260nm/280nm. The DNA 
was stored at -20oC until required. 
 
2.4 Identification of Potential Sources of M. kansasii Infection  
2.4.1 Collection and Processing of Water and Biofilm Samples 
Water and biofilm samples were collected randomly from drinking water taps in mine 
hostels, change rooms, kitchens, boreholes, shower-heads, piped underground water and 
dams. The taps and showerheads were run for about 1min to clear the service lines prior to 
sample collection. At each collection site, water samples were collected in 1 litre sterile 
polyethylene bottles each containing 20mg of sodium thiosulphate to neutralise residual 
chlorine (Clesceri et al, 1999). Biofilms were collected by scraping interior surfaces of 
either taps or shower-heads with a sterile cotton-tipped swab and transferred to a 2ml 
solution of Ringer’s solution (8.6g sodium chloride, 0.3g potassium chloride, and 0.33g 
calcium chloride per litre of water). A total of 27 water and 29 biofilm samples were 
obtained from the Vaal River gold-mining region, while 17 water and 15 biofilm samples 
were obtained from the Secunda coal-mining complex. Immediately after collection, all 
samples were placed in a cool box containing ice packs for transportation to the laboratory 
where they were stored at 4oC until processed. The samples were processed within 48hrs 
of collection. Briefly, 1 litre of water was filtered through 0.45µl nitrocellulose membrane 
filters (Millipore Corporation, Bedford, MS, USA) by vacuum filtration using a Manifold 
Filtration System (Sartorius AG, Goettingen, Germany). The membranes were transferred 
into sterile screw-capped specimen containers with 10ml of 0.005% cetylpyridinium 
chloride (CPC) (Sigma-Aldrich, Steinheim, Germany) to reduce background organism 
levels. The surface of the membranes were abraded vigorously and thoroughly with a 
sterile platinum inoculating loop and cup-sonicated in a Brunson 1200 Sonifier (Brunson 
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Cleaning Equipment Company, Shelton, CT, USA) at 47kHz for 5min. Biofilm samples 
were first vortexed to dislodge bacteria from the swabs, centrifuged and the pellet 
resuspended in 10ml of 0.005% CPC. Both the water and biofilm samples were then 
exposed to the decontaminant at room temperature for 30min on a shaking platform. The 
decontaminated solution was then transferred into 15ml screw-capped tube, centrifuged at 
3800rpm for 20min, the deposit washed twice with 1ml sterile normal saline and 
resuspended in 500µl of normal saline.  
 
The choice and detection limit of the decontamination method for the isolation of M. 
kansasii from water was determined by comparing five of some of the commonly used 
decontamination methods. These included the use of 1% sodium hydroxide plus 3% 
sodium dodecyl sulphate, 2% NaOH plus 3% SDS, 3% NaOH plus 3% SDS and 4% 
NaOH plus 3% SDS and 0.005% CPC on a culture of M. kansasii ATCC 12478. One litre 
of sterile water was spiked with fresh liquid culture of M. kansasii to obtain final 
concentrations of 101, 102, 103, 104 and 105 colony forming units (CFU) per litre. The 
water samples were treated as described above. As compared to the other decontaminants, 
CPC was able to detect the presence of low levels of bacteria (102) and was thus selected 
as the ideal decontaminant for this work. 
 
2.4.2 Isolation and Identification of Mycobacteria 
One hundred microlitres of each of the resuspended decontaminated samples (from 
Section 2.2.1 above) were inoculated in triplicate on the surface of M7H10 agar medium 
(BD-Difco Laboratories, Sparks, MD, USA) supplemented with 10% OADC (Merck 
Chemicals, Darmstadt, Germany). The remaining pellets were used to make smears on 
microscope slides for acid-fast staining and for direct PCR screening of M. kansasii. The 
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plates were sealed with Parafilm (Pechiney Plastic Packaging Company, Chicago, IL, 
USA) and incubated at 25, 30 and 37oC. The plates were examined every 2 days for the 
first 10 days and once a week thereafter for 2 months until considered negative. The 
number of colonies per litre or per swab of the original sample and colony type were 
noted. Single colonies of putative acid-fast bacteria, stained by the Ziehl-Neelsen (ZN) 
method, were picked and subcultured on LJ medium (Diagnostic Media Products, 
Johannesburg, South Africa). Identification to species level was done by biochemical tests, 
which included production of catalase, nitrate reductase, pyrazinamidase and Tween 80 
hydrolysis tests (Leão et al, 2004) and by molecular methods described below.  
 
The identity of M. kansasii clinical isolates was carried out and confirmed by West Vaal 
Hospital Tuberculosis Laboratory according to standard procedures such as morphology, 
growth rate, biochemical tests and by the use of the AccuProbe Assay (Gen-Probe, San 
Diego, CA, USA). 
 
2.4.2.1 PCR Screening of M. kansasii isolates 
In order to help in confirming the identity of M. kansasii strains obtained from both 
clinical and environmental sources, a M. kansasii-specific PCR identification method was 
employed, as it proved to be a rapid and cheaper alternative to the biochemical tests and 
the AccuProbe test. The test was performed on both decontaminated water and biofilm 
sample deposits and on isolated acid-fast colonies. This assay utilises primers, Fw1 (5’-
CGGCCATTGTTCTACAGTCT-3’) and Rv1 (5’-TAGAGATCCTCGCTTTGGT-3’) that 
result in a 167bp PCR product. The primer sequences were freely accessed from 
http://www.freepatentsonline.com/ EP1881068.html (“Primer and probe for use in 
detection of Mycobacterium kansasii and method for detection of Mycobacterium kansasii 
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using the same”). Briefly, a loopful of mycobacterial growth was suspended in 400µl of 
TE-Triton X-100 buffer (10mM Tris, 1mM EDTA, pH 8.0, 1% Triton X-100) in a 
microcentrifuge tube and boiled for 15min. The lysate was subjected to three 10min cycles 
of freeze-thaw cycles, centrifuged for 5min at 10 000rpm and the supernatant subjected to 
PCR with the M. kansasii-specific primers. The amplification was achieved by the 
addition of 5µl of the supernatant DNA to a reaction mixture containing 200µM of each 
deoxynucleoside triphosphate (dNTP), 1µM of each primer, 1x Mastermix (50mM KCl, 
10mM Tris-HCl [pH 8.3], 1.5mM MgCl2, 0.001 [wt/vol] gelatine, and 1.25U of Taq 
polymerase [Fermentas Life Sciences, Glen Burnie, MD, USA]) in a total volume of 25µl. 
The reaction tube was first heated for 5min at 94°C and then subjected to 35 cycles of 
amplification for 1min at 94°C, 1min at 57°C, 1min at 72°C, followed by a 10min 
extension step at 72°C on an iCycler Thermocycler (Bio-Rad, Hercules, CA, USA). The 
presence of the 167bp amplicon was detected by electrophoresis of 5µl of the amplicon on 
a 1.5% SeaKem LE agarose gel (Lonza, Rockland, ME, USA). The specificity of these 
primers was assessed by including DNA samples from other mycobacterial strains: M. 
gastri, M. tuberculosis, M. bovis, M. scrofulaceum, M. gordonae, M. avium, M. 
intracellulare, M. xenopi, M. fortuitum, M. abscessus, M. peregrinum and M. chelonae. 
None of these mycobacterial species was PCR-positive with the M. kansasii-specific 
primers. 
 
2.4.3.2 PCR-Restriction Analysis 
Polymerase Chain Reaction-Restriction Analysis (PRA) was primarily employed to assist 
in the subtyping of M. kansasii isolates and was carried out as described previously 
(Telenti et al, 1993). The test was carried out in three stages: genomic DNA was prepared 
in the form of supernatants, subjected to PCR amplification by targeting the heat shock 
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protein 65 gene (hsp65 gene) and the resulting amplicons analysed by restriction enzymes. 
The results of the restriction fragments were then evaluated with the help of a published 
algorithm (Devallois et al, 1997; Chimara et al, 2008) and compared to PRASITE 
(http://app.chuv.ch/parasite/index.html), an internet database maintained by the Swiss 
National Centre for Mycobacteria.  
 
2.4.3.2.1 DNA Extraction and PCR Amplification of the hsp65 Gene 
Genomic DNA was prepared in the form of thermolysates as described under section 
2.2.3.1 above. The hsp65 gene was amplified from the cell supernatants by PCR using 
primers Tb11 (5'-ACC AAC GAT GGT GTG TCC AT-3') and Tb12 (5'-CTT GTC GAA 
CCG CAT ACC CT-3'), which result in a 441bp amplicon (Telenti et al, 1993).  
 
The PCR was carried out in a final volume of 50µl consisting of 10µl of DNA and 40µl of 
PCR premixed solution containing 200µM of each dNTP, 1µM of each primer, 1x 
Mastermix (Fermentas Life Sciences, Glen Burnie, MD, USA). DNA from M. kansasii 
type strain ATCC 12478 was used as a positive control while deionised water was used as 
a negative control. The reaction tube was first heated for 10min at 94°C and then subjected 
to 45 cycles of amplification for 40s at 94°C, 50s at 60°C, 1min at 72°C, followed by a 
10min extension step at 72°C on an iCycler Thermocycler (Bio-Rad, Hercules, CA, USA). 
The presence of the 441bp amplified product was detected by electrophoresis of 5µl of the 
amplicon on a 1.5% SeaKem LE agarose gel (Lonza, Rockland, ME, USA).  
 
2.4.3.2.2 Enzyme Restriction and Analysis of the hsp65 gene PCR products 
Twenty microlitres of PCR products were digested separately with 10U of BstEII and 
HaeIII (Fermentas Life Technologies, Glen Burnie, MD, USA) in 1x restriction buffer 
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(Fermentas Life Sciences, Glen Burnie, MD, USA) in sterile deionised water. The reaction 
mixtures were incubated for 3hr at 60°C for the BstEII digestions and at 37°C for the 
HaeIII digestions. Restriction patterns were analysed by agarose gel electrophoresis. 
Briefly, samples were prepared for electrophoresis by adding 3µl of 6x gel loading buffer 
(Fermentas Life Sciences, Glen Burnie, MD, USA) to 22µl of the digest and loaded onto a 
3% SeaKem LE agarose gel (Lonza, Rockland, ME, USA) containing 0.5µg/ml ethidium 
bromide. A 50bp marker (Fermentas Life Sciences, Glen Burnie, MD, USA) was loaded 
on opposite sides and centre of the gel and was used for sizing the resulting fragments. 
The gel was prepared and electrophoresed in 0.5x Tris-Borate-EDTA (TBE) 
electrophoresis buffer (10x buffer: 108g Tris, 55g boric acid, 9.3g EDTA in a litre of 
water [pH 8.0]) for 60 min at 100V, 300mA. After electrophoresis, the gels were imaged 
on a Gel Doc XR Documentation System (Bio-Rad Laboratories, Hercules, CA, USA). 
For the analysis and interpretation of the PRA patterns, Quantity One Software version 
4.6.8 (Bio-Rad, Hercules, CA, USA) that converts the migration distance in millimetres to 
apparent molecular size in base pairs, was used. The results for the restriction fragments 
were then evaluated with the help of a published algorithm (Devallois et al, 1997; Chimara 
et al, 2008) and compared to PRASITE (http://app.chuv.ch/parasite/index.html), an 
internet database maintained by the Swiss National Centre for Mycobacteria. Any 
restriction fragment below 50bp was disregarded in order to avoid confusion with primer-
dimer bands.  
 
2.4.3.3 DNA Sequencing 
To confirm the identity of the mycobacteria detected, DNA sequencing of the 
mycobacterial hsp65, secA1, gyrB genes or 16S-23S rDNA Internal Transcribed Sequence 
(ITS) was performed. The genes were first amplified by PCR in a final volume of 50µl 
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containing 10µl of mycobacterial thermolysate, prepared as described under Section 
2.2.3.1 above, and 40µl PCR master mix: 200µM of each dNTP, 2µM of each primer 
(Tb11 and Tb12 for the hsp65 gene or ITS1, 5’-GATTGGGACGAAGTCGTAAC-3’ and 
ITS2, 5’-AGCCTCCCACGTCCTTCATC for the ITS gene [Roth et al, 2000] or RPO5, 
5´-TCAAGGAGAAGCGCTACGA-3´ and RPO3, 5´-GGATGTTGATCAGGGTCTGC-
3´ for the gyrB gene [Lee et al, 2003] or MtuF, 5’-GACAGYGAGTGGATGGGYCGS 
GTGCACCG-3’ and MtuR, 5’-ACCACGCCCAGCTTGTAGATCTCGTGCAGCTC-3’ 
for the secA1 gene [Zelazny et al, 2005]), 1x Mastermix (50mM KCl, 10mM Tris-HCl 
[pH 8.3], 1.5mM MgCl2, 0.001 [wt/vol] gelatine, and 1.25U of Taq polymerase 
[Fermentas Life Sciences, Glen Burnie, MD, USA]). The reaction tube was first heated for 
10min at 95°C and then subjected to 35 cycles of amplification for 1min at 95°C, 1min at 
60°C (for the Tb and RPO primers) or 57°C (for the ITS primers) or 65°C (for Mtu 
primers), 1min at 72°C, followed by a 10min extension step at 72°C on an iCycler 
thermocycler (Bio-Rad, Hercules, CA, USA). The presence of the 480, 441, 700 and 
360bp amplified products for the ITS sequence, hsp65, secA1 and gyrB genes, 
respectively, was detected by electrophoresis of 5µl of the amplicons on a 1.5% SeaKem 
LE agarose gel (Lonza, Rockland, ME, USA).  
 
Prior to sequencing, the PCR products were first purified from agarose gels with the 
QIAquick PCR Purification Kit (Qiagen GmbH, Hilden, Germany) following the 
manufacturer’s instructions. Forward and reverse linear amplification was performed in 
10µl using 2µl of the purified PCR product (about 20 to 200ng), 2µl BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), 1µl BigDye 
Sequencing Buffer (Applied Biosystems, Foster City, CA, USA) and 1µM of Tb11 or 
Tb12 or ITS1 or ITS2 or RPO5 or RPO3 or MtuF or MtuR primer. Linear amplification 
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consisted of 25 cycles of denaturation at 96oC for 10s, annealing at 60oC for 30s and 
elongation at 72oC for 60s using the iCycler Thermocycler (Bio-Rad, Hercules, CA, 
USA). Fluorescence-labelled DNA was purified using the ethanol precipitation method 
(Ausubel et al, 2001). Briefly, the entire extension products were transferred into 80µl of 
freshly prepared precipitation solution (3µl of 3M sodium acetate [pH 4.6], 62.5µl of non-
denatured 95% ethanol and 14.5µl deionised water), incubated for at least 1hr at room 
temperature and centrifuged at 14000rpm for 20min. After carefully removing the 
supernatant, 250µl of 70% ethanol was added to the pellet, vortexed and the contents re-
centrifuged at 14000rpm for 8min. The ethanol was carefully aspirated and the pellet air-
dried for 15min at room temperature. The samples were analysed at the Inqaba 
Biotechnical Industries Sequencing Facility (Pretoria, South Africa) on an ABI PRISM 
3730XL DNA analyser (Applied Biosystems, Foster City, CA, USA). The DNA sequence 
reads were edited using Ridom TraceEdit software (Ridom Bioinformatics GmbH, 
Würzburg, Germany) and used to search the National Center for Biotechnology 
Information (NCBI) RefSeq database using BLASTN software 
(http://www.ncbi.nlm.nih.gov/BLAST). A distance score of 0.00% to less than 1.00% was 
used as the criteria for species identity. 
 
2.5 Determination of Genetic Diversity Amongst Clinical and Environmental Isolates 
of M. kansasii by Macrorestriction Analysis using PFGE 
The M. kansasii clinical isolates were first subtyped by PRA of the hsp65 gene as 
described in Section 2.4.3.2. Confirmation of M. kansasii isolates not showing the typical 
M. kansasii restriction patterns was carried out by DNA sequencing of the secA1 and gyrB 
genes, and the ITS spacer region. The predominant subtype, subtype 1, was then subjected 
to further analysis by macrorestriction analysis as described below.  
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To assess the clonal relationships amongst the subtype I M. kansasii clinical and 
environmental isolates, an analysis of chromosomal DNA restriction patterns was 
performed by Pulsed-Field Gel Electrophoresis (PFGE) (Chapter 4). DNA for PFGE was 
prepared from stirred broth cultures as previously described (Hughes et al, 2001).  
 
 
Figure 2.2. An IKAMAG (IKA-Werke GmbH & Co.KG, Staufen, Germany) multiple position magnetic 
stirrer used in the culture of M. kansasii isolates for PFGE analysis. Ten millilitre cultures, contained in 
universal containers, were stirred continuously using magnetic stirrer bars on an IKAMAG to prevent 
clumping (Adapted from Hughes et al, 2001). 
 
2.5.1 Preparation of Agarose Plugs 
Briefly, loopfuls of each isolate were inoculated into 10ml of Middlebrook 7H9 broth 
(BD-Difco Laboratories, Sparks, MD, USA) supplemented with 10% oleic acid-albumin-
dextrose-catalase (OADC) (Merck Chemicals, Darmstadt, Germany), 0.05% Tween 80 
and 2.5% glycerol in 30ml sterile plastic disposable universal containers. After adding 
sterile magnetic stirring bars (12 x 6mm) to the containers and sealing them with parafilm, 
they were placed on a 15 Point IKAMAG Magnetic Stirrer (IKA-Werke GmbH & Co.KG, 
Staufen, Germany) (Figure 2.2) and incubated at 37oC for about 7 days or until turbid 
(OD550nm 2.0). Two millilitres of cells were harvested at room temperature by 
centrifugation at 3800rpm for 20min and resuspended in 500µl spheroplasting buffer 
(20mM citrate phosphate buffer, pH 5.6 [0.2M citric acid, 0.5M disodium hydrogen 
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phosphate], 50mM EDTA and 0.1% (w/v) Tween-80). After warming the cell suspension 
to 55oC for 15min in a waterbath, an equal volume (500µl) of 1.5% low melting agarose 
(Bio-Rad Laboratories, Hercules, CA, USA) in 50mM EDTA was added and the mixture 
was then poured into pre-cooled moulds (Bio-Rad Laboratories, Hercules, CA, USA) and 
allowed to set for approximately 20 to 30min. The cells in the agarose plugs were 
incubated in freshly prepared Tris-EDTA (TE) buffer (pH 8.0) containing 4mg/ml of 
lysozyme (Sigma-Aldrich, Steinheim, Germany) for at least 48hrs at 37°C and then in 
freshly prepared ESP solution (2mg/ml proteinase K and 1% N-lauryol sarcosine [Sigma-
Aldrich, Steinheim, Germany] in 0.5M EDTA, pH 8.0) for 7 days at 55°C.  At the end of 
the incubation period, the plugs were topped up with 2ml 0.5M EDTA, sealed with 
parafilm and stored at 4oC until required. 
 
2.5.2 DNA Quality Check 
Plugs were gently transferred to a Petri dish and 3mm sections were cut with a scalpel 
blade. The plug sections were transferred into microcentrifuge tubes and gently washed 3 
times (10min each) in 1ml TE buffer on a shaking platform. The plugs were then 
transferred to other tubes with as little TE buffer as possible. The remaining TE buffer was 
spun down, removed with a pipette and the tube placed in a 70oC waterbath for 
approximately 1min to melt the sections. The sample was mixed thoroughly and 30µl 
loaded onto a 1% agarose mini gel in 0.5x TBE. The gel was electrophoresed at 70V for 
approximately 30min. Upon examination, the intact DNA appeared as a distinct band 
close to the wells while degraded DNA appeared as a smear. 
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2.5.3 Restriction Endonuclease Digestion  
Slices 5mm thick were cut from the plugs in Petri dish, washed 7 times with 1hr changes 
in TE buffer (pH 8.0), pre-equilibrated in 300µl of 1x restriction buffer containing 
0.1mg/ml BSA (Fermentas Life Sciences, Glen Burnie, MD, USA) for 1hr at room 
temperature and then incubated in 100µl of 1x restriction buffer containing 0.1mg/ml BSA 
and 30U DraI (Fermentas Life Sciences, Glen Burnie, MD, USA). After overnight 
incubation at 37°C, fresh restriction reaction mixture was added and incubated for a 
further 4 to 6hrs to ensure complete digestion of the samples.  
 
2.5.4. Electrophoresis 
The restricted sample was loaded onto a 1% (wt/vol) low-meting point agarose gel (Bio-
Rad Laboratories, Hercules, CA, USA) in 0.5x TBE (10x stock: 89mM Tris, 89mM boric 
acid, 2mM EDTA [pH 8.0]), sealed with 1% agarose in 0.5x TBE and allowed to set.  PFG 
MidRange II DNA markers (New England BioLabs, Ipswich, USA) were loaded onto gels 
as molecular size standards and the gel was pre-equilibrated for 1hr at 14°C in a CHEF-
DRIII electrophoretic tank (Bio-Rad Laboratories, Hercules, CA, USA) filled with 2 litres 
of 0.5x TBE. The gel was then run for 40hrs at 14oC using the following parameters: 
angle, 120°; gradient, 6v/cm; pump setting, 70pmb; ramp, linear; and switch times, 6.75 to 
35.38s. The parameters were selected to separate fragments in the range 30 to 400kb. 
Following electrophoresis, the gels were stained with 0.5µg/ml ethidium bromide for 
30min, and after destaining for 30min, the gels were imaged with a Gel Doc XR 
Documentation System (Bio-Rad Laboratories, Hercules, CA, USA).  
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2.5.5 Macrorestriction Pattern Analysis 
A TIFF image of each gel was exported to the Gel Compar 6.0 System (Applied Maths, 
Kortrijk, Belgium) for analysis. A PFG MidRange II DNA marker (New England 
BioLabs, Ipswich, Glen Burnie, USA) was included on each gel to facilitate molecular 
weight assignments and inter-gel comparisons. For inter-gel comparisons, the two 
outermost and centre lanes of each gel were used. 
 
2.6 Identification of Genetic Differences Between Clinical and Environmental 
Isolates of M. kansasii 
Hybridisation-Monitored Genome Differential Analysis (HMDA) was used to directly 
detect and clone genomic differences between M. kansasii subtype I (tester) and the other 
selected M. kansasii subtypes III, V and VI (driver) with a view to identifying unique or 
divergent sequences found in subtype I. HMDA is a PCR-based solid subtractive 
hybridisation method that utilises a ribosomal DNA (rDNA) monitoring system to tract the 
entire subtraction process between two DNA populations (Yueqing et al, 2006). The 
selection of M. kansasii subtype I as the target strain was based on the fact that it is the 
most frequently isolated subtype from human clinical samples and is generally considered 
to be pathogenic as compared to the other subtypes (Zhang et al, 2004; Goh et al, 2006). 
 
2.6.1 Preparation of Tester DNA 
2.6.1.1 Restriction of Tester DNA 
M. kansasii subtype I clinical isolate genomic DNA was used as the tester DNA in the 
subtraction process. To prepare the tester DNA for hybridisation, the DNA was digested 
with Tsp509I (New England BioLabs, Ipswich, MA) as previously described (Yueqing et 
al, 2006). Tsp509I creates 5’-AATT overhangs on genomic DNA fragments that allow 
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subsequent ligation to compatible ends, in this case an adapter molecule. Four micrograms 
of genomic DNA was digested in total volume of 50µl containing 10U of Tsp509I and 1x 
Tsp509I restriction buffer 1 (New England BioLabs, Ipswich, MA, USA) in deionised 
water. The reaction was incubated at 65oC for 4hr. The efficiency of digestion was 
assessed by running 5µl of the digest mixture on a 1% gel. 
 
2.6.1.2 Purification of Tester DNA 
The digested DNA was then purified using the phenol-chloroform method. Briefly, 50µl 
of phenol/chloroform/isoamyl alcohol (24:24:1) (Merck Chemicals, Darmstadt, Germany) 
were then added, vortexed and centrifuged for 10 min at 14 000rpm at room temperature. 
The aqueous supernatant was carefully collected and transferred to a fresh tube. Fifty 
microlitres of chloroform/isoamyl alcohol (24:1) (Merck Chemicals, Darmstadt, Germany) 
were then added, vortexed and centrifuged for 5 min at 14 000rpm. The 
chloroform/isoamyl extraction process was repeated. The resulting aqueous supernatant 
was transferred to a fresh tube and 0.5 volume of 4M ammonium acetate and 2.5 (of the 
resulting volume) of 95% ethanol were then added to precipitate the DNA. After 
thoroughly vortexing and centrifugation at 14 000rpm for 20min, the pellet was washed 
once for 8min at 14 000rpm with 200µl of 70% ethanol, air-dried and dissolved in 30µl of  
1x TE buffer . The DNA was stored at -20oC until required. 
 
2.6.1.3 Preparation of Adaptor DNA 
The next step in the preparation of the tester DNA involved ligation of a phosphorylated 
adaptor to the digested tester (M. kansasii subtype I) DNA. This adaptor molecule was 
used as a target for PCR amplification of the tester DNA. Two oligonucleotides, 5’-CGG 
GTA CCG AGC TCG-3’ and 5’-AAT TCG AGC TCG GTA CCC G-3’ (phosphorylated 
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at the 5’ end) (Yueqing et al, 2006), from a commercial source were annealed as follows: 
40µl of each of the 5µM oligonucleotides (to give a final concentration of 2µM) were 
mixed in a microcentrifuge tube containing 10µl annealing buffer (10mM Tris, pH 8.0, 
50mM NaCl, 1mM EDTA) and 10µl deionised water. The oligonucleotides were then 
boiled in a beaker of water for 5min and allowed to cool slowly to room temperature to 
permit them to anneal and avoid single-stranded oligonucleotides to self-anneal.  
 
2.6.1.4 Ligation of Adaptors to Tester DNA 
One hundred to five hundred nanograms of tester DNA were mixed with 5l of the 
annealed phosphorylated linkers in tube containing 2U of T4 DNA ligase (0.4l) and 1x 
ligation buffer (Promega, Madison, WI, USA) in total volume of 20l. The tube contents 
were briefly vortexed, spun for 3-5s at high speed and incubated overnight at 4°C. 
Inactivation of the DNA ligase was achieved at 65°C for 10min. The ligation mixture was 
then used in the hybridisation experiment. 
 
2.6.1.5 PCR Verification of Tester-Adaptor Ligation 
This was performed to verify the presence or absence of the ligated adaptors on the tester 
genomic DNA using an adaptor-specific primer P1 primer (5’-CGG GTA CCG AGC TCG 
AAT T-3’) (Yueqing et al, 2006). This PCR amplification step was also used for selecting 
tester DNA-specific sequences after hybridisation with the Driver genomic DNA. The 
amplification of the tester DNA was achieved by the addition of 100 to 500ng of the 
template DNA to a reaction mix containing 10mM potassium chloride, 50mM Tris-HCl, 
pH8.3, 2U FastStart Taq DNA polymerase (Roche Applied Science, Mannheim, 
Germany), 1x GC-rich solution, 5mM ammonium sulphate, 200M of each dNTP, 2mM 
magnesium chloride, 1M P1 primer in a total volume of 25l. Thermal cycling was 
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performed on a Bio-Rad iCycler thermocycler using a programme consisting of an initial 
melting phase of 5 min at 94°C, followed by 25 cycles of a 30s melt at 94°C, annealing of 
30s at 60°C and extension of 2min at 72°C, then a final extension hold for 10min at 72°C. 
 
2.6.2 Preparation of Driver (Blocking) DNA  
M. kansasii subtypes III, V and VI were selected and used for the preparation of driver 
genomic DNA. About 30g/ml of the DNA was fragmented by heating to 95°C on a Bio-
Rad iCycler thermocycler. Briefly, the DNA in 100µl of TE buffer was subjected to heat 
at 95°C using a time series of 5 to 45min to generate fragments between 1 to 5kb. The size 
of the fragments was ascertained on a 1% agarose gel. The DNA fragments were 
precipitated with equal volumes of 4M ammonium acetate and 100% ethanol, and 
dissolved in 30µl TE buffer (Shanks et al, 2006a). The DNA was then denatured with 
4mM sodium hydroxide and 100mM EDTA, to a final concentration of 0.4mM and 
10mM, respectively, and incubated for 5min at room temperature. Two microlitres of the 
denatured driver DNA were transferred onto each side of a 6mm diameter Hybond N+ 
nylon membrane disc (Amersham Biosciences, Buckinghamshire, UK) pre-wetted with 
distilled water. The wet discs were exposed to ultraviolet (UV) radiation for 3 to 5min to 
allow the DNA to bind covalently to the membrane. The discs were then baked for 1hr at 
80oC. The discs were rinsed twice for 1 hr (30 min x 2) with 5x SSC and twice again with 
2x SSC (30 min x 2) at 60oC. The washings were retained for detection of rDNA by PCR. 
This helped to confirm whether or not the driver DNA was removed from the discs. The 
quantity of driver DNA immobilised on each disc was the difference between the amount 
of DNA initially loaded onto the disc and the amount found eluted during the washing 
process (Yueqing et al, 2006). The discs were dried, sealed and store at 4oC until required. 
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2.6.3 Subtractive Hybridisation and Monitoring 
The methodology for subtractive hybridisation was performed as previously described 
with some modifications (Yueqing et al, 2006). The tester DNA, in 5x SSC buffer, was 
first denatured by heating to 95oC for 5min and rapidly cooling on ice. Hundred 
microlitres of the denatured DNA were transferred to a 96-well flat-bottomed microtitre 
plate containing a nylon disc with immobilised driver DNA. Adjacent wells were filled 
with distilled water to avoid evaporation of the hybridisation buffer. The hybridisation 
process was carried out on an MS1 Microtitre Plate Minishaker (400rpm) (IKA Works 
Inc, Wilmington, NC, USA) at 60oC for 24 to 30hrs. Ten microlitre samples were 
collected after every 4hrs for 16S rDNA analysis and the hybridisation process repeated by 
heat-denaturing the liquid phase containing the tester and by adding the liquid to a new 
well with a new disc. The hybridisation process was monitored by PCR analysis of the 
partial sequence of the 16S rDNA of the tester using primer pairs BC70 and BC71. The 
PCR was carried out in a total volume of 25µl containing 200µM of each dNTP, 2µM of 
each primer (BC70, 5’-TAACACATGCAAGTCGAACG-3’ and BC71, 5’-
CGTATTACCGCGGCTGCTGG-3’ for the 16S rRNA gene, 1x Mastermix (50mM KCl, 
10mM Tris-HCl [pH 8.3], 1.5mM MgCl2, 0.001 [wt/vol] gelatine, and 1.25U of Taq 
polymerase [Fermentas Life Sciences, Glen Burnie, MD, USA]). The reaction tube was 
first heated for 10min at 95°C and then subjected to 35 cycles of amplification for 1min at 
95°C, 1min at 61°C, 1min at 72°C, followed by a 10min extension step at 72°C on an 
iCycler thermocycler (Bio-Rad, Hercules, CA, USA). The presence of the 475bp was 
detected by electrophoresis of 5µl of the amplicons on a 1.5% SeaKem LE agarose gel 
(Lonza, Rockland, ME, USA).  
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After completion of subtraction of homologous sequences, a minimum of five P1 single 
primer PCR amplifications in 50µl volumes, as described under Section 2.5.1.5 were 
carried out using the FastStart High Fidelity Taq DNA polymerase (Roche Applied 
Science, Mannheim, Germany). After pooling the PCR products, the amplicons were then 
purified using a QIAquick PCR Product Clean-up Kit (Qiagen GmbH, Mannheim, 
Germany) according to the manufacturer’s instructions.  
 
2.6.4 Cloning of Enriched Tester PCR Products 
The purified PCR products were ligated into a pGEM T-Easy vector (Promega, Madison, 
WI, USA). The purified insert and vector were mixed at a ratio of 3:1, respectively, and 
ligated overnight at 4oC in a total volume of 10µl containing 1U of T4 DNA ligase and 1x 
ligase buffer (Promega, Madison, WI, USA). A ligation control consisting of a linearised 
vector was also set up to monitor the reaction. Inactivation of the DNA ligase was 
performed at 65oC for 15min. The ligation products were then used to transform 
competent DH5α E. coli cells (Invitrogen Life Technologies, Paisley, UK). 
 
2.6.5 Transformation of Competent Cells 
Fifty microlitres of DH5α E. coli competent cells (Invitrogen Life Technologies, Paisley, 
UK) were gently mixed with 2µl of the ligation mix in a pre-cooled microcentrifuge tube 
by flicking the bottom of the tube and left on ice for 30min. The cells were then subjected 
to heat shock at 42°C without shaking for 30s and immediately transferred to ice for 2min. 
Phenotypic expression of the cells was allowed by the addition of 250µl of room 
temperature antibiotic-free SOC (Super Optimal Catabolite repression) medium (2.0g 
tryptone, 0.5g yeast extract, 1ml 1M NaCl, 0.25ml 1M KCl, 1ml 2M Mg2+ stock, 1ml 2M 
glucose up to 100ml, final pH 7.0) (Invitrogen Life Technologies, Paisley, UK), 
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incubating and shaking the tubes horizontally at 150rpm for at least 1hr at 37°C. The 
transformed cells were then selected by plating 50µl aliquots of each transformation 
reaction onto pre-warmed duplicate Luria-Bertani (LB) agar plates (Sigma-Aldrich, 
Steinheim, Germany) containing 100µg/ml ampicillin (Sigma-Aldrich, Steinheim, 
Germany), 100µl 100mM isopropyl -D-1-thiogalactopyranoside (IPTG) and 50µl 
20mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Promega, Madison, 
WI, USA). The plates were incubated overnight at 37°C and examined for growth of white 
and blue colonies. White colonies were further analysed as these generally contain inserts. 
 
2.6.6 Screening of Cloned DNA Fragments  
2.6.6.1 PCR Screening  
In order to detect the presence of the cloned PCR inserts in the vector, PCR was directly 
performed on lysed bacterial colonies using the P1 primer (sequence information under 
Section 2.6.1.5).  Briefly, template DNA was prepared by picking fresh single bacterial 
colonies from the LB plates with sterile tooth picks and suspending them in 50µl of sterile 
distilled water in microcentrifuge tubes. The suspension was boiled for 15min, centrifuged 
and 5µl of the resulting supernatant was used in the PCR reaction. The PCR conditions 
were set as described under Section 2.6.1.5. 
 
2.6.6.2 Enzymatic Analysis 
A single colony of the DH5α E. coli cells containing the pGEM T-Easy plasmid with the 
insert was used to inoculate 3ml of LB broth (Sigma-Aldrich, Steinheim, Germany) 
containing 100µg/ml ampicillin (Sigma-Aldrich, Steinheim, Germany) and grown in a 
shaking incubator overnight at 37oC. After centrifuging the cells at 3800rpm for 15min, 
the plasmid DNA was prepared using the Qiagen Spin Plasmid Miniprep Kit (Qiagen 
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GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The DNA 
concentration for each sample was estimated at A260nm in a spectrophotometer and stored 
at 20oC until required. 
 
Plasmid DNA from PCR positive clones were further analysed for the presence of the 
tester DNA inserts by EcoRI digestion. Briefly, plasmid DNA was digested in a total 
volume of 20µl containing 2µl DNA, 1x restriction buffer and 10U of EcoRI (Promega, 
Madison, WI, USA). After incubation for 2hrs at 37oC, the restriction fragments were 
separated on a 1% agarose gel and photographed. 
 
2.6.6.3 Dot Blot Hybridisation Analysis 
To determine the efficiency of the subtraction process, dot blot analysis was carried out 
using the subtracted tester DNA and driver DNA as probes. 
 
2.6.6.3.1 Probe Preparation 
Tester and driver DNA was prepared as described under Sections 2.5.1 and 2.5.2, 
respectively. For the preparation of the driver probe, a defined terminal sequence was first 
added to the fragmented genomic DNA. Briefly, about 10µl (about 100ng) of DNA in a 
microcentrifuge tube were boiled for 10min in beaker of water in the presence of 125µM 
K9 DNA primer (5’-GACACTCTCGAGACATCACCGGTACCNNNNNNNNN-3’) 
(Grothues et al, 1993; Shanks et al, 2006a) and 5µl of 10X Klenow buffer (Fermentas Life 
Sciences, Glen Burnie, MD, USA) in a total volume of 40µl. After cooling the tube on ice, 
the DNA was centrifuged briefly and 5U of DNA polymerase Klenow I fragment 
(Fermentas Life Sciences, Glen Burnie, MD, USA) and 3µl (0.33mM) dNTPs were added 
and the volume raised to 50µl with distilled water. The mixture was incubated at 37oC for 
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2hrs and the reaction stopped by heating at 75oC for 10min. The labelled DNA fragments 
were then purified with the QIAquick PCR Product Clean-Up Kit (Qiagen GmbH, Hilden, 
Germany).  
 
For tester DNA probe synthesis, the DNA was amplified using the P1 primer as it 
contained the attachment site for the primer (refer to Section 2.5.1.5) while driver DNA 
was amplified by the K9 PCR primer (5’-GACACTCTCGAGACATCACCGG-3’ 
(Grothues et al, 1993; Shanks et al, 2006a) using the Digoxigenin (DIG) Labelling Kit 
(Roche Applied Sciences, Mannheim, Germany) according to the manufacturer’s 
instructions. The probes were then purified with a QIAquick PCR Product Clean-Up Kit 
(Qiagen GmbH, Hilden, Germany). Approximately 1µg of the probe was added to the 
hybridisation solution (5x SSC buffer, 0.1% N-lauroyl sarcosine, 1% blocking reagent 
[skimmed milk powder dissolved in maleic acid buffer {0.1M maleic acid and 0.15M 
sodium chloride, pH 7.5}], and 0.02% SDS) and stored at -20oC until required. 
 
2.6.6.3.2 Dot Blotting 
For dot blot analysis, inserts from positive clones were first amplified with the P1 primer. 
The PCR products were purified with the QIAquick PCR Product Clean-Up Kit (Qiagen 
GmbH, Hilden, Germany) and 10µl resuspended in 45µl of denaturation solution (0.5M 
sodium hydroxide, 1.5M sodium chloride). The denatured DNA from each clone was then 
applied to a separate well of a 48-well dot blot apparatus (Bio-Rad Laboratories, Hercules, 
CA, USA) and transferred under vacuum to a Hybond N+ membrane (Amersham 
Biosciences, Buckinghamshire, UK) which had been pre-equilibrated in 6x SSC buffer 
(prepared from 20x SSC buffer [3M sodium chloride, 0.3M sodium citrate, pH 7.0). The 
DNA was then neutralised with 20µl neutralisation solution (1M Tris-HCl, pH 8.0, 1.5M 
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sodium chloride), washed with 2x SSC buffer, the membrane air-dried and the DNA fixed 
by exposure to ultraviolet light for 3min on a transilluminator (Spectroline Corporation, 
New York, USA). Two membranes were prepared, one for probing with the tester probe 
and the other one for probing with the driver probe. 
 
2.6.6.3.3 DNA Hybridisation and Detection 
The nylon membranes were inserted into Thermo-Hybaid HB-OV-BS tubes (Thermo 
Hybaid, Middlesex, UK) containing 50ml pre-hybridisation solution (5x SSC buffer, 0.1% 
N-lauroyl sarcosine, 1% blocking reagent and 0.02% SDS) and pre-hybridised at 65oC for 
1.5hrs in a Mini Hybridisation Oven MK II (MWG-Biotech AG, Ebersberg, Germany). 
The DIG-labelled probes were denatured by boiling in water for 5min, rapidly chilled on 
ice, added to the hybridisation tubes to replace the prehybridisation solution, and left to 
hybridise to the immobilised DNA overnight at 65oC. The probes were carefully decanted 
into 15ml tubes and stored at -20oC for re-use. The membranes were first washed twice 
(15min each time) at room temperature on a mechanical shaker in a solution containing 2x 
SSC and 0.1% SDS, and twice again at 68oC with washing solution (0.5x SSC and 0.1% 
SDS) in hybridisation tubes for 15min each time. The membranes were then removed 
from hybridisation tubes, equilibrated in 1x washing buffer (0.3% Tween 20 in maleic acid 
buffer [0.1M maleic acid, 0.15M NaCl, pH 7.5]) for 1min at room temperature and 
blocked in 1x blocking solution (prepared from a 10x solution in maleic acid buffer) on a 
mechanical shaker for 30min at room temperature. The membranes were stained with anti-
digoxigenin-alkaline phosphatase antibody (Roche Applied Science, Mannheim, 
Germany), diluted 1:10 000 in 1x blocking reagent, for 30min at room temperature on a 
mechanical shaker. After washing twice with the wash buffer (15min each time) the 
membranes were equilibrated in detection buffer (100mM Tris-HCl, pH9.5, 100mM 
65 
 
sodium chloride) for 2min and sealed in a hybridisation plastic bag using leaving one side 
unsealed. Three millilitres of freshly prepared CSPD (sodium 3-{4-meth-oxyspiro[1,2-
dioxetane-2,2’-(5’-chloro) tricycle[3.3.1.13,7] decan phenyl phosphate) (Roche Applied 
Science, Mannheim, Germany) substrate solution (diluted 1:100 in 1x detection buffer) 
were added to each membrane, air bubbles removed and the remaining side of the bag 
sealed. The membranes were then incubated for 15min at room temperature. The substrate 
was expelled from the bags by rolling out the liquid using a disposable 10ml serological 
pipette through a hole cut at the top right hand corner of the bag. The bag was heat-sealed, 
wiped, transferred into a 24 x 30cm film cassette (Amersham Biosciences, 
Buckinghamshire, UK) and exposed to a high performance chemiluminescence film 
(Amersham Biosciences, Buckinghamshire, UK) at room temperature for about 15min in a 
dark room. The film was processed on a Kodak RPX-OXMAT Processor (Eastman Kodak 
Company, Rochester, New York, USA) at the Radiology Department of the Charlotte 
Maxeke Johannesburg Academic Hospital. 
 
2.6.7 DNA Sequencing  
Cloned inserts showing hybridisation to the tester, and not to the driver probe, were 
sequenced using T7 primers (Promega, Madison, WI, USA). Briefly, plasmid DNA from 
PCR positive clones was prepared using the Qiagen Spin Plasmid Miniprep Kit (Qiagen 
GmbH, Hilden, Germany) as stated above. Forward linear amplification was performed in 
10µl using 2µl of the purified plasmid DNA (about 20 to 200ng), 2µl BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Warrington, UK), 1µl BigDye 
Sequencing Buffer and 1µM of T7 primer (Promega, Madison, WI, USA). Linear 
amplification consisted of 25 cycles of denaturation at 96oC for 30s, annealing at 50oC for 
30s and elongation at 72oC for 4min using the Bio-Rad iCycler (Bio-Rad Laboratories, 
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Hercules, CA, USA). Fluorescence-labelled DNA was purified using the ethanol 
precipitation described under Section 2.2.3.3 and analysed on an ABI PRISM 3730XL 
DNA analyser (Applied Biosystems, Foster City, CA, USA) by Inqaba Biotechnical 
Industries (Pretoria, South Africa). 
 
2.6.8 Sequence Analysis  
DNA sequences were edited with VecScreen Software (http://www.ncbi.nlm.nih.gov 
/VecScreen/VecScreen.html) and Ridom TraceEdit (Ridom Bioinformatics GmbH, 
Würzburg, Germany), and used to search the National Centre for Biotechnology 
Information (NCBI) database using the Protein Clusters Database (ProtClustDB) with 
BLASTX software (http://www.ncbi.nlm.nih.gov/ BLAST) (Altschul et al, 1997). The 
sequences were also compared to the M. kansasii ATCC 12478 genome draft assembly 
consisting of 299 major contigs and 6.4 Mb using the NCBI BLASTX 
(http://www.ncbi.nlm.nih.gov//genomes/ geblast.cgi? gi=6107). BLASTX sequence 
matches with E (expectation) values of ≤ 10-3 and sequence identities of  60% were 
regarded to be similar protein sequences (Pearl et al, 2000; Shanks et al, 2006b). DNA 
sequences were organised into functional gene categories using the Protein Clusters 
Database (ProtClustDB) (http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein clusters) 
(last accessed April 6, 2010) which contains both curated and uncurated clusters of 
proteins grouped by sequence similarity (Klimke et al, 2009).  
 
2.7 Determination of Immunomodulatory Ability of M. kansasii Lymphocyte In Vitro 
3.7.1 Preparation of Mycobacterial Cell Lysates 
Mycobacterial cell lysates were used for pulsing human mononuclear cells. Mycobacteria 
were either obtained from LJ slopes by scraping colonies and suspending them in normal 
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saline or from broth cultures. The organisms were heat-killed, centrifuged at 3800rpm for 
10min in a standard bench-top microcentrifuge to remove any traces of medium, washed 
three times with normal saline at 3800rpm for 30min and sonicated at 4oC to disrupt the 
cells. Protein concentrations of the bacterial cell lysates were determined using the 
Bradford method (Bio-Rad Laboratories, Hercules, CA, USA) according to the 
manufacturer’s instructions. The lysates were then aliquoted and stored at -20oC until 
required.  
 
2.7.2 Preparation of Mononuclear Cells  
Venous blood samples from normal healthy volunteers were collected in preservative-free 
heparin tubes (BD Biosciences, Plymouth, UK). Mononuclear (MN) cells were separated 
at room temperature by centrifugation for 40min at 4000rpm on a Hypaque-Ficoll (Sigma-
Aldrich, Steinheim, Germany) gradient and collected from the plasma-Ficoll interface. 
The cells were washed 3 times in normal saline by centrifugation at 1200rpm for 7min and 
resuspended at various concentrations in RPMI-1640 with L-glutamine (Lonza, 
Wilkerville, MD, USA) containing 10% heat-inactivated foetal calf serum and 1% 
penicillin/streptomycin, depending on the experimental requirements. 
 
2.7.3 Production of Suppressor Cell Activating Factors 
It has been previously demonstrated that when macrophages ingest mycobacteria from 
their environment, they release bacterial components rich in lipids. These lipids have been 
termed Suppressor Cell Activating Factors (SCAF), and they have a suppressive effect on 
lymphocyte proliferation (Wadee et al, 1983). In this study SCAF was produced from 
U937 cells, a human monocytic cell line (courtesy of Professor Mary Gulumian, National 
Institute of Occupational Health, Johannesburg, South Africa). The cells were first grown 
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at 3 x106 cells/ml in RPMI-1640 at 37oC in 5% CO2 for 2hrs in the presence of 60µg/ml of 
protein from each of the mycobacterial lysates (M. kansasii subtypes I-VI, M. 
tuberculosis) in sterile 24-well plates (Becton-Dickinson and Company, New Jersey, 
USA) to stimulate the production of SCAF (Wadee et al, 1983). After 2hrs, the medium 
was discarded and the cells were washed 3 times at 1200rpm for 7min and resuspended in 
fresh RPMI-1640 medium to their original volume. The cultures were incubated for an 
additional 48hrs, after which time the supernatants were collected and stored at -20oC until 
required. Control supernatants were prepared by incubating monocytes alone without the 
mycobacterial lysates. 
 
2.7.4 Effect of SCAF on Lymphocyte Blastogenesis  
To determine whether M. kansasii has the ability to induce a suppressive effect on 
lymphocyte proliferation, a lymphocyte transformation assay was performed. MN cells 
(n=5 healthy donors), at 2 x 105cell/ml, were cultured in 96-well round-bottomed 
microtitre plates (Nunc A/S Roskilde, Denmark) in the presence of an equal volume of 
SCAF. Cells were stimulated with 40µg/ml of concanavalin A (Pharmacia Biotech, 
Upsalla, Sweden). All experiments were performed in triplicate. Plates were incubated at 
37oC in 5% CO2 in humidified air for 72hrs. Tritiated thymidine ([methyl-3H]thymidine, 
24 Ci/mmol) (Amersham, Buckinghamshire, England) at 1µCi, was added for the final 
18hrs of culture. The cells were harvested onto glass fibre filters (Packard Instruments BV 
Chemical Operations, Groningen, The Netherlands) by using an automated FilterMate Cell 
Harvester (Perkin Elmer) and transferred into vials containing Insta-Gel II Universal 
Scintillation liquid (Packard Instruments BV Chemical Operations, Groningen, The 
Netherlands). Radioactivity was counted by liquid scintillation on a 1900TR Liquid 
Scintillation Counter (Packard Instrument Company Inc, Downers Grove, Illinois, USA). 
69 
 
Lymphocyte proliferation was expressed as the mean of counts per minute of radioactivity 
incorporated by triplicate cultures of 2 x 105cell/ml. 
 
2.7.5 Effect of SCAF on Lymphocyte Activation 
Previous studies have demonstrated that SCAF induced CD8+ T cells produce Suppressor 
Carbohydrates (SC) in response to M. tuberculosis, which had a modulatory effect on 
CD4+ T cells (Wadee et al, 1983; Sussman and Wadee, 1991). Thus, SC was found to 
induce a Th2 response rather than a protective Th1 response in human mononuclear (MN) 
cells. In this study we investigated whether SCAF from M. kansasii would modulate the 
activity of lymphocytes in the MN cells cell population through cytokine production or 
suppression. To establish the longitudinal profile of cytokine expression by MN cells 
pulsed with various mycobacterial preparations, cytokine expressions were measured at 
three different time points, i.e., 24, 48 and 72hrs. The 72hr time point was found to be the 
suitable optimal time point for the analysis.  
 
2.7.5.1 Stimulation of MN Cells 
MN cells at a concentration of 2 x 106cell/ml were cultured in 24-well plates (Nunc A/S 
Roskld, Denmark) in the presence of an equal volume of SCAF (M. kansasii subtypes I-
VI) or positive control SCAF (M. tuberculosis H37Rv) or negative control SCAF 
(medium only) at 37oC in 5% CO2 in humidified air for 4hrs. The cells were stimulated 
with 12.5g/ml of Phytohaemagglutinin (PHA) (Sigma-Aldrich, Steinheim, Germany). A 
positive control with only PHA, but no SCAF added and a non-stimulated negative control 
with medium only were also prepared.  
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2.7.5.2 Cytokine Analysis 
To evaluate the levels of cytokines released by T cells in the presence of SCAF, the BD 
CBA Human Th1/Th2/Th17 Kit (BD Biosciences, San Jose, CA, USA) was used 
according to manufacturer’s instructions. The kit is used to measure Interleukin-2 (IL-2), 
IL-4, IL-6, IL-10, Tumour Necrosis Factor- (TNF-), Interferon- (IFN-) and IL-17A 
protein levels in a single sample. MN cells (n=7 healthy donors), at 2 x 106cells/ml, were 
exposed to SCAF supernatants for 4hrs after which the supernatant was harvested at 
12000rpm for 7 min.  
 
The cells were then be resuspended in fresh RPMI-1640 to their original volume. The 
cultures were incubated for an additional 72hrs, after which the supernatants were 
collected. Fifty microlitres of supernatant were then used in the assay. The assay was 
performed according to the manufacturer’s instructions and analysed on a FACS Calibur 
Flow Cytometer (BD Biosciences, San Jose, CA, USA). 
 
2.8 Statistical Analysis 
Data analysis was performed with GraphPad Prism Software Version 5.0 for Windows 
(GraphPad Software, San Diego, California, USA). Results were expressed as medians± 
SEM. Multiple comparisons were done with the Kruskal-Wallis test, followed by the 
Dunn’s multiple comparison adjustment test. Tests were interpreted at 5% significance 
level (two-sided). For cytokine expression, all values were calculated with regard to the 
negative control in each assay (MN cells + PHA + untreated culture supernatant). *p<0.05, 
**p<0.01, ***p<0.001 compared with the negative control. 
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2.9 Ethics Approval 
Ethics approval for this study was granted by the University of the Witwatersrand Human 
Research (Medical) Ethics Committee. The Ethics Clearance Certificate Number was 
M050707 (Appendix I). Permission to collect the environmental samples from the Vaal 
River region and M. kansasii clinical isolates was obtained from the Mine Health and 
Safety Council of South Africa, the AngloGold Ashanti Health Services, South Africa. 
Permission for environmental samples from the Secunda coal-mining complex was 
obtained from the Secunda Collieries, South Africa. 
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CHAPTER 3 
Identification of Potential Environmental Sources of  
M. kansasii Infection 
 
3.0 Abstract 
M. kansasii is a major cause of NTM pulmonary disease in South African gold miners, but 
the source of infection is unknown. Since there is no evidence of person-to-person 
transmission and the organism has typically been isolated from water in other settings, the 
environment is considered the most likely source of infection. This study examined the 
presence of M. kansasii in water distribution systems supplying mines. Five M. kansasii 
strains, as well as 10 other potentially pathogenic mycobacteria, were isolated from 
biofilm and water samples obtained from showerheads and water taps. PCR-restriction 
analysis (PRA) of  the 5 M. kansasii isolates revealed three subtype I strains, one subtype 
IV strain and a unique isolate that did not show a typical M. kansasii PRA pattern. The 
unique isolate may probably represent a new subtype of M. kansasii. Macrorestriction 
analysis, using PFGE, of the three subtype I isolates demonstrated that they were at least 
85.6% similar to a set of clinical isolates. One of the significant findings was the 
observation that one of the three subtype I isolates was identical to a clinical isolate, 
suggesting that water, particularly from showerheads, is a potential source of M. kansasii 
infection for the miners and that water may present a significant health risk associated 
with this organism and other opportunistic pathogenic mycobacteria for the miners. 
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3.1 Introduction 
A number of NTM infections have been attributed to contaminated water, and most of 
these NTMs have been isolated from public water distribution systems and natural water 
bodies (Peters et al, 1995; Kubalek and Mysak, 1996; Falkinham et al, 2001; Le Dantec et 
al, 2002; September et al, 2004; Vaerewijck et al, 2005; Falkinham et al, 2008). This 
suggests that water may be the vehicle by which these organisms infect or colonise 
humans. Exposure to mycobacteria in water may occur by drinking and by inhalation of 
aerosols generated through swimming, bathing and showering (O'Brien et al, 2000; Glazer 
et al, 2007; Feazel et al, 2009). Most of the NTMs responsible for these diseases are 
highly resistant to common disinfectants and other forms of treatment such as heat, which 
allow them to persist for long periods of time in water (Taylor et al, 2000; Bagh et al, 
2004). Another factor in the survival of mycobacteria in water is their association with 
free-living amoebae and other protozoa. These protozoa may represent an environment 
that increases their resistance to disinfectants and harsh environmental conditions (Thomas 
et al, 2006; Goy et al, 2007). Recently, it was shown that pathogenic subtype I M. kansasii 
strains grew better in Acanthamoeba castellani than non-pathogenic subtype III M. 
kansasii strain (Goy et al, 2007). Protozoa may, therefore, represent an environment for 
enhancing the virulence and ability of mycobacteria to spread to vulnerable persons 
through water (Winiecka-Krusnell and Linder, 2001; Thomas et al, 2006; Goy et al, 
2007). 
 
South African gold miners have an unusually high incidence of M. kansasii infection that 
is attributable to the high prevalence of risk factors for NTM disease, including HIV 
infection, high incidence of tuberculosis, silicosis, extensive use of aerosolised water for 
dust control and an unusually high occupational exposure to NTM organisms (Corbett et 
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al, 1999; Corbett et al, 2000; Churchyard, 2000).  In spite of the identification of these risk 
factors and a high incidence of M. kansasii disease in gold-mining regions of South 
Africa, the sources of infection for M. kansasii disease remain an enigma since M. kansasii 
has not been previously isolated despite previous attempts, precluding any epidemiological 
link.  
 
3.2 Objective of the Study 
The objective of this study was to determine whether mining and/or residential water was 
the potential source of M. kansasii infection for the gold-mining workforce. Attention was 
focused on water distribution systems since they appeared to be a major source of the 
mycobacterium in other studies (Engel et al, 1980; Steadham, 1980; Chobot et al, 1997; 
Vaerewijck et al, 2005). Provision of such information would aid in devising strategies for 
preventing or reducing transmission of disease caused by M. kansasii and other potentially 
pathogenic mycobacteria to the miners.  
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3.3 Results  
3.3.1 Experimental Design 
This was a descriptive study carried out on biofilm and water samples obtained from the 
Vaal River gold-mining region and the Secunda coal-mining complex. The identity of the 
M. kansasii and other mycobacterial isolates was performed by biochemical tests, PCR 
and DNA sequencing. Subtyping of M. kansasii isolates was carried out by PRA, whilst 
the determination of an epidemiological link between environmental and clinical isolates 
was performed by macrorestriction analysis using PFGE. Refer to Chapter 2 for 
experimental details. 
 
3.3.2 Optimisation of the Isolation Procedure for M. kansasii from Water Samples 
To select a suitable method for decontaminating samples for the isolation of M. kansasii, 
five commonly-used water decontamination methods were compared. As shown in Table 
3.1, 0.005% CPC yielded more mycobacteria (275 CFU/L) than the other decontaminants, 
followed by 1% NaOH plus 3% SDS, which yielded only 15 CFU/L. The other 
decontaminants yielded no mycobacteria. In view of these results, CPC was selected as 
suitable decontaminant for this study. This was in agreement with results from other 
studies (Neumann et al, 1997; Radomski et al, 2010). 
 
Table 3.1: Effect of different concentrations of NaOH with 3% SDS and CPC on the isolation of M. kansasii 
from water 
 
Decontaminant     Number of CFU/L plated 
 
   101  102  103  104  105 
1% NaOH + 3% SDS NG  NG  NG  NG  15 
2% NaOH + 3% SDS NG  NG  NG  NG  NG 
3% NaOH + 3% SDS NG  NG  NG  NG  NG 
4% NaOH + 3% SDS NG  NG  NG  NG  NG 
0.005% CPC  NG  10  25  45  275 
 
NG = No Growth; CFU = Colony Forming Units; CPC = Cetylpyridinium chloride 
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3.3.3 Isolation of Mycobacteria 
A total of 57 (27 water and 30 biofilm) samples from 35 sites in the Vaal River gold-
mining region, and 32 (16 water and 16 biofilm) samples from 18 sites in the Secunda 
coal-mining complex were examined. Culture results showed that 37/57 (64.9%) of the 
samples from the Vaal River gold-mining region were positive for NTM (Table 3.2). Out 
of these, 29/37 (78.4%) were isolated from biofilm samples, while 8/37 (21.6%) were 
isolated from water. For samples from the Secunda coal-mining complex, 17/32 (53.1%) 
of the samples were positive for NTM (Table 3.2). Sixteen (94.1%) of these NTM were 
isolated from biofilm samples and only 1 (5.9%) of the mycobacteria was isolated from 
water samples. Only one underground sample (biofilm) from the Vaal River gold-mining 
region was positive for NTM, while none was positive from the Secunda coal-mining 
complex. Counts in biofilm samples ranged from 10 to 233 CFU/swab, while those from 
water samples ranged from 17 to 197 CFU/L. For both regions, the majority of the NTMs 
were isolated from biofilm samples obtained from residential and office water distribution 
systems (Appendix II). Most of the NTM were isolated at 30oC. In spite of measures to 
control contamination with CPC, fungal overgrowth was a major problem with some water 
samples. This was particularly evident with surface water samples from the Secunda coal-
mining complex.  
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Table 3.2. Distribution of samples positive for NTM species isolated from water and biofilm samples obtained from the Vaal River gold-mining and Secunda coal-mining 
complex water distributing systems 
  
      Surface water       Underground water         Biofilm samples                  All samples 
Mycobacterial Isolate                                                                                                                                                                                                                                                                
                        No. of Positive %                  No. of Positive     %           No. of Positive    %           No. of Positive     % 
          Samples                Samples                              Samples                               Samples 
Vaal River gold-mining region         8              34.7    0       0.0    29      96.6      37        64.9          
Potentially pathogenic NTM         6              26.0    0       0.0    19       63.3      25        43.9           
 M. kansasii          0                     0.0    0       0.0      5      16.7        5          8.8          
 M. avium          0  0.0    0       0.0      4      13.1        4          7.0          
 M. fortuitum          4             17.4    0       0.0      3      10.0        7        12.3          
 M. peregrinum          1  4.3    0       0.0      1        3.3        2          3.5          
M. chelonae          0  0.0    0       0.0      3      10.0        3          5.3          
M. abscessus          0  0.0    0       0.0      1        3.3        1          1.8 
M. parascrofulaceum         1  0.0    0       0.0      1        3.3        1               1.8 
M. montefiorense          1  4.3    0       0.0      0                0.0         1           1.8          
 M. setense          0  0.0    0       0.0      1        1.8        1          1.8  
        Saprophytic NTM               2  8.7    0       0.0    10      33.3      12        21.0           
 M. goodii          0  0.0    0       0.0      1        3.3        1          1.8 
M. gordonae          2  8.7    0       0.0      9      30.0      11        19.2          
           
Secunda coal-mining complex         1  7.1    0       0.0   16    100.0      17        53.1          
Potentially pathogenic NTM         0  0.0    0       0.0   11      68.8      11        34.4          
 M. avium          0  0.0    0       0.0     2      25.5        2          6.3          
 M. intracellulare          0  0.0    0       0.0     1        6.3        1          3.1          
 M. peregrinum          0  0.0    0       0.0     3      18.8        3          9.4          
 M. chelonae          0  0.0    0       0.0     4      25.0        4        12.5 
        M. tusciae          0  0.0           0       0.0     1        6.3        1          3.1  
        Saprophytic NTM          1  7.1    0       0.0     5      31.3        6             18.8 
 M. gordonae          1  7.1    0       0.0     5      31.3        6        18.8     
          
• Total number of samples from the Vaal River gold-mining region = 57 (biofilms = 30; surface water = 23; underground water = 4). Culture positive, 37/57 (64.9%). Of 
these positive samples, 29/37 (78.4%) were recovered from biofilms and 8/37 (21.6%) were recovered from water.  
• Total number of samples from the Secunda coal-mining complex = 32 (biofilms = 16; surface water = 14; underground water = 2). Culture positive, 17/32 (53.1%). Of 
these positive samples, 16/17 (94.1%) were recovered from biofilms and 1/17 (5.9%) were recovered from water. NTM, Nontuberculous mycobacteria.  
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3.3.4 Identification of Mycobacteria 
Based on culture, biochemical tests, PCR and DNA sequencing results, several NTM 
species, including potentially pathogenic and saprophytic species, were isolated from 
samples obtained from the two regions (Tables 3.2; Appendix II). Potentially pathogenic 
mycobacteria from the Vaal River gold-mining region included 5 (8.8%) M. kansasii, 4 
(7.0%) M. avium, 7 (12.3%) M. fortuitum, 2 (3.5%) M. peregrinum, 3 (5.3%) M. chelonae, 
1 (1.8%) M. abscessus and 1 (1.8%) M. parascrofulaceum, 1 (1.8%) M. setense, 1 (1.8%) 
and M. montefiorense, while saprophytic species included 11 (19.2%) M. gordonae and 1 
(1.8%) M. goodii (Table 3.2). Potentially pathogenic mycobacteria from the Secunda coal-
mining complex included 2 (6.3%) M. avium, 1 (3.1%) M. intracellulare, 3 (9.4%) M. 
peregrinum and 4 (12.5%) M. chelonae, 1 (3.1%) M. tusciae, whereas saprophytic 
mycobacteria included 6 (18.8%) M. gordonae (Table 3.2). No M. kansasii were isolated 
from the Secunda coal-mining complex. In both regions, potentially pathogenic NTM 
represented the majority of the isolates, 43.9% and 34.4%, respectively (Table 3.2). Most 
of the potentially pathogenic NTM were isolated from biofilm samples obtained from 
showerheads and water taps. Showerhead biofilms were the main sources for M. kansasii 
isolates (Appendix II).  
 
3.3.5 PCR Identification and PRA Analysis of M. kansasii Isolates 
To identify the five strains of M. kansasii isolated from the Vaal River gold-mining 
region, a PCR-based identification test, using Fw1 and Rv1 primers, was performed 
(Chapter 2). All five isolates were positive for M. kansasii, yielding a 167bp PCR 
amplified product (Fig 3.1). None of the other mycobacterial species tested (M. gastri, M. 
tuberculosis, M. bovis, M. scrofulaceum, M. gordonae, M. avium, M. intracellulare, M. 
xenopi, M. fortuitum, M. abscessus, M. peregrinum and M. chelonae) were positive with 
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this PCR test. The PCR test results were confirmed to be true positives by DNA 
sequencing of the internal transcribed sequence (ITS) using the ITS1-ITS2 primers. 
 
 
                M               1                  2                  3              4                     5                 6                 7               8 
 
 
Figure 3.1:  PCR detection of environmental isolates of M. kansasii. Lane M, 50bp DNA marker; lane 1, No 
DNA control (water); lanes 2, M. kansasii ATCC 12478; lane 3, M. gastri; lane 4-8, M. kansasii isolates: 
lane 4,  LRRSH-1; lane 5,  WSQR; lane 6, KPUGW; lane 7, LRR; and lane 8, NCHSH. bp, base pair. 
 
 
 
                                          BstEII-digested                                    HaeIII-digested                             
  
                          M         1             2           3            4           5          M         1          2           3              4           5           M 
 
 
Figure. 3.2: PRA patterns of representative environmental isolates of M. kansasii. Lane M, 50bp DNA 
marker; lane 1, subtype I (LRRSH-1); lane 2, subtype IV (LRR); lane 3, unique isolate 1 (NCHSH); lane 4, 
subtype II (Clinical isolate); and lane 5, subtype I (WSQR). bp, base pair. 
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To determine the subtypes of the M. kansasii isolates, PRA was performed on the five 
isolates and three isolates (LRRSH-1, KPUGW and WSQR) were classified into subtype I 
(BstEII, 240/210; HaeIII, 130/105/80), one isolate (LRR) into subtype IV (BstEII, 
240/120/85; HaeIII, 130/115/70/50), and one isolate (NCHSH identified as unique isolate 
1) did not match the typical M. kansasii PRA pattern (BstEII, 240/120/85; HaeIII, 
165/115/60) (Fig 3.2). The isolate with the unique PRA pattern was re-confirmed as 
belonging to the M. kansasii species by DNA sequencing of the 16S-23S rDNA spacer 
region, the gyrB and the secA1 genes.  
 
 
3.3.6 Macrorestriction Analysis of Environmental and Clinical Isolates  
To determine whether water was the possible source of M. kansasii infection for the gold 
miners, the PFGE macrorestriction profiles of the three subtype I environmental isolates 
were compared to subtype I M. kansasii clinical isolates. The results demonstrated at least 
83.5% similarity amongst the isolates, i.e, were categorised as a cluster (Fig 3.3). 
Particularly striking was the finding that LRRSH-1, an isolate from a mine hostel 
showerhead, showed similarity of 100% with clinical isolate MK010, and was 91.7% 
identical to clinical isolates MK128, MK167 and MK221 and 88.0% to MK092. The other 
two environmental isolates, KPUGW and WSQR, obtained from a mine underground 
water pipe biofilm and a mine hostel showerhead, respectively, were 100% identical to 
each other and were 83.5% similar to LRRSH-1 and the clinical isolates (Figure 3.3). 
These isolates were obtained from three different sites. 
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                                M         1*         2        3          4         5         M         6*       7          8         9        10        M 
 
Figure 3.3:  Macrorestriction analysis of genomic DNA from clinical and environmental isolates  of  M. 
kansasii .  Lane M, PFG MidRange II marker (NEB); Lane 1, LRRSH-1*; lane 2, MK072, lane 3, KPUGW; 
lane 4, WSQR; lane 5, MK008; lane 6, MK010*, lane 7, MK078; lane 8, MK015; lane 9, MK027; lane 10, 
MK165). LRRSH-1, KPUGW and WSQR are environmental isolates, while the rest are clinical isolates. 
Numbers above the lanes represent isolates and M denotes the molecular weight marker. 
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Figure 3.4:  Dendrogram and schematic representation of macrorestriction, using PFGE, patterns of 
environmental (LRRSH-1*, KPUGW and WSQR) and clinical (MK010*, MK092, MK128 and MK167) 
isolates of M. kansasii subtype I. The clinical isolates were selected based on the highest similarity to the 
environmental isolates 
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3.4 Discussion 
Data presented in this study demonstrate the occurrence of a variety of culturable NTM 
obtained from water distribution systems in the Vaal River gold-mining region and in the 
Secunda coal-mining complex. The majority of the mycobacteria were potentially 
pathogenic species such as M. kansasii, M. avium, M. peregrinum, M. chelonae, M. 
fortuitum, M. parascrofulaceum and M. intracellulare M. montefiorense, M. setense and 
M. tusciae. Saprophytic mycobacteria were also isolated and these included M. goodii and 
M. gordonae. Potentially pathogenic mycobacteria other than M. kansasii were isolated 
from biofilms obtained from showerheads and water taps. M. kansasii were isolated from 
biofilms from showerheads and from a mine underground water pipe. Biofilms are 
significant sources of mycobacteria in water distribution systems (Falkinham et al, 2001). 
A recent study employing a culture-independent molecular survey of the nature of 
showerhead microbiology in the USA showed that the majority of the bacteria detected 
were NTM, and that M. avium represented the highest load of the mycobacteria (Feazel et 
al, 2009). This was attributable to the enrichment effect showerheads have on bacterial 
populations and to the waxy content of mycobacteria that imparts resistance to shear 
forces generated by shower operation. A South African study reported the presence of 
NTM in 18% of the 78 biofilm samples collected from urban and semi-urban sources 
(September et al, 2004). Nearly all the NTM strains isolated were potential pathogens, 
which included M. fortuitum, M. abscessus and M. septicum. However, no M. kansasii was 
found. Several other studies have also reported NTM to occur in biofilms of water 
distribution systems (Falkinham et al, 2001; Le Dantec et al, 2002; Falkinham et al, 
2008). Our findings, along with those from other studies, indicate that exposure to water in 
distribution water systems could pose a health risk, especially to immunocompromised 
individuals (Falkinham et al, 2001; Le Dantec et al, 2002; Torvinen et al, 2004). 
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Showerheads, in particular, pose the greatest risk of infection with pathogenic NTM 
(Falkinham et al, 2008; Feazel et al, 2009). Although previous epidemiological studies in 
South Africa have identified predisposing factors such as HIV infection and occupational 
lung disease as being strongly associated with an increased risk of NTM disease (Corbett 
et al, 1999abc; 2000), it was not possible for us to correlate our data with the incidence 
and severity of these infections in the South African mining areas as we did not have 
access to patient data and no scientific record of this information is yet available on mine 
or other workers in South Africa. This risk of NTM infection in workers and the general 
public is highlighted in numerous international publications. At present there are no 
epidemiological data with which to assess the risk for NTM infection. 
 
The five strains of M. kansasii were isolated from the Vaal River gold-mining region, and 
none were isolated from the Secunda coal-mining complex. The strains isolated included 
three subtype I, one subtype IV and a unique isolate that did not show the typical M. 
kansasii PRA pattern. This unique isolate may probably represent a new M. kansasii 
subtype. It is not clear whether the detection of M. kansasii in this region was unusual as 
systematic studies of other South African sites need to be done to assess the local 
prevalence. Reports have shown that there is a high prevalence of risk factors for NTM 
disease in this region (Corbett et al, 1999; Churchyard, 2000; Corbett et al, 2000), and 
these risk factors may predispose the mining workforce to M. kansasii disease. However, a 
previous attempt at isolating the organism from water distribution systems in this region 
failed (G. J Churchyard, personal communication), making it difficult to link the infection 
to the environment. Only other pathogenic mycobacteria, including M. scrofulaceum and 
M. avium complex, were isolated. M. scrofulaceum was the most common species 
isolated, and previously this organism was reported to be the second most important cause 
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of NTM disease, after M. kansasii, in the workforce of this mining region (Corbett et al, 
1999). Failure to isolate M. kansasii from water can occur due to technical issues, and its 
isolation from water has been reported to be intermittent (Joynson, 1979).  Data in our 
study show that M. kansasii is found both in underground mine water and in the domestic 
water supply of the mine residences. To our knowledge, this is the first study in South 
African to report the isolation of M. kansasii from the environment.  
 
It was initially thought that underground water could have been the possible source of 
infection since the gold mines use aerosolised water extensively for settling dust 
(Churchyard et al, 2000). However, macrorestriction analysis showed that an M. kansasii 
environmental isolate, from a mine hostel showerhead biofilm, and a clinical isolate were 
100% similar to each other. This suggests that potable water may be a possible source of 
M. kansasii infection for the miners in the Vaal River gold-mining region. Aerosols 
generated from activities such as bathing and showering may put the miners at risk of 
acquiring infection caused by M. kansasii. However, these data do not establish that water 
is the source of the infection, but implicates it as a possible source of infection. In the 
absence of an experimental infection model, it is difficult to prove that the miners acquired 
the infection from water. It may be difficult to reduce the possible exposure of the miners 
to pathogenic mycobacteria in water, but susceptible individuals should be advised to wear 
masks while engaging in activities that generate aerosols with water. Other measures to 
minimise the risk of infection to the miners can include repeated (fortnightly) mechanical 
cleaning of service water tanks and steaming of the pipeline system, including shower 
heads, using water heated to 85oC or 90oC for 30min; continuous warming of water to 
85oC and its subsequent cooling to 40oC performed once a month; continuous ozone 
treatment of water; and the installation of ultra-violet (UV) radiation devices in hot water 
86 
 
distribution systems (Chobot et al, 1997; Martinková et al, 2001). It may also be necessary 
to slow-down the water flow rate to make these measures more effective (Martinková et 
al, 2001). 
 
3.5 Conclusion 
NTM were isolated from 64.9% and 53.1% of the samples obtained from the Vaal River 
gold-mining region and the Secunda coal-mining complex, respectively. Most of the NTM 
were isolated from biofilm samples, which included both potentially pathogenic (43.9% 
from the Vaal River region and 34.4% from the Secunda region) and saprophytic 
mycobacteria. Of interest was the isolation of M. kansasii strains from the Vaal River 
region. One of the isolates detected had a unique PRA pattern and may probably represent 
a new M. kansasii subtype. Another significant finding was the detection of an M. kansasii 
subtype I isolate that was found to share 100% similarity with a clinical isolate. This study 
indicates that exposure to water distributing systems containing potentially pathogenic 
NTM could pose a health risk to people, especially to individuals who are 
immunocompromised, and that the possible source of M. kansasii infection in the mine 
workforce in the Vaal River gold-mining region is water.  
 
The study had a number of limitations. Some of the negative findings, especially with 
water samples, may be attributed to the limited number of samples and sites studied. Only 
one gold-mining region was studied. In addition, the decontamination procedure for the 
samples, prior to plating on solid media, may have reduced the number of culturable NTM 
since this has been shown to kill bacteria (Brooks et al, 1984). Another limitation of the 
study was that most NTM are difficult to culture and grow very slowly, making them 
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vulnerable to overgrowth by other organisms (Brooks et al, 1984). A problem observed in 
this study was with fungal overgrowth, especially with water samples. 
 
Further studies are needed to examine the factors that influence the survival and growth of 
M. kansasii in water distribution systems and the development of an infection model to 
demonstrate transmission of M. kansasii from water to humans. 
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CHAPTER 4 
Genetic Diversity Amongst Clinical and Environmental Isolates of M. kansasii 
 
4.0 Abstract 
The incidence of M. kansasii disease in the South African gold-mining workforce is one of 
the highest in the world (Corbett et al, 2000). However, nothing is known about the 
subtypes or the molecular epidemiology of M. kansasii in the country. This study 
investigated the genetic diversity 191 clinical and environmental isolates obtained from a 
gold-mining workforce and its environment. M. kansasii subtypes were defined by PCR-
restriction analysis of the hsp65 gene. M. kansasii subtype I strains comprised 157 
(82.2%) of the isolates, while subtypes II and IV comprised 8 (4.2%) and 5 (2.6%) of the 
isolates, respectively. Two sets of isolates, a group of 16 (8.4%) and another of 5 (2.6%), 
did not show the typical M. kansasii PRA patterns. These isolates were confirmed to 
belong to the M. kansasii species by DNA sequencing of the 16S-23S rDNA spacer 
region, the gyrB and secA1 genes, and probably represent new subtypes. Macrorestriction 
analysis of 114 clinical and 3 environmental subtype I isolates segregated the strains into 
12 clusters that showed at least 80% similarity. The strains showed genetic diversity with 
clustering, but with no association of any cluster with the location of the hospital attended 
by patients. Taken together, these results showed that M. kansasii disease in the gold 
mining workforce was almost exclusively caused by subtype I strains and that these strains 
exhibited genetic diversity with no association of clusters with the area of residence of the 
patients. 
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4.1 Introduction 
The understanding of pathogen distribution and genetic relatedness within species is 
essential in the determination of the epidemiology of infectious diseases and designing of 
effective intervention (Singh et al, 2006). This can be achieved through the use of 
molecular typing techniques such as macrorestriction analysis, which utilises infrequently 
cutting restriction endonucleases to fragment complete bacterial genomes, followed by 
separation of DNA fragments by PFGE to give reliable DNA fingerprints. 
Macrorestriction analysis compares the presence or absence of restriction sites, as well as 
the length of fragments generated (Blanc, 2004; Andrei and Zervos, 2006; Singh et al, 
2006). Substitutions, insertions, deletions, duplications and rearrangements in the 
nucleotide sequences change the relative position of the restriction sites and thus change 
the length of the DNA fragments generated. Differences in the number of DNA fragments 
generated define strain diversity (Tenover et al, 1995). 
 
The epidemiology of M. kansasii disease is poorly understood. This is partly attributable 
to the lack of an effective molecular epidemiological typing system for M. kansasii. In 
addition, the investigation of the reservoir, routes of transmission and pathogenicity of M. 
kansasii has been complicated by the existence of about 7 subtypes of M. kansasii 
(Picardeau et al, 1997; Taillard et al, 2003; Santin et al, 2004). This heterogeneity in the 
M. kansasii species has been demonstrated by the use of PCR restriction analysis (PRA) of 
the hsp65 gene (Telenti et al, 1993; Picardeau et al, 1997; Chimara et al, 2008). M. 
kansasii subtype I is the most frequently isolated subtype from clinical sources, while the 
remaining subtypes are mainly isolated from the environment (Alcaide et al, 1997; Zhang 
et al, 2004). However, M. kansasii disease has not been demonstrated to be 
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communicable, and the environment appears to be the source of infection (Engel et al, 
1980; Steadham, 1980; Chobot et al, 1997; Vaerewijck et al, 2005).  
 
The epidemiology of M. kansasii disease is predominantly urban and has been associated 
with high density and low income communities (Chobot et al, 1997; Bloch et al, 1998; 
Churchyard, 2000; Santin et al, 2004). In South African gold miners, there is an unusually 
high incidence of M. kansasii disease which has been estimated to be about 320 per 100 
000 (Corbett et al, 2000). The structure of the mines and health system in the mining 
regions make it easy to measure this incidence, but its incidence is not known in the non-
mining population of South Africa.  
 
South African gold miners have a high occurrence of risk factors for NTM disease, 
including HIV infection, a high incidence of tuberculosis, silicosis and considerable 
occupational exposure to NTM organisms due to the extensive use of aerosolised water for 
dust control by the gold mines (Churchyard, 2000). These miners are mostly a diverse 
mobile group of migrant workers from rural South Africa and neighbouring countries. 
Most of them live in shared rooms in densely populated mine hostels, which may increase 
the chances of person-to-person transmission of a range of organisms (G. J. Churchyard, 
personal communication). Despite the high incidence of M. kansasii disease amongst 
South African gold miners, no epidemiological studies have been conducted to determine 
the genetic diversity of M. kansasii isolates from patients.  
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4.2 Objective of the Study 
 The objective of this study was to determine the genetic diversity amongst the clinical and 
environmental isolates of M. kansasii obtained from a South African gold-mining region. 
Determination of the clonal identity of M. kansasii strains is important in understanding 
whether patients are infected with the same or different strains of M. kansasii and provides 
information for understanding and controlling the spread of M. kansasii disease.  
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4.3 Results 
4.3.1 Experimental Design 
PCR restriction analysis (PRA) of the hsp65 gene and macrorestriction analysis were used 
to subtype M. kansasii isolates and to determine their clonality, respectively (Refer to 
Chapter 2 for experimental details). Sixty-seven M. kansasii clinical isolates from the 
town of Orkney and 47 isolates from the town of Carltonville were obtained from patients 
presenting with confirmed pulmonary M. kansasii disease. Both these towns are located in 
the gold-mining region of the North-West Province. All samples were processed at the 
West Vaal Hospital TB laboratory in Orkney. No patient information was available due to 
a lack of access to patient records.  
 
4.3.2 PCR-Restriction Enzyme Analysis  
To investigate the distribution of subtypes among M. kansasii isolates, 191 single patient 
isolates were analysed by PRA. Consistent with previous findings (Alcaide et al, 1997; 
Zhang et al, 2004), subtype I was found to be the predominant subtype (157, 82.2%), 
followed by subtype II (8, 4.2%) and subtype IV (5, 2.6%) (Table 4.1). Subtypes III, V, VI 
and VII were not detected in this study. Unexpectedly, two sets of isolates did not produce 
any of the typical M. kansasii PRA patterns. The two sets comprised 16 (8.4%) and 5 
(2.6%) isolates, respectively. The BstEII digestion pattern for the first 16 isolates resulted 
in a pattern identical to that of subtype IV (240, 120 and 85bp), while the HaeIII digestion 
gave a unique pattern (165, 115 and 60bp). The PRA pattern of this set of isolates was 
found to be identical to that of environmental isolate NCHSH (Fig. 3.2, Chapter 3). The 
BstEII digestion pattern for the remaining 5 isolates was identical to that of subtype I 
isolates (240 and 210bp), while that of HaeIII was also unique (130 and 105bp) (Table 
4.1; Appendix III). The two sets of isolates were confirmed to belong to the M. kansasii 
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species by DNA sequencing of the gyrB and the secA1 genes, and 16S-23S rDNA spacer 
region (Appendix IV), and may probably represent new subtypes. 
 
Table 4.1. PRA patterns of the M. kansasii DNA after BstEII and HaeIII digestion 
 
M. kansasii subtype BstEII fragment  HaeIII fragment  Number of isolates 
   size (bp)   size (bp)   in this study (n, %) 
 1  240/210   130/105/ 80  157 (82.2) 
 2  240/130/85  130/105       8 (4.2)  
 3  240/130/85  130/95/70      - 
 4  240/120/85  130/115/70/50      5 (2.6) 
 5  325/120   130/95/75/60      - 
 6  240/130/85  130/100/75      - 
 7  240/130/85  130/95/80      - 
Unique isolate 1  240/120/85  165/115/60    16 (8.4) 
Unique isolate 2  240/210   130/105       5 (2.6) 
 
 
 
 
 
 
Figure.4.1: Representative gel of macrorestriction analysis, using PFGE, of M. kansasii genomic DNA after 
DraI digestion. Numbers above the lanes represent isolates and M denotes the molecular weight marker, 
PFG MidRange II (New England BioLabs). kb, kilobase. 
24 
121 
97 
73 
218 
194 
170 
145 
48 
267 
315 
400 
363 
1 2 3 4 5 6 7 8 9 10 M
5 
M
5 
M
5 
kb
95 
 
4.3.2 Macrorestriction Analysis 
Previous studies have indicated that M. kansasii subtype I strains are predominantly clonal 
in nature (Alcaide et al, 1997; Picardeau et al, 1997; Zhang et al, 2004). To investigate 
whether this was the case with the subtype I strains isolated in our study, macrorestriction 
analysis was performed on the strains with DraI, which generated fragments ranging in 
size from about 50 to 400kb (Figure 4.1). An attempt to use XbaI was made but the 
restriction fragments generated were too complex to analyse (refer to Appendix IV). DraI 
produced about 10 to 17 fragments, which were easily analysable. However, out of the 157 
subtype I strains, only 114 were analysable due to problems associated with DNA 
degradation and fungal contamination. The three subtype I environmental isolates, 
LRRSH-1, KPUGW and WSQR, were also included in the analysis. In general, the PFGE 
analysis demonstrated diversity amongst the isolates. When electrophoretic profiles were 
compared using GelCompar software, 12 clusters, A-L, of at least two isolates whose 
PFGE patterns were similar by at least 80%, could be observed (Figure 4.3). This 
similarity index (SI) was determined by comparing three possible SI cut-offs, 75%, 80% 
and 90%. The SI cut-off that provided the best discrimination, after visual inspection of 
the dendrogram, was 80% as it correctly assigned the isolates to their respective clusters. 
Acceptability of these clusters was assessed by visual inspection of gels to check for 
similarities or identities of the patterns. It was confirmed that macrorestriction patterns of 
the isolates within each cluster differed by a maximum of six bands, which is suggested to 
correspond to two mutations and is considered to represent a significant level of genetic 
relatedness (Tenover et al, 1995). Isolates with seven or more distinct bands were 
designated “unrelated”. Cluster B contained the largest number of isolates (42) which 
shared 82.2 to 100% similarity, followed by clusters A (19) and F (15), each with strains 
sharing 81.0 to 100% and 80.4 to 100% similarities, respectively; clusters E and H were 
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represented by 7 isolates each, showing similarities of more than 81.3%; clusters C and K 
each represented by 5 isolates showing a similarity of at least 80.7%; clusters D and L 
contained 2 isolates, each exhibiting at least 87.0% and 88% similarity, respectively; 
cluster G was represented by 4 isolates with at least 84.6% similarity; and clusters I and J 
with 3 isolates each, exhibited at least 82.1% similarity. Only two isolates, including the 
M. kansasii ATCC 12478 reference strain, remained outside these clusters. The most 
interesting cluster was F, which comprised 14 clinical and 3 environmental isolates. As 
stated in Chapter 3, one of these isolates, LRRSH-1 showed 100% identity with clinical 
isolate MK010 (Figure 4.2). The remaining two isolates, KPUGW and WSQR, were also 
100% identical to each other but were only 86.1% identical to LRRSH-1 and a number of 
selected clinical isolates. There was no evidence of clustering or association between 
PFGE pattern and the location of the hospital attended by patients.  
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Figure 4.2. Dendrogram showing the genetic relationships amongst the macrorestriction (using PFGE) 
profiles of M. kansasii isolates analysed in this study. An 80% similarity index (SI) (green vertical line) was 
chosen as it provided best discrimination of the isolates compared to the other two SI cut-offs tested, 75% 
and 90%. 
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4.4 Discussion 
It has been estimated that the incidence of M. kansasii disease in the South African gold-
mining workforce is about 320 per 100 000 employees (Corbett et al, 2000). However, this 
figure could be an underestimation of the actual number of cases considering this estimate 
was made about 10 years ago when the HIV positivity rates may have been lower than 
those seen currently. A number of predisposing risk factors, including HIV and silicosis, 
are considered to contribute to this high incidence of disease (Corbett et al, 1999; Corbett 
et al, 2000). However, it was not within the scope of this study to determine whether or 
not these risk factors influenced the clustering patterns obtained. 
 
Molecular epidemiology of human bacterial pathogens provides valuable information for 
understanding the reservoir, pathogenicity and control of these bacteria (Singh et al, 
2006). In this study the genetic diversity amongst M. kansasii strains isolated from gold 
miners and their environment was determined using PRA and PFGE analysis. The 
majority (82.2%) of the patients were infected with subtype I, the most prevalent 
subspecies from human sources worldwide (Alcaide et al, 1997; Gaafar et al, 2003; 
Taillard et al, 2003; Santin et al, 2004; Zhang et al, 2004). The predominance of this 
subtype may present an association with virulence, conferring upon it enhanced capacity 
for colonisation and pathogenic activity for humans (Alcaide et al, 1997; Taillard et al, 
2003; Goy et al, 2007). In fact a number of studies have shown that this subtype is the 
predominant subspecies regardless of the HIV status of patients (Chimara et al, 2004; 
Santin et al, 2004). Other subtypes detected included subtypes II (4.2%), IV (2.6%) and 
two sets of isolates with unique PRA restriction patterns not matching any of the typical 
M. kansasii restriction patterns. One set of these isolates matched the PRA restriction 
pattern of an M. kansasii environmental isolate (Chapter 3). This set of isolates was 
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confirmed to be M. kansasii by DNA sequencing of the gyrB and the secA1 genes, and 
16S-23S rDNA spacer region. It was also of interest to ascertain whether these new 
isolates could be detected by the current detection system in our TB laboratory. 
Interestingly, the AccuProbe assay used in the laboratory was able to identify all of them 
as being M. kansasii species. The two sets of isolates may probably represent new 
subtypes of M. kansasii. The detection of these two sets of isolates in this study may 
reflect the existence of a unique ecological niche for the bacterium that influences its 
evolution resulting in the observed change in the PRA restriction pattern (Taillard et al, 
2003).  
 
Macrorestriction analysis of the subtype I isolates generally demonstrated genetic diversity 
amongst the isolates, and 12 clusters were observed. Several previous studies have 
demonstrated a tight clonal structure amongst subtype I strains. One of the first studies by 
Picardeau and co-workers reported the use of large restriction fragment-PFGE analysis to 
differentiate 24 subtype I strains which generated 4 patterns with DraI restriction enzyme 
(Picardeau et al, 1997). They found that the strains were clonal in nature when single-
enzyme Amplified-Fragment Length Polymorphism (AFLP) analysis was used with PstI 
enzyme. Only a few strains generated patterns different from those shared by the majority 
of the isolates. Similar observations were made in a Spanish study which utilised PFGE 
with DraI. Limited genetic polymorphism was observed amongst the 111 strains tested, 
which were segregated into 5 clusters with minor differences (Alcaide et al, 1997). An 
American study found similar results with the use of PFGE and restriction enzymes DraI 
and AseI. It demonstrated marked clonality amongst the isolates studied, with only minor 
differences (Zhang et al, 2004). When compared to isolates from France and Japan, the 
DraI and AseI pulsotypes showed 44% and 42% similarity, respectively. A more recent 
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study from Taiwan, using PFGE and AseI, also corroborated the above findings (Wu et al, 
2009).  The 22 subtype I isolates were also found to be clonal in nature. In an attempt to 
address the tight clonal structure observed in subtype I strains, Gaafar and co-workers 
evaluated the usefulness of a single-enzyme AFLP method for further differentiating the 
strains (Gaafar et al, 2003). The method was able to segregate the strains into 12 distinct 
clusters, demonstrating its potential use in the typing of the M. kansasii strains.  
 
The underlying reasons for the observed diversity of the strains in our study are unclear 
but may be caused by the distinct susceptible population at the mines. The high prevalence 
of risk factors such HIV infection and silicosis, which are not very common in the 
developed world, could influence the adaption of the strains in the patients, resulting in the 
observed pattern. In addition the observed diversity could be due to a combined result of 
recombinational events and unique ecological factors in the South African gold-mining 
region studied that dictate these changes (Coenye and LiPuma, 2003; Feil et al, 2001; Feil 
and Spratt, 2001).  
 
It is not known whether M. kansasii disease is communicable or whether it is acquired 
from the environment, but evidence does tend to suggest environmental reservoirs as the 
sources of infection. Nonetheless, two cases of M. kansasii infection in the same 
household have been reported, and this was suspected, but not proven, to be due to intra-
familial infection (Penny et al, 1982). Another study documented a case involving a 
mother and a son, both of which were infected with the same strain of M. kansasii (Leal-
Arranz et al, 2005). It was not possible to establish whether the infection was transmitted 
from one person to another or whether it was acquired from a common source (Leal-
Arranz et al, 2005). In our study no association of the PFGE pattern and the location of 
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hospital attended was noted in the two patient populations studied. The diversity of the 
clinical isolates also supports an environmental origin such as water.  
 
One of the significant findings in this study was the observation that one of the 
environmental isolates, obtained from a mine hostel showerhead biofilm, showed 100% 
identity with a clinical isolate (Chapter 3). The clinical isolate was obtained from a patient 
attending a mine hospital in Cartonville, whilst the environmental isolate was obtained 
from a mine hostel in Orkney. This may be explained by the fact that there is a high degree 
of mobility between the gold-mine workforces in the two regions, resulting in possible 
infection (G. J. Churchyard, personal communication). Though the PFGE pattern for some 
isolates were 100% identical, it was impossible to assess retrospectively whether 
transmission had occurred amongst the patients or if infection was acquired from the 
environment. 
 
4.5 Conclusion 
This is the first study undertaken in South Africa to employ molecular tools to subtype 
strains of M. kansasii. The study demonstrated that subtype I is the predominant M. 
kansasii strain causing infection in the gold miners studied and corroborates findings from 
other parts of the world. Two new restriction patterns were detected using PRA, and may 
probably reflect the identification of new subtypes of M. kansasii. In contrast to the close 
relationships amongst the Japanese, European, American, and Taiwanese isolates, South 
African M. kansasii subtype I isolates generally exhibited a degree of diversity. No 
association between the PFGE pattern and hospital location could be observed amongst 
the patient isolates that clustered together. 
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One major limitation of this study was the lack of epidemiological data. Unfortunately, 
these data were not available due to logistical problems and lack of access to patient 
records. Further work is warranted to determine the distribution of M. kansasii strains 
isolated from other parts of South Africa. This will give an accurate picture of the M. 
kansasii strains circulating in the country. 
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CHAPTER 5 
Genetic Differences Between Clinical and Environmental Isolates of M. kansasii 
 
5.0 Abstract 
M. kansasii species comprises about 7 genetically very similar subtypes, and subtype I is 
considered to be the most pathogenic of all of the subtypes. However, little is known about 
the genetic basis for its virulence. To address this, Hybridisation-Monitored Genome 
Differential Analysis (HMDA) and bioinformatic analysis were used to identify genetic 
differences between M. kansasii subtype I clinical isolate and M. kansasii subtypes III, V 
and VI environmental isolates. Following solid-phase hybridisation, 150 plasmid clones 
were sequenced to define unique or divergent genomic sequences in subtype I. Putative 
DNA sequences were analysed by dot blot hybridisation, which confirmed the uniqueness 
of the isolated fragments. Comparative DNA analysis identified 45 open reading frames 
(ORFs) predicted to encode putative secreted or membrane-associated proteins. These 
included six genes encoding putative virulence associated factors (MCE family protein, 
two polyketide synthases [Pk8 and Pk12], acyltransferase [PaPA5] and an O-
methyltransferase), two members of the transcription regulators for drugs and xenobiotics, 
three members of multidrug efflux systems, those associated with lipid and carbohydrate 
metabolism and transport, and a number of hypothetical proteins of unknown function. 
These results indicate that M. kansasii subtype I can be distinguished from other subtypes 
by a number of divergent ORFs, some of which encode virulence-associated factors. 
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5.1 Introduction 
The enormous amount of data generated from whole genome sequencing projects and the 
availability of comparative genomic tools for analysis of the generated data enable the 
characterisation of genetic differences in microorganisms. Biological properties such as 
gene function, virulence traits, immunity and evolution can be inferred from analysis of 
the full genome sequences (Clark, 1999; Brosch et al, 2001; Gordon et al, 2002; Behr, 
2008). In the context of pathogenic organisms, the results from such studies can help in 
developing new methods for diagnosis and identification of therapeutic targets (Fitzgerald 
and Musser, 2001; Randhawa and Bishai, 2002). However, whole genome sequencing of 
multiple bacterial strains or species is very cumbersome, expensive and, in most cases, 
impractical for most laboratories (Shanks et al, 2006a).  
 
During the past two decades, alternative genomic methods to whole genome sequencing 
methods have been developed to identify and isolate unique sequences present in one 
genome but absent in another. Most of these methods are based on subtractive 
hybridisation, in which target sequences in one population (tester) are enriched by 
hybridising with an excess amount in another population (driver), resulting in the removal 
of common sequences between the two populations (Wieland et al, 1990; Graham and 
Clark-Curtiss, 1999; Shanks et al, 2006a; Lamar and Palmer, 1984; Lisitsyn et al, 1993). 
The selected tester DNA molecules may be enriched by PCR amplification after each 
round of subtraction (Shanks et al, 2006a) or by consecutive subtraction with PCR 
amplification only applied after the final subtraction round (Yueqing et al, 2006). This 
approach has not only identified genetic differences among different strains or species but 
has also defined genes that are associated with virulence of an organism (Tinsely and 
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Nassif et al, 1996; Graham and Clark-Curtiss, 1999; Hou et al, 2002; Dwyer et al, 2004; 
Shanks et al, 2006a). 
 
Amongst the 7 subtypes of the  M. kansasii, subtype I is the most frequently isolated 
subtype from human infection, and is generally regarded as the most pathogenic of the 
subtypes (Santin et al, 2004; Zhang et al, 2004; Goy et al, 2007). However, nothing is 
known about the genetic basis for its virulence. A better understanding of the genetic 
variations amongst the M. kansasii strains is needed and will be important in studying the 
evolution and diversity of pathogenicity. In addition, this will allow the identification of 
markers for use in the development of accurate diagnostic tools and therapeutic targets. 

   
 5.2 Objective of the Study 
The objective of this study was to identify genetic differences between an M. kansasii 
subtype I clinical isolate and M. kansasii (subtypes II, IV and VI) environmental isolates.  
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5.3 Results 
5.3.1 Experimental Design 
HMDA was utilised to directly identify and clone genomic differences between M. 
kansasii subtype I (tester) and M. kansasii subtypes III, V and VI (drivers) with a view to 
identifying divergent DNA segments in subtype I. Experimental details for HMDA are 
described in Chapter 2 under Section 2.6. Multiple rounds of hybridisation were used to 
enrich M. kansasii subtype I-specific DNA fragments and the hybridisation monitoring 
process was performed by targeting the 16S rDNA, a gene that is highly conserved 
amongst bacterial species (Rogall et al, 1990; Harmsen et al, 2002). The identification of 
unique subtype I genome fractions in the enriched DNA was performed by dot blotting, 
DNA sequencing and analysed by the BLASTX programme at the National Center for 
Biotechnology Information (http://ncbi.mlm.nlm.gov/BLAST).  The DNA sequences were 
then organised into functional gene categories using the Protein Clusters Database 
(ProtClustDB) (http://www.ncbi.nlm.nih/gov/sites/entrez?db=proteinclusters). BLASTX 
sequence matches with E values of  ≤ 1 x 10-3 and sequence identities of  60% were 
regarded to be similar protein sequences (Pearl et al, 2000; Ribeiro-Guimaraes and 
Pessolani, 2007; Punta and Ofran, 2008). Figure 5.1 below illustrates the principle behind 
the HMDA approach used.  
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M. kansasii subtype I DNA (Tester)            M. kansasii subtype III, V or VI DNA (Driver) 

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                   
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  

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Figure 5.1: Schematic representation of the HMDA strategy used to identify M. kansasii subtype I-specific 
DNA sequences that are absent or divergent in M. kansasii subtypes III, V, VI (Adapted from Yueqing et al, 
2006). 
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5.3.2 Preparation of Tester and Driver DNA 
Tester and driver DNA were prepared by enzymatic digestion and heat fragmentation, 
respectively. Tester DNA, from an M. kansasii subtype I clinical isolate, was prepared by 
digestion with Tsp509I (New England BioLabs, Ipswich, MA) and ligation with a P1 
primer-specific PCR target adaptor molecule. Successful preparation of the Tester DNA 
was confirmed by the presence of PCR fragments ranging from 250 to 2000bp (Figure 
5.2). 
 
To prepare driver DNA, environmental M. kansasii subtypes III, V and VI were selected 
and fragmented at 95oC using a time series of 20 to 45min (Figure 5.3). Fragments from 
150 to 1000bp (from the 30min fragmented sample) were then selected and immobilized 
on 6mm diameter Hybond N+ Nylon membranes (Amersham Biosciences, 
Buckinghamshire, UK) for use in the hybridisation process. 
 
5.3.3 Monitoring of the Subtraction Process and Hybridisation 
To monitor the efficiency of the subtraction and hybridisation process, PCR analysis of the 
16S rDNA in the tester sample was performed. After the fifth round of hybridisation, no 
16S rDNA was detectable (Figure 5.4A). This suggested that most of the homologous 
sequences between the tester and driver DNA populations had been removed and that the 
remaining fragments were mainly unique to the tester sample. 
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M        1       2        3      4 


Figure 5.2: Verification for the presence of successful preparation of tester DNA. Lane M, 1 kb marker 
(Promega); Lane 1, Negative control (water); Lane 2, Negative control (adaptor molecule only); Lane 3, 
adaptor-tester DNA, Lane 4, Negative control (Tsp509I-digested Tester DNA) 
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Figure 5.3: Heat (95oC) fragmentation of Driver DNA. Lane M, 1kb DNA marker (Promega); Lane 1, 
unheated genomic driver DNA; Lane 2-6, heated genomic DNA samples: lane 2, 20min; lane 3, 25min; lane 
4, 30min; lane 5, 35min; lane 6, 40min. bp, base pair. 
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Figure 5.4:  Monitoring of the hybridisation process and isolation of M. kansasii subtype I-specific DNA 
fragments. Panel A: Monitoring of the hybridisation process using 16S rDNA. Lane M, 50bp DNA marker 
(Fermentas); lane 1 = no DNA control; lane 2, positive control (unsubtracted tester DNA), lanes 3 to 7, 
subtracted tester DNA after 4, 6, 8, 24 and 28 hrs of hybridisation, respectively. Panel B: Isolation of tester 
DNA not present in the Driver sample through subtractive hybridisation. Lane M, 1 kb DNA marker 
(Promega); lane 1, final Tester DNA PCR product; lane 2, unsubtracted Tester DNA for comparison. bp, 
base pair. 
 
 
Genomic subtraction resulted in the enrichment of M. kansasii-specific sequences (Figure 
5.4, panel B). Agarose gel electrophoresis of products in the final round of PCR 
amplification revealed fragments ranging from 300 to 2000bp in the subtracted DNA 
fractions. 
            
5.3.4 Screening of Cloned DNA Fragments 
PCR products from the final round of the hybridisation process were cloned and 135 
randomly selected clones were screened for the presence of tester DNA using PCR, 
restriction enzyme analysis and dot blotting.  
 
To detect the presence of the cloned tester fragments, PCR and enzymatic analysis were 
performed on DNA extracted from a number of selected clones using the P1 primer and 
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EcoRI enzyme, respectively. Both screening tests revealed the presence of the tester 
fragments, ranging from 500 to 1500bp, in the selected clones (Figures 5.5 and 5.6). 
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Figure 5.5: PCR-screening of a number of randomly selected clones using the P1 primer. Lane M, 50bp 
marker (Fermentas); Lane 1, no DNA control; lanes 2 to 20, amplification products of randomly-selected 
tester clones. bp, base pair. 
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Figure 5.6: Enzymatic screening of a number of randomly selected clones using EcoRI. Lane M, 1 kb marker 
(Promega); Lane 1, uncut pGEM T-Easy vector; lanes 2 to 10, restriction products of randomly-selected 
tester clones. bp, base pair. 
 
 
To determine the specificity of the isolated tester DNA fractions, dot blotting was used. 
Using a subtracted tester and a driver DNA probe, dot blotting confirmed that most of the 
M. kansasii subtype I-specific DNA fragments were unique to the subtype I (Figure 5.7).  
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Figure 5.7: Dot blot hybridisation analysis of M. kansasii-specific DNA fragments. Positive controls 
included driver (E1), subtracted and unsubtracted tester (E2 and E3, respectively) genomic DNA. Panels A 
and B show membranes containing subtracted M. kansasii subtype I genomic DNA probed with tester DIG 
probe and driver DIG probe, respectively. 
 
 
5.3.5 Analysis of DNA Sequences 
A total of 135 clones were analysed for divergent sequences in M. kansasii subtype I. 
Nineteen DNA sequences (14.1%) had no significant matches to the draft genome 
sequence of the M. kansasii ATCC 12478 (subtype I) reference strain by BLASTX 
analysis (Figure 5.8). The remaining 116 sequences had significant similarity to the 
sequences in the NR protein database, and a total of 45 open reading frames (ORFs) were 
detected. Forty-four (32.6%) of these ORFs were detected in M. kansasii ATCC 12478 
genome and one (0.7%) was detected in M. gilvum PYC-GCK genome. Most fragments 
frequently showed similarity to the same protein, suggesting that the same gene was 
represented several times within the HMDA library (Table 5.1). All the ORFs detected 
were assigned to one of the eighteen functional categories described in the Protein Clusters 
Database (ProtClustDB) (http://www.ncbi.nlm.nih.gov/sites/entrez?db=proteinclusters) 
(Figure 5.8). The category most frequently assigned was lipid metabolism (10.4%), 
followed by cell wall and membrane (8.1%), unknown function (7.4%), carbohydrate 
metabolism and transport (5.2%), secondary metabolism and transport (5.2%), energy 
metabolism (3.7%), cell secretion (2,2%), amino acid metabolism and transport (2.2%), 
coenzyme metabolism (1.5%), signal transduction mechanisms (1.5%), nucleotide 
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metabolism and transport (0.7%), inorganic ion transport (0.7%), molecular chaperones 
(0.7%), and DNA replication, recombination and repair (0.7%) (Figure 5.8). 
 
 
 
   
Figure 5.8: Functional group assignments of HMDA-enriched M. kansasii subtype I DNA sequences using 
the Cluster of Orthologous Groups of proteins (COG) classification based on the top BLASTX hits. 
Sequence matches with E-values of ≤10-3 and sequence identities of 60% were considered to be similar 
protein sequences. Functional groups are listed on the y-axis, while the percentage of the sequences for each 
group is shown on the x-axis (total number of sequences = 135).  
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Table 5.1: ORFs identified as being divergent in M. kansasii subtype I generated from DNA sequences obtained by HMDA 
 
Number of  Top BLASTX Match with   ORF   E-value  Proposed Functional Category 
Clones  M. kansasii ATCC 12478      
29  Conserved hypothetical protein  MkanA1_09104  8e-75  Putative lauroyl/myristoyl acyltransferase 
14  O-methyltransferase   MkanA1_02222  2e-21  Mycolic acid oxygenation; biosynthesis of proteins 
             interfering with DNA-binding antibiotics 
  1  FeS oxidoreductase    MkanA1_09109  2e-24  General catalytic function; arylsulphatase regulator 
  1  Ydjk     MkanA1_22260  5e-76  Permease: facilitates movement of substances across 
             cytoplasmic membrane 
  1  Endo-1,4-β-glucanase   MkanA1_19721  1e-109  Cellulose breakdown to glucose 
  1  Glycoside hydrolase family protein  MkanA1_07384  4e-57  Carbohydrate metabolism 
  1  Methylmalonyl-CoA mutase α subunit  MkanA1_19676  2e-74  Cabalamin-dependent enzyme – propionate acid formation 
  1  Isopentyl pyrophosphate isomerase  MkanA1_19761  4e-62  Catalysis of 3-isopentyl pyrophosphate to dimethylally 
             pyrophosphate (metabolism) 
  1  MCE family protein   MkanA1_27376  1e-96  Host cell invasion; virulence factor for mammalian cell 
             entry (mce) 
  1  Transmembrane transport protein, MmpL13_1 MkanA1_19751  3e-67  Predicted drug exporter of the RND family 
  3  Putative transmembrane ATP-binding protein MkanA1_02417  1e-16  ABC-type multi-drug transporter 
  1  TetR family transcription regulator  MkanA1_07199  1e-40  Transcription regulation; control of level of antibiotic & 
             detergents 
12  Predicted integral membrane protein  MkanA1_28696  1e-26  Unknown 
  8  Predicted integral membrane protein  MkanA1_05680  5e-73  Unknown 
  1  Hypothetical protein   MkanA1_23416  2e-15  Unknown 
  1  Hypothetical protein   MkanA1_24335  2e-15  Unknown 
  3  Hypothetical protein   MkanA1_12371  7e-16  Molecular chaperon 
  1  PE family protein, PE19_1   MkanA1_24070  6e-76  Pro-Glu-rich, uncertain function 
  3  PE-PGRS family protein, PE-PGRS  MkanA1_27316  1e-73  Glycine-rich, uncertain function 
  4  PE-PGRS family protein, PE-PGRS1  MkanA1_29646  3e-26  Glycine-rich, uncertain function 
  1  PE-PGRS family protein, PE-PGRS2  MkanA1_29416  5e-75  Glycine-rich, uncertain function 
  1  PPE family protein    MkanA1_24065  2e-108  Pro-Pro-Glu, uncertain function 
  1  Putative lipoprotein    MkanA1_27726  1e-48  Unknown 
  1  Polyketide synthase, pks8   MkanA1_12468  3e-106  Synthesis of mycocerosic acid (fatty acid); Secondary 
metabolite synthesis, transport & catabolism; virulence- 
associated 
  1  Polyketide synthase, pks12   MkanA1_14385  1e-53  Synthesis of mycocerosic acid (fatty acid); Secondary 
metabolite synthesis, transport & catabolism; virulence- 
associated 
     
continued on next page 
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Table 5.1: continued from previous page 
 
Number of Top BLASTX  Match with   ORF   E-value  Proposed Functional Category 
Clones  M. kansasii ATCC 12478 
  1  Acyltransferase, PaPA5   MkanA1_09847  4e-100  Biosynthesis & transport of phthiocerol dimycerosate 
             & phenolic glycolipids; virulence-associated 
  1  Enoyl-CoA-hydratase   MkanA1_03967  1e-93  Lipid transport & metabolism 
  3  Acetylglutamate kinase   MkanA1_27791  7e-26  Amino acid metabolism & transport 
  2  DNA gyrase subunit A   MkanA1_22465  2e-35  DNA replication, recombination and repair 
  1  Zinc-type alcohol dehydrogenase  MkanA1_02387  6e-26  NAD-dependent reversible oxidation of ethanol 
  1  Hypothetical transmembrane protein  MkanA1_04077  1e-31  Chloride channel protein, EriC 
  2  Short-chain dehydrogenase   MkanA1_21648  9e-99  Secondary metabolism: biosynthesis, transport & 
             catabolism 
  1  3-ketoacyl-(acyl-carrier protein) reductase (fabG) MkanA1_04087  4e-23  Essential for type II fatty acid metabolism 
  1  Glucosyl transferase   MkanA1_02302  1e-56  Carbohydrate metabolism 
  1  4’-phosphopantetheinyl transferase  MkanA1_00465  4e-41  Aspartate aminotransferase family  
  1  Putative transferase    MkanA1_28691  2e-16  Possible glucosyl transferase 
  1  ADP-ribosyltransferase   MkanA1_03662  2e-33  Synthesis of second messenger cyclic ADP ribose 
  1  Oxidoreductase, fadB5   MkanA1_24990  2e-22  Fatty acid degradation; energy production & conversion; 
             general function prediction 
  1  NADH dehydrogenase subunit G  MkanA1_10142  1e-21  NADH dehydrogenase/ubiquinone oxidoreductase 
  1  Para-aminobenzoate synthase component II MkanA1_22545  1e-26  Amino acid & folate metabolism 
  2  Glucose 1-phosphate cytidylyltransferase MkanA1_11550  6e-83  Nucleoside pyrophorylase, lipopolysaccharide biosynthesis 
             & degradation of surface polysaccharides 
  2  XRE family transcription regulator  Mflv_5549  1e-51  Xenobiotic response element family of transcription 
  (M. gilvum PYR-GCK)        regulators 
     
19  No significant hits          
 
These putative proteins were obtained from a total of 45 ORFs. RND, Resistance, Nodulation & Division protein; ABC, ATP-Binding Cassette; MCE, Mammalian Cell Entry 
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Table 5.2: Putative ORFs (virulence genes) identified in M. kansasii subtype I showing sequence identity to known protein sequences in some pathogenic mycobacteria 
 
ORF   Homologous Gene in other Pathogenic Mycobacteria Gene Product   E-value  Sequence similarity (%)   
 
MkanA1_02222  MUL_4809 (M. ulcerans Agy99)    O-methyltransferase   0.0   83   
   MMAR_0313 (M. marinum)        0.0   83   
   MAV_5200 (M. avium 104)        0.0   86 
   MAB_3463 (M. abscessus)        1e-44   70 
MkanA1_09847  Rv2939 (M. tuberculosis H37Rv)   Acyltransferase (PapA5)  0.0   91 
   Mb2964 (M. bovis AF2122/97)        0.0   91 
   ML2349 (M. leprae TN)        0.0   90 
   MMAR_1768 (M. marinum)        0.0   77 
MkanA1_12468  MMAR_2472 (M. marinum)    Polyketide synthase (pks8)  0.0   86 
   MAV_3108 (M. avium 104)        0.0   86 
   Rv1661 (M. tuberculosis H37Rv)       0.0   86 
   Mb1689 (M. bovis AF2122/97)        0.0   86 
MkanA1_14385  MMAR_3025 (M. marinum)    Polyketide synthase (pks12)  0.0   93 
   MUL_2266 (M. ulcerans Agy99)        0.0   93 
   Mb2074c (M. bovis AF2122/97)        0.0   93 
   MAV_2450 (M. avium 104)        0.0   91 
MkanA1_24065  MAV_3356 (M. avium 104)    PPE Family Protein   1e-30   79 
   MMAR_2669 (M. marinum)        7e-30   86 
   Rv1808 (M. tuberculosis H37Rv)       4e-29   89 
   Mb1837 (M. bovis AF2122/97)        4e-28   89 
MkanA1_24070  MUL_3088 (M. ulcerans Agy99)    PE19_1    6e-20   83 
   Rv1788 (M. tuberculosis H37Rv)       6e-20   84 
   MMAR_2670 (M. marinum)        6e-20   83 
   Mb1816c (M. bovis AF2122/97)        6e-20   83 
MkanA1_27316  MUL_3292 (M. ulcerans Agy99)    PE-PGRS Family Protein  5e-26   77 
   MT0855 (M. tuberculosis CDC1551)       8e-26   75 
   Mb0857c (M. bovis AF2122/97)        8e-26   75 
   MMAR_2053 (M. marinum)        1e-25   76 
MkanA1_27376  MMAR_4705 (M. marinum)    MCE Family Protein   0.0   89 
   MAP0765 (M. avium subsp. paratuberculosis K10)      0.0   87 
   MUL_3923 (M. ulcerans Agy99)        0.0   82 
   Rv1971 (M. tuberculosis H37Rv)       0.0   71 
MkanA1_29416  Rv3595c (M. tuberculosis H37Rv)   PE-PGRS2   6e-28   83   
   Mb0857c (M. bovis AF2122/97)        6e-28   83 
   MMAR_3728 (M. marinum)        2e-27   82 
   MUL_3671 (M. ulcerans Agy99)        3e-27   82 
MkanA1_29646  MMAR_0299 (M. marinum)    PE-PGRS1   2e-19   85 
   MUL_0572 (M. ulcerans Agy99)        2e-18   82 
   Rv0834c (M. tuberculosis H37Rv)       3e-18   80 
   Mb0857c (M. bovis AF2122/97)        3e-18   80 
  
 
Proposed functions of these putative proteins are given above in Table 5.1 .        
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Amongst the ORFs detected were potential virulence factors, which included an mce gene 
(MkanA1_27376), five PE, PE-PGRS and PPE family genes, one methyltransferase gene, 
two polyketide synthase genes (pks8 and pks12), an acyltransferase gene, papA5 (Tables 
5.1 and 5.2); three predicted drug exporters (MkanA1_19751 and MkanA1_02417); two 
transcription regulators involved in controlling levels of antibiotics (MkanA1_07199) and 
xenobiotics (Mflv_5549) in cells; putative glycosyltransferases and hydrolases involved in 
carbohydrate metabolism and transport (e.g, MkanA1_07384, MkanA1_02302, 
MkanA1_28691, MkanA1_11550); lipid metabolism and transport (e.g, MkaA1_09104, 
MkanA1_22222); and energy metabolism (e.g, MkanA1_24990) (Table 5.1). Other ORFs 
encoded oxidoreductases (MkanA1_24990, MkanA1_09190), dehydrogenases (e.g, 
MkanA1_21648, MkanA1_21648), isomerases (e.g, MkanA1_19761) and hydratases (e.g, 
MkanA1_03967) (Table 5.1).  
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5.4 Discussion 
The M. kansasii species currently comprises seven 7 genetically very similar subtypes. 
Subtype I is considered to be the most pathogenic and commonly isolated subtype from 
humans infections. The other subtypes are mostly isolated from the environment, and are 
generally regarded to be non-pathogenic (Santin et al, 2004; Alcaide et al, 1997; Picardeau 
et al, 1997; Taillard et al, 2003). Due to their close relatedness, it is difficult to distinguish 
pathogenic subtype I from the other non-pathogenic subtypes. To identify differences 
between subtype I and the other subtypes, HMDA was used, a well-suited and cost-
effective approach in such a case. The intent was not to exhaustively characterise all the 
genetic differences between the selected subtypes, but to determine if HMDA could isolate 
sequences divergent in subtype I.  
 
Forty-five M. kansasii subtype I ORFs encoding predicted membrane-associated and 
secreted proteins were identified. Some of the ORFs obtained were those associated with 
virulence in other pathogenic mycobacterial species such as M. marinum, M. ulcerans, M. 
tuberculosis and M. bovis. These included mce, PE, PE-PGRS and PPE family genes, O-
methyltransferase gene, an acyltransferase gene (papA5) and two polyketide synthase 
genes (pks8 and pks12). MCE (mammalian cell entry) proteins facilitate mycobacterial 
host cell invasion and intracellular cell survival (Arruda et al, 1993). Analysis of the draft 
genome sequence of M. kansasii ATCC 12478 (available on December 16, 2008 and last 
accessed on April 6, 2010) shows that it contains a number of putative mce genes. A 
recent study on actinomycetes has suggested that an increased number of mce operons 
may be associated with pathogenicity (Ishikawa et al, 2004). This may offer a significant 
advantage to pathogenic mycobacteria in their normal ecological niche (Romero and 
Palacios, 1997). The PE, PE-PGRS and PPE are gene families which possess 
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characteristic proline-glutamate (PE) or proline-proline-glutamate (PPE) residues at the N-
terminus of their gene products (Cole et al, 1998; Brennan et al, 2001; Mackenzie et al, 
2009). The other subgroup, PE-PGRS, contains multiple tandem repeats of glycine-
glycine-alanine or glycine-glycine-asparagine encoded by genes with polymorphic GC-
rich sequences (PGRS) motif (Poulet and Cole, 1995). These gene families are highly 
expanded in pathogenic members of mycobacteria but their functions are not clearly 
defined. They are often associated the ESX gene clusters, which encode ATP-dependent 
specific secretion systems (Cole et al, 1998; Gey van Pittius et al, 2006; Abdallah et al, 
2009). Some members of this family have been found to be expressed on the cell surface 
(Brennan et al, 2001; Delogu et al, 2004), and to modulate immune responses (Choudhary 
et al, 2003; Basu et al, 2007; Abdallah et al, 2008). Studies in M. marinum have also 
suggested that they have a role in mycobacterial virulence (Brennan et al, 2001; 
Ramakrishnan et al, 2000).  
 
O-methyltransferase and acyltransferase papA5 are part of the polyketide synthase 
biosynthetic pathway. O-methyltransferase is involved in the oxygenation of 
dimycocerosate (DIM) esters and phenolic glycolipids (PGL) (Onwueme et al, 2005a; 
Krzywinska et al, 2005; Ferreras et al, 2008; Huet et al, 2009), while acyltransferase 
papA5 is associated with the biosynthesis and transport of phthiocerol dimycocerosate 
(PDIM) and PGL (Buglino et al, 2004; Onwueme et al, 2004). The subtrates for these 
enzymes are major virulence factors of clinically relevant mycobacteria such as M. 
kansasii and M. tuberculosis (Onwueme et al, 2005b; Huet et al, 2009). The putative pks8 
and pks12 genes products are members of polyketide synthases, a group of structurally and 
functionally diverse proteins important in the biosynthesis of complex mycobacterial 
lipids. Gene products of pks8 and pks12 are important in the generation of PDIM (Azad et 
121 
 
al, 1996; Sirakova et al, 2003; Cheng et al, 2009; Chopra and Gokhale, 2009). M. kansasii 
virulence factors have not been extensively studied, although it is known that some of its 
cell lipids modulate immune responses (Guerardel et al, 2003; Vignal et al, 2003; Fujita et 
al, 2007). All the genes described above may be important virulence factors contributing 
to the pathogenicity of M. kansasii subtype I. Elucidation of the potential role for these 
putative genes in the virulence of M. kansasii should be explored. 
 
Bacteria generally respond to their changing environmental cues through their membrane 
proteins and DNA response elements. Identification of genes encoding transcription 
regulators and drug exporters from M. kansasii suggests that these systems may play a 
vital role in the environmental adaption of the bacterium to sites of infection in the host. 
TetR (name originally derived from Tetracycline Resistance) family proteins are 
repressors that control the level of susceptibility to hydrophobic antibiotics and detergents 
(Aramaki et al, 1993; Aramaki et al, 1995; Ramos et al, 2005), while the XRE (xenobiotic 
response element) family proteins are responsible for controlling the levels of xenobiotics 
in the cell (Tran et al, 2005). Two other genes encoding multidrug efflux systems, a 
transmembrane transport protein (MmpL13_1) and a putative transmembrane ATP-
binding protein (ABC-type transporter), were also detected. MmL13_1 (MmpL stands for 
Mycobacterial membrane protein Large) is member of the RND (Resistance, Nodulation 
and Cell Division) protein family associated with multidrug resistance pumps, and are 
responsible for mediating the secretion of a diversity of compounds, including drugs, 
detergents and fatty acids (Poelarends et al, 2000; Putman et al, 2000a; Putman et al, 
2000b). The role of MmL13_1 has not been confirmed, but some members of the RND 
family have been shown to be involved in the transport of PDIM (Cox et al, 1999; 
Camacho et al, 2001) and the synthesis of sulpholipid 1(Converse et al, 2003; Domenech 
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et al, 2005). Thus, this family of proteins may contribute to the virulence and drug 
resistance of mycobacteria (Domenech et al, 2005; Converse and Cox, 2005). 
 
It was interesting to find that HMDA was also able to detect the presence of the gyrA gene 
in M. kansasii subtype I, and this raised the question as to whether the other three subtypes 
tested did not possess it. This gene is an important house-keeping gene in bacteria that 
encodes the A subunit of DNA gyrase, GyrA. The gene product is responsible for 
mediating double-strand breakage and reunion of DNA (Perler et al, 1994, Nucleic Acid 
Res 22: 1125-1127). Analysis of the gyrA locus from different mycobacterial species 
revealed the presence of unusual coding sequences inserted in-frame with a protein-coding 
sequence (Perler et al, 1994). The protein products of these sequences are referred to as 
inteins and are putative homing endonucleases. However, in genetically heterogeneous 
species such as M. kansasii, the presence and absence of intein-coding sequences has been 
reported (Fsihi et al, 1996; Sander et al, 1998). Investigation of the presence of these 
coding sequences in gyrA revealed that inteins were invariable associated with M. kansasii 
subtype I and not with M. kansasii subtype II strains (Sander et al, 1998). It is feasible that 
the presence of an intein-coding sequence in the gyrA of M. kansasii subtype I and its 
absence in the gyrA sequences of M. kansasii subtypes III, V and VI, explains the 
observation made in this study. To confirm this observation, sequence analysis of gyrA 
PCR amplification data from the M. kansasii subtypes has to be performed.  
 
The identification of the large number of ORFs involved in lipid and carbohydrate 
metabolism and transport in this study suggests that most of these ORFs may participate in 
cell wall metabolism. This indicates that the major differences between subtype I and the 
other subtypes may lie in genes encoding cell wall components and some secreted 
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proteins. This difference might reflect that M. kansasii subtype I might have gained some 
additional genes during the course of its evolution (Koonin et al, 2001; Kinsella et al, 
2003; Krzywinska et al, 2004)   
 
5.5. Conclusion 
Using HMDA, 45 ORFs divergent in M. kansasii subtype I and encoding predicted 
membrane proteins and secreted proteins were identified. The majority of the ORFs were 
predominantly genes predicted to encode for membrane proteins. Particularly striking was 
the identification of six ORFs encoding virulence-associated proteins. These virulence 
genes were also found to have orthologs in genomes of other pathogenic mycobacteria 
such as M. tuberculosis, M. bovis, M. marinum and M. ulcerans. These findings may 
support the notion that genes associated with host specificity are often involved in 
interactions involving distinct host cells, in modifying bacterial cell surface and in 
acquiring necessary nutrients from highly defined external sources. In addition, the genetic 
differences identified between the subtypes studied may indicate a process of diversifying 
the selection pressure to avoid host immune responses (Maiden et al, 1997; Selander et al, 
1997; Tettellin et al, 2000).  
 
Other genes detected included those encoding proteins involved in lipid and carbohydrate 
metabolism and transport, protein metabolism and transport, transcription regulators, 
efflux membrane pumps and those with unknown function. The HMDA technique used in 
this study represents one of the first attempts at identifying genetic differences between 
subtypes of M. kansasii. 
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Functional analysis of genes, especially those encoding proteins for virulence factors, 
identified by HMDA is expected to provide further insights into important aspects of host-
pathogen interactions and pave a way for the development of diagnostic tests and 
therapeutic agents against M. kansasii disease. The functions of these genes can be 
investigated using a macrophage cell culture model and a murine infection model. First 
deletion mutants have to be created from M. kansasii subtype I, followed by the 
investigation of changes in phenotypes in a macrophage or mouse model (Pelicic et al, 
1997; Silver et al, 1998). 
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CHAPTER 6 
Modulatory Ability of M. kansasii on Human Lymphocyte Activity In Vitro 
 
 
6.0 Abstract 
 
M. kansasii has been identified as an important emerging opportunistic pathogen (Griffith, 
2002; Smith et al, 2003), but little is known about its actual pathogenesis. Recent data 
suggest that cell wall lipids of pathogenic mycobacteria modulate host immune responses 
(Jozefowski et al, 2008). The purpose of this study was to determine whether M. kansasii 
induces such immunomodulation on lymphocyte activity in vitro. T cell responses to cell 
wall lipids (Suppressor Cell-Activating Factor [SCAF]), generated by exposing monocytes 
to M. kansasii cell lysates, were assessed in a classical Lymphocyte Transformation (LT) 
assay and in a Cytometric Bead Array (CBA) assay. The LT assay showed marked 
suppression (p<0.0001) with all SCAFs from the six M. kansasii subtypes tested, which 
ranged from 37 to 51%. Subtype II showed the highest level of suppression, while subtype 
VI showed least suppression. In the CBA assay, of the Th2 cytokines, IL-4 was markedly 
increased, whilst the levels of IL-6 or IL-10 were not. The levels of two of the Th1 
cytokines tested, IFN-γ and TNF-α were significantly suppressed by the SCAFs from 
three subtypes (I, II and III) tested (p<0.0001). Il-17A expression by MN cells exposed to 
SCAF was also dramatically and significantly reduced. Paradoxically, the expression 
levels of IL-2 were elevated in all the test samples. These results suggest that SCAF from 
M. kansasii modulates immune responses through suppression of lymphocyte 
blastogenesis and by altering the expression of Th1/Th2/Th17 cytokines by human 
lymphocytes in vitro for its own survival. 
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6.1 Introduction 
 
The pathogenesis of M. kansasii is poorly understood, and unlike M. tuberculosis, very 
little information is available on the mechanisms of immune evasion and on what 
constitutes a protective immune response. In recent years there has been a lot of interest in 
understanding the role of cell wall lipids in mycobacterial disease. The mycobacterial cell 
wall is rich in lipids and polysaccharides (Lowary, 2001; Brennan, 2003), and some of 
these molecules are potent modulators of immunes response that arise from infection by 
these organisms (Briken et al, 2004; Karakousis et al, 2004; Manca et al, 2004). An 
important observation in patients with TB has been the in vitro dysfunction of circulating 
T cells. T cells from patients with active TB show altered proliferative responses when 
primed with M. tuberculosis antigens (Delgado et al, 2002; Chen et al, 2010). Other 
studies have also shown that activation and antigen presentation in M. tuberculosis-
infected macrophages are strongly inhibited (Noss et al, 2001; Gehring et al, 2004; Chang 
et al, 2005; Pecora et al, 2006).  
 
A number of mycobacterial lipids have been implicated in the modulation of CD4+ T cell 
function. These molecules include lipoarabinomannans (LAM) and their biosynthetic 
precursors, lipomannans (LM), trehalose 6,6’-dimycolate (TDM, the cord factor), 
lipoproteins, phosphatidylinositol mannosides (PIM), phthiocerol dimycocerosate and 
sulpholipids (Guerardel et al, 2003; Vignal et al, 2003; Briken et al, 2004; Karakousis et 
al, 2004; Fujita et al, 2007; Jozefowski et al, 2008; Mahon et al, 2009). Some of these 
lipid molecules have been shown to be secreted by macrophages and affect the functioning 
of other immune cells in a paracrine manner (Wadee et al, 1983; Beatty et al, 2000; Beatty 
et al, 2001).  
 
128 
 
This immunomodulatory phenomenon induced by pathogenic mycobacteria on the host is 
complex and not well understood. It involves multiple mechanisms, including regulatory T 
cells, immunosuppressive cytokines and T cell anergy after prolonged exposure to 
mycobacterial antigens (Briken et al, 2004; Mahon et al, 2009; Sinsimer et al, 2010). Most 
of these mechanisms have been studied in TB but very little is known about how they 
operate in M. kansasii disease. 
 
6.2 Objective of the Study 
The objective of this study was to determine whether M. kansasii has the ability to induce 
immunomodulation of human lymphocyte activity in vitro. Such data is vital for the 
provision of insights into the pathogenic mechanisms mediated by M. kansasii, and 
eventually for paving a way in the development of a vaccine for controlling disease caused 
by M. kansasii. 
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6.3 Results 
6.3.1 Experimental Design 
An in vitro model developed by Wadee and co-workers (1983) for M. tuberculosis was 
used to aid the design of this study (Figure 6.1). Suppressor Cell-Activating Factor 
(SCAF) was produced from U937 cells, a human monocytic cell line, after exposure to M. 
kansasii subtypes I to VI cell sonicates. Mononuclear (MN) cells obtained from healthy 
donors were exposed to SCAF or control supernatants and its effects on MN cells were 
assessed by the Lymphocyte Transformation assay and by the Cytometric Bead Array 
(CBA) Th1/Th2/Th17 Cytokine Kit assay (BD Bioscience, San Diego, CA, USA). For 
experimental details refer to Material and Methods Section 2.7 in Chapter 2. 
 
Figure 6.1: Experimental design. SCAF was produced by monocytes (U937 cells) in response to M. kansasii 
extracts (M. tuberculosis used as positive control). MN cells obtained from healthy donors were exposed to 
SCAF  in the presence of ConA or PHA and lymphocyte blastogenesis or cytokine expression were assessed, 
respectively. SCAF, Suppressor Cell Activating Factor; SC, Suppressor Carbohydrates; PI, 
Phosphatidylinositol; PE, Phosphatidylethanolamine. Adapted from Smit van Dixhoorrn et al, 2008. 
 
 
6.3.2 Effect of SCAF on Lymphocyte Blastogenesis 
Studies have shown that SCAF generated from M. tuberculosis inhibits lymphocyte 
blastogenesis (Wadee et al, 1983). To determine whether SCAF from M. kansasii could 
induce similar inhibitory effects on lymphocyte proliferation, MN cells were stimulated 
with concanavalin A (Con A) for 72hrs in the presence or absence of SCAF. As shown in 
CD8+ T cells 
M. kansasii or M. tuberculosis 
U937 cells 
PI+PE 
(SCAF) 
SC 
CD4+ T cells 
IL-4  
IFN-
TNF- 
IL-17A 
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Figure 6.2, SCAF from all six M. kansasii subtypes significantly (p<0.0001) inhibited the 
proliferation of lymphocytes. The levels of SCAF-mediated suppression ranged from 37 to 
51% of unstimulated control, with subtype II showing the most suppression and subtype 
VI showing the least suppression (Table 6.1). These data indicate that SCAF generated 
from M. kansasii suppresses lymphocyte blastogenesis. 
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Figure 6.2: Effect of SCAF from M. kansasii subtypes I-VI on lymphocyte blastogenesis after 72hrs. Data 
are medians ± SEM of five independent experiments. P values were calculated using the Kruskal-Wallis test. 
The level of significance between the negative control (Medium alone) and the test samples was set at p < 
0.05; cpm, counts per minute; Unstim, unstimulated; SCAF, Suppressor Cell Activating Factor; Mtb, 
Mycobacterium tuberculosis; MK, Mycobacterium kansasii 
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Table 6.1. Effect of SCAF from M. kansasii subtypes on the incorporation of tritiated thymidine in MN 
cells: suppression percentages 
 
 
MN cells pulsed with  Subtype  Average cpm  SD  Suppression (%) 
      (n=5) 
M. tuberculosis H37Rv    22410   1608  51.5 
M. kansasii   I  24840   980  46.3 
II  22840   2871  50.6 
III  28060   4369  39.3 
    IV  26930   4113  41.8 
    V  26370   2427  43.0 
    VI  28880   3098  37.0 
Medium alone + Con A    46270   4783 
Medium alone (unstimulated)   1873   1396 
 
The percentage of suppression for each condition was calculated as follows: ([MN cells treated with Medium 
alone] – [MN cells treated with SCAF]/[MN cells treated with Medium alone]) × 100%. Kruskal-Wallis test 
was performed to compare the SCAF-treated and Medium alone-treated samples. A significant (p<0.0001) 
level of SCAF-mediated suppression of lymphocyte blastogenesis was observed for all six M. kansasii 
subtypes tested. cpm, counts per minute; SCAF, Suppressor Cell Activating Factors; Con A, Concanavalin 
A.. 
  
 
6.3.3 Effect of SCAF on Cytokine Production 
To determine whether the inhibitory effect observed in the Lymphocyte Transformation 
assay above could have been due to the suppression of Th1 and Th17 or promotion of Th2 
T cell responses, levels of cytokines from these cells were measured in cell culture 
supernatants. Cytokine production by MN cells, obtained from seven healthy donors after 
exposure to SCAF generated from M. tuberculosis and M. kansasii subtypes I to III, was 
evaluated by the CBA Th1/Th2/Th17 Cytokine Kit assay that measures levels of IL-2, IL-
4, Il-6, IL-10, IL-17A, IFN-γ and TNF-α. M. tuberculosis was used as a positive control, 
whereas Medium alone (MN cells + PHA + untreated culture supernatant) was used as a 
negative control. All values were calculated with regard to the negative control in each 
assay. The Kruskal-Wallis test, followed by the Dunn’s multiple comparison adjustment 
test, was used for determining the statistical significance for the production of the 
cytokines. 
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The levels of IFN-γ, TNF-α and IL-17A were all observed to be significantly decreased 
for all the mycobacterial strains tested with regard to the negative control (all p<0.0001) 
(Figures 6.3A, B and G, respectively). The levels of suppression amongst the three M. 
kansasii subtypes were not significantly different from each other. The following were the 
medians for the three cytokines: IFN-γ (M. tuberculosis: 1879 pg/ml; M. kansasii subtype 
I-III: 2281, 2234 and 2356 pg/ml, respectively; negative control: 3925 pg/ml), TNF-α (M. 
tuberculosis: 273.9pg/ml; M. kansasii subtypes I-III: 305.2, 324.8 and 288.2pg/ml, 
respectively; negative control: 492.5pg/ml) and IL-17A (M. tuberculosis: 53.3pg/ml; M. 
kansasii subtypes I-III: 55.2, 59.3, and 60.9pg/ml, respectively; negative control: 
172.8pg/ml). These data clearly indicate that SCAF from both M. tuberculosis and M. 
kansasii inhibits the production of signature cytokines of Th1 and Th17 T cells. In contrast 
to the other two Th1 cytokines, the levels of IL-2 were increased after exposure to all the 
SCAFs (Figure 6.3C). 
 
SCAFs from all the four mycobacterial strains tested elicited significantly high levels of 
IL-4, which were more than double those of the negative control (p<0.0001) (Figure 6.3D) 
(M. tuberculosis median: 150.2 pg/ml; M. kansasii subtype I-III medians: 102.3, 88.8 and 
119 pg/ml, respectively; negative control median: 36.8 pg/ml). The highest levels were 
observed with M. tuberculosis (four-fold increase), followed by subtype III, I and II, 
which showed at least a two-fold increase as compared to the negative control. In contrast, 
the levels of expression for the other two Th2 cytokines, IL-6 and IL-10, showed no 
statistically significant differences compared to the negative control (p<0.9148 and 
p<0.9693, respectively) (Figures 6.3E and F). 
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Figure 6.3. Cytokine production by MN cells after exposure to SCAF (M. tuberculosis or M. kansasii). 
Cytokine production by MN cells was stimulated for 72hrs in the presence of PHA and measured using the 
CBA Human Th1/Th2/Th17 Kit Assay. P values were calculated using the Kruskal-Wallis test. The level of 
significance between the negative control (Medium alone) and the test samples was set at p < 0.05. Unstim, 
unstimulated; SCAF, Suppressor Cell Activating Factor; Mtb, Mycobacterium tuberculosis; MK, 
Mycobacterium kansasii. 
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6.4 Discussion 
One of the major thrusts in bacterial research is the understanding of the mechanisms 
responsible for pathogenesis. Lipids and glycolipids from pathogenic mycobacterial cell walls 
appear to be major molecules responsible for immune evasion (Guerardel et al, 2003; Vignal 
et al, 2003). Previous studies have demonstrated that human macrophages incubated with M. 
tuberculosis release mycobacterial lipids, termed SCAF, that are suppressive on CD4+ T cell 
activity (Wadee et al, 1983). Since M. kansasii is one of the most virulent respiratory 
pathogens, it was postulated that it may also be employing its cell wall lipids to evade 
immune recognition through suppression of immune cells. The aim of the present study was 
undertaken not to completely explore the mechanism involved in immune suppression, but to 
extend the observations previously made with M. tuberculosis by examining the effects of 
SCAF from M. kansasii on the activation of MN cells obtained from a group of healthy 
donors. Its purpose was not to exhaustively analyse all the cytokines induced by M. kansasii 
but simply to provide preliminary data on the potential of M. kansasii to modulate immune 
responses. In line with previous findings above, SCAF from M. kansasii inhibited lymphocyte 
blastogenesis dramatically and modulated cytokine production from helper T cells 
significantly. 
 
In the LT assay, inhibition of lymphocyte blastogenesis was observed with M. tuberculosis 
and all the M. kansasii subtypes tested (I-VI). This effect was also previously observed with 
M. tuberculosis, where the suppression was attributable to two lipid molecules, 
phosphatidylethanolamine (PE) and phosphatidylinositol (PI) (Wadee et al, 1983). Upon 
phagocytosis of mycobacteria, macrophages release PE and PI of bacterial origin into their 
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immediate surroundings, leading to the activation of CD8+ T cells, which in turn produce 
another factor, termed Suppressor Carbohydrate (SC) (Sussman and Wadee, 1991; Smit van 
Dixhoorn et al, 2008). SC was shown to have the ability to suppress CD4+ T cell activation as 
evidenced by the increased production of Th2 cytokines, and a drop in the expression levels 
of Th1 cytokines (Sussman and Wadee, 1991; Smit van Dixhoorn et al, 2008) (Figure 1). It is 
well-recognised that CD4+ T cells and Th1 cytokines are critical in cell-mediated immune 
responses against mycobacterial infection (Flynn, 2004). In Th1 responses macrophages are 
activated by IFN-, which causes increased expression of inducible nitric oxide synthase 
(iNOS), indoleamine 2,3-deoxygenase, TNF- and IL-6 (Voskuil et al, 2003; Pena et al, 
2008). This activation process leads to the elimination of intracellular pathogens (Flynn et al, 
1993; Szabo et al, 2003 Pena et al, 2008). Similarly, TNF- plays a role in immunity against 
TB by helping to recruit immune cells to the site of infection and by inducing macrophage 
activation. TNF- also enhances IFN--induced production of reactive nitrogen intermediates 
and may, therefore, contribute to the killing of mycobacteria (Flynn et al, 1995; Ordway et al, 
2004). We find that supernatants produced by U937 cells, pulsed with M. kansasii and M. 
tuberculosis, significantly abrogate the expression of IFN- and TNF- by MN cells. This 
suggests that M. kansasii exploits the early stages of infection to drive cytokine expression to 
its own advantage, namely into a Th2 rather than into a self-destructive Th1 direction.  
 
Data from other studies show that mycobacterial lipids suppress expression levels of IL-2 
(Shabaana et al, 2005; Mahon et al, 2009; Palma-Nicolas et al, 2010). Thus, it was surprising 
to find that significantly increased levels of IL-2 were observed in this study following 
exposure of MN cells to SCAF. IL-2 is a T cell growth factor produced by CD4+ effector T 
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cells to promote their proliferation and differentiation into antigen-specific T cells (Dooms et 
al, 2004). Recent evidence seems to suggest that distinct CD4+ T cell subpopulations 
producing IL-2 and IFN-γ exist based on their expression of phenotypic surface markers and 
their ability to produce cytokines (Ahmed and Gray, 1996), and this may probably explain the 
incongruence observed in this study. IL-2 is predominantly produced by the long-lived (days) 
central memory T cells (TCM), while IFN-γ is predominantly produced by the short-lived 
(hours) effector T cells (TEM) (Sallusto et al, 1999; Lanzavecchia and Sallusto, 2000). A 
recent study showed that individuals with latent TB had higher frequencies of TCM cells 
secreting IL-2 than those with active TB when exposed to purified peptide derivatives (PPD) 
or M. bovis BCG (Sargentini et al, 2009). This was attributed to an expanded population of 
IL-2-producing TCM cells compared to the number of IFN-γ-producing TEM cells which were 
reduced in these individuals, the absence of replicating M. tuberculosis and a small number of 
epitope-specific cells in the TCM population (Millington et al, 2007; Sargentini et al, 2009). 
The IL-2 produced this way may be used for maintaining Tregs or Th2 cell population. It is 
feasible that the above phenomenon, i.e., the outgrowth of TCM cells in our cultures and the 
autocrine production of Il-2 by effector CD4+ T cells in general, explains the overall 
increased expression in our study. 
 
Increased Th2 responses have been postulated to play a role in the susceptibility to TB 
because cytokines such as IL-4 can suppress Th1-mediated immunity and drive inappropriate 
alternative activation of macrophages (Sallusto et al, 1999; Lanzavecchia and Sallusto, 2000). 
When macrophages are exposed to high levels of IL-4, an increased expression of arginase 
occurs (which hydrolyses L-arginine to urea and ornithine, the latter being important in 
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fibrosis) rather than that of iNOS (Millington et al, 2007; Sargentini et al, 2009). The 
observation made in our study in which expression levels of IL-4 were high and those of IFN-
 and TNF- were low, match these observations. 
 
Induction of Th17 responses to SCAF-treated MN cells was also examined. IL-17A, a pro-
inflammatory cytokine produced by the recently described Th17 T cell subset (Harrington et 
al, 2006), was also suppressed by SCAF from all the mycobacterial strains tested. IL-17A is a 
potent inflammatory cytokine induced by M. tuberculosis (Khader and Cooper, 2008; 
Pasquinelli et al, 2009) and has been shown to up-regulate chemokines which led to increased 
recruitment of Th1 T cells (Khader et al, 2007) and facilitating granuloma formation 
(Umemura et al, 2007). Other data suggest that this suppression effect is mediated via RORγt, 
a Th17 cell differentiation transcription factor (Manel et al, 2008). Down-regulation of the IL-
6 receptor (IL-6R) expression on CD4+ T cells by M. tuberculosis may be a possible 
mechanism responsible for the observed suppression (Chen et al, 2010). Our experiment 
corroborates these findings, namely that M. kansasii significantly down-regulates IL-17A 
expression by MN cells, probably to escape a protective immune response. 
 
The expression levels of IL-6 and IL-10 in response to SCAF were found to be non-
specifically induced by PHA and not significantly different with regard to the negative control 
samples. IL-6 is a pro-inflammatory cytokine that is produced by a variety of cells such as T 
cells, macrophages, endothelial cells and fibroblasts. It plays a role in the initiation of T cell 
activation and has been shown to activate effector T cells to overcome immune suppression 
by CD4+CD25+ Tregs (Saunders and Cooper, 2000; Pasare and Medzhitov, 2003). IL-10 is 
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associated with reduced resistance and chronic progression of mycobacterial disease. It has 
multiple effects that interfere with functions of protective cells and cytokines, thereby 
promoting mycobacteria to survive inside cells despite abundant production of IFN-γ (Turner 
et al, 2002; De la Barrera et al, 2004; Rook, 2007). On the other hand, absence of IL-10 has 
been shown to accelerate mycobacterial clearance (van Crevel et al, 2002). Apparently, in our 
model M. kansasii and M. tuberculosis exert their immunomodulatory effects on cytokine 
expression through IL-4, IFN-, TNF-, and IL-17A, rather than through IL-6 and IL-10. 
 
A number of other lipids, including lipoarabimannan (LAM), from both M. kansasii 
(kanLAM, mannose-capped) and M. tuberculosis (ManLAM, mannose-capped) have also 
been implicated in immune cell modulation (Guerardel et al, 2003; Vignal et al, 2003; Briken 
et al, 2004). ManLAM has been shown to stimulate Antigen Presenting Cells (APC) through 
the mannose receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN), CD14, TLR-1 and TLR-2 in and on macrophages and dendritic cells to 
produce cytokines and chemokines that modulate the functioning of CD4+ T cells (Chatterjee 
et al, 1992; Briken et al, 2004; Elass et al, 2007; Garg et al, 2008). Macrophages activated by 
ManLAM produce IL-10 and transforming growth factor-β (TGF-β), two of the cytokines 
contributing to the inhibition of Th1 T cells through the activation of regulatory T cells 
(Tregs) (Garg et al, 2008). More recently phosphatidylinositol mannosides (PIM), AraLAM 
(non-mannose-capped) and ManLAM were shown to directly inhibit CD4+ T cell activation 
by interfering with the proximal T cell receptor (TCR) signalling and by abolishing IL-2 
production (Mahon et al, 2009). It is thought that ManLAM is able to interfere with proximal 
TCR signalling by binding through the glycosylphatidylinositol (GPI) anchor in the plasma 
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membrane or through the lipid rafts of the CD4+ T cells (Shabaana et al, 2005; Mahon et al, 
2009). This recapitulates findings of earlier studies that also showed that binding of ManLAM 
to the lipid rafts on these cells leads to a reduction in the production of Th1 cytokines, IL-2 
and IFN-γ and increased production of Th2 cytokines IL-4 and IL-5 (Shabaana et al, 2005).  
 
Another glycolipid molecule, 2,3-di-O-acyl-trehalose (DAT) has also been shown to suppress 
the production of Th1 cytokines (Saavedra et al, 2001; 2006; Palma-Nicolas et al, 2010) 
through the down-regulation of the di-acyl-glycerol-dependent activation of the MAPK-
ERK1/2 pathway (Palma-Nicolas et al, 2010). DAT is considered to be a mycobacterial 
virulence factor (Besra et al, 1992; Saavedra et al, 2006). Indeed these lipids are considered to 
be virulence factors, and we postulate that M. kansasii also mediates its exploitative effects on 
Th1/Th17 cytokine expression through these mechanisms. The consequence of this is a 
decline in protective immunity that results in the facilitation of the growth of the bacillus and 
disease progression. 
 
However, our study has its limitations in that humoral and other cell mechanisms (e.g. cell-
cell contact or secretion of other substances like perforin and granzymes) in addition to 
cytokine secretion or suppressor carbohydrates may also be involved in mechanisms of 
suppression but were not analysed. Recent insights into the possible mechanisms of 
immunosuppression suggest that galectins, a family of conserved glycan-binding proteins 
considered to play critical roles in the regulation of innate and adaptive immune responses 
(Barboni et al, 2005; Rabinovich et al, 2007; Yang et al, 2008; Lee et al, 2009), shift the 
balance from Th1 and Th17 towards a Th2-polarized immune response (Toscano et al, 2007; 
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Motran et al, 2008). In addition to the modulation of Th1 and 17 responses, galectins have 
been shown to favour the expansion of CD+CD25+ T regulatory cells (Toscano et al, 2006; 
Garin et al, 2007), arginase activity and prostaglandin E2 production, and the inhibition of 
inducible nitric oxide synthase activity (Rangel-Moreno et al, 2002; Correa et al, 2003; 
Rabinovich et al, 2007). How these endogenous lectins selectively amplify Th2 and T 
regulatory cells remains to be explored.  
 
6.5. Conclusion 
This study demonstrates that M. kansasii adversely affects host immune responses through 
suppression of lymphocyte blastogenesis and inhibition of Th1 and Th17 T cell responses. 
These suppression effects, as evidenced by elevated expression levels of IL-4, a Th2 cytokine, 
and suppression of expression levels of Th1 cytokines, IFN-γ and TNF-α, and that of Th17 
cytokine, IL-17A, are postulated to be mediated through cell wall lipids present in SCAF 
(Wadee et al, 1983). These effects may contribute to disease progression, especially in 
individuals whose immune responses are impaired such as those infected with HIV. 
Surprisingly, levels of IL-2, a Th1 cytokine, were elevated and this may suggest possible 
selection of TCM cells amongst the T cell effector cells for maintenance of Tregs and/or Th2 
cells.  
 
Further work is required to identify the major components of SCAF responsible for the 
observed suppression effects and to unravel the molecular mechanisms responsible for these 
effects. The examination of the role of galectins in mycobacterial immune escape mechanisms 
is also warranted. This is critical for the better understanding of the interaction between M. 
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kansasii and the human immune system to facilitate the development of a vaccine against M. 
kansasii or other mycobacterial disease. 
142 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
General Conclusions and Future Work 
 
 
 
143 
 
CHAPTER 7 
General Conclusions and Future Work 
 
7.1 General Conclusions 
M. kansasii has recently emerged as an important environmental opportunistic pathogen that 
causes both pulmonary and extrapulmonary disease in immunocompetent and 
immunosuppressed individuals (Campo and Campo, 1997; Taillard et al, 2003; Arend et al, 
2004; Marras et al, 2004). Clinical and radiological features of M. kansasii pulmonary disease 
resemble those of tuberculosis (Field and Cowie, 2006; Shitrit et al, 2006; Cattamanchi et al, 
2008). This may suggest that M. kansasii and M. tuberculosis share certain features such as 
virulence factors that are involved in their pathogenesis. While the sources of infection, 
genetic basis and pathogenic mechanisms have been widely studied in M. tuberculosis, little 
or nothing is known about them in M. kansasii. The work presented in this study makes some 
steps in contributing to the investigations of these problems. 
 
The source of M. kansasii infection is an enigma. Available data in literature seem to suggest 
that water distribution systems are the main sources of M. kansasii infection (Engel et al, 
1980; Kubin et al, 1980; Steadham, 1980; Chobot et al, 1997). Therefore, the need to confirm 
that water is the source of its infection is evident. The observation that M. kansasii is mainly 
isolated from water distribution systems necessitated the focus of the investigation of the 
source of infection in this study to be placed on water distribution systems in the two regions 
studied. Results presented in Chapter 3 clearly demonstrate that the water distribution systems 
in both the Vaal River gold-mining region and the Secunda coal-mining complex harbour a 
high NTM diversity that included both potentially pathogenic and non-pathogenic species. 
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Potentially pathogenic NTMs from the Vaal River gold-mining region included M. kansasii, 
M. avium, M. fortuitum, M. peregrinum, M. chelonae, M. abscessus, M. parascrofulaceum, M. 
montefiorense and the newly described species, M. setense, while the non-pathogenic species 
included M. gordonae and M. goodii. The predominant potentially pathogenic species from 
the Secunda coal-mining included M. avium, M. intracellulare, M. peregrinum and M. 
chelonae and M. tusciae, whilst the non-pathogenic ones included only M. gordonae. In 
agreement with other studies (Falkinham et al, 2001; Le Dantec et al, 2002; Falkinham et al, 
2008; Feazel et al, 2009), the majority of the NTMs were isolated from showerhead biofilms. 
This finding is a very important public health issue as it suggests that showerheads pose a 
health risk to a lot of people, particularly to individuals with impaired immune responses (Le 
Dantec et al, 2002; Torvinen et al, 2004; Falkinham et al, 2008; Feazel et al, 2009). 
 
There were five M. kansasii strains recovered from the Vaal River region, four of which were 
isolated from mine hostel showerheads and one from an underground pipe biofilm. They 
included subtypes I, IV and an isolate with a unique PRA pattern, probably representing a 
new subtype. No M. kansasii strain was isolated from the Secunda coal-mining complex. This 
contrasts some reports from Europe which have indicated that M. kansasii is prevalent in coal-
mining regions (Kubin et al, 1980; Chobot et al, 1997).  
 
Recent population genetics of M. kansasii have demonstrated that there is diversity amongst 
M. kansasii isolates recovered throughout the world and that subtype I is the predominant 
subtype recovered from clinical sources, while the other subtypes are generally isolated from 
the environment (Picardeau et al, 1997; Taillard et al, 2003; Zhang et al, 2004). No such 
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studies have been performed in South Africa despite the high incidence of M. kansasii disease 
reported from the gold mines. This warranted an investigation into the molecular 
epidemiology of the isolates from these mines. In line with other studies from other countries, 
this study showed that subtype I was also the predominant subtype amongst the clinical 
isolates (Chapter 4). Subtypes II and IV were also detected among the clinical isolates. One of 
the major findings was the detection of two sets of isolates with unique PRA patterns not 
previously reported, with one set giving a restriction pattern identical to that detected in an 
environmental isolate (Chapter 3). The detection of these two sets of unique isolates probably 
suggests the existence of new subtypes of M. kansasii in the Vaal River gold-mining region. 
Analysis of both clinical and environmental subtype I isolates generally showed that the 
isolates were genetically diverse in nature with clustering (Chapter 4). One of the three 
environmental subtype I isolates was found to be identical to a clinical isolate, suggesting that 
water distribution systems in the Vaal River gold-mining region are potential sources of M. 
kansasii infection for the gold-mining workforce (Chapters 3 and 4).  
 
The genetic diversity pattern of subtype I isolates observed in this study contrasts that 
observed in studies from Japan, Europe and the United States, in which a tight clonal structure 
was observed within individual geographical regions (Iinuma et al, 1997; Picardeau et al, 
1997; Zhang et al, 2004). This may be attributable to host risk factors such as HIV and 
silicosis that may influence the adaption of the strains in the susceptible miners or could be as 
a result of unique ecological factors in the South African gold-mining environment (Feil et al, 
2001; Feil and Spratt, 2001; Coenye and LiPuma, 2003). To our knowledge this is the first 
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report from South Africa to document the isolation of M. kansasii from the environment and 
to show a clonal relationship between an environmental and a clinical isolate of M. kansasii.  
 
However, this study had a number of limitations, including insufficient number of water 
samples and sites sampled, problems with fungal contamination of some cultures due to the 
lack of selective media and the slow growth of mycobacteria, and lack of patient data. 
 
Since M. kansasii subtype I is regarded to be the most pathogenic subtype amongst the known 
seven subtypes (Alcaide et al, 1997; Taillard et al, 2003; Goy et al, 2007), it was of interest to 
identify genetic differences between this subtype and the other environmental isolates. Using 
a comparative genomic approach, it was hoped that subtype I unique or divergent sequences 
important for understanding its physiology, virulence and evolution would be identified 
(Boucher et al, 2001; McLeod et al, 2004). An application of such an approach to closely 
related microorganisms has revealed the presence of unique genes, some of which encode 
virulence factors (Kucerova et al, 2010). The majority of the ORFs identified in this study 
were predicted to encode membrane-associated proteins (Chapter 5). A total of 45 ORFs 
encoding predicted membrane and secreted proteins were identified that included 6 sets of 
putative virulence factors (MCE, two polyketide synthases, five PE family proteins, an 
acyltransferase, and an O-methyltransferase), 2 members of the transcription regulators for 
drug and xenobiotic metabolic pathway, 3 members of the multidrug efflux systems, a number 
of proteins associated with lipid metabolism and transport, carbohydrate metabolism and 
transport, and those with undefined function. The predominance of proteins associated with 
the bacterial membrane suggests that one of the major differences between subtype I and the 
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other subtypes is in the cell membrane. These results support findings from other studies in 
which large sequence differences in genes associated with membrane proteins have been 
reported in closely related organisms (Selander et al, 1997; Tarr et al, 2000; Tettellin et al, 
2001; Shanks et al, 2006a). The observed genetic differences between closely related 
organisms may reflect a process of diversifying the selection pressure to avoid host immune 
responses, especially in pathogens (Maiden et al, 1997; Selander et al, 1997; Tettellin et al, 
2000). To our knowledge this first time that differences between a pathogenic and non-
pathogenic M. kansasii isolates have been shown at a genetic level.  
 
The pathogenesis of M. kansasii is poorly understood. Recent immunological studies have 
demonstrated that M. tuberculosis and other pathogenic mycobacteria modulate immune 
responses through their cell wall lipids (Wadee et al, 1983; Elass et al, 2007; Garg et al, 2008; 
Mahon et al, 2009). However, little is known about the role of these lipids in M. kansasii 
disease. Previous studies have shown that when lymphocytes are exposed to SCAF (culture 
supernatant containing cell wall lipids) generated with M. tuberculosis, their proliferation is 
suppressed (Wadee et al, 1983). In this study SCAFs from 6 M. kansasii subtypes were also 
tested on human lymphocytes to determine whether they would induce a similar effect as that 
observed with M. tuberculosis. The results obtained in Chapter 6 clearly indicate that SCAFs 
from all the M. kansasii subtypes tested markedly suppressed lymphocyte blastogenesis, 
supporting earlier findings observed with M. tuberculosis (Wadee et al, 1983).  
 
Further analysis of the SCAFs on CD4+ T cell activity showed that they all suppressed the 
expression of protective Th1 signature cytokines, IFN- and TNF-, and Th17 cytokine, IL-
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17A, and promoted the expression of ‘inappropriate’ Th2 responses, indicated by the 
increased levels of IL-4 (Chapter 6). This was in-keeping with observations made in other 
studies (Rook et al, 2004; Manel et al, 2008; Mahon et al, 2009; Pasquinelli et al, 2009). 
Taken together, these data show that SCAF from M. kansasii suppresses lymphocyte 
blastogenesis and modulates the expression of cytokines from CD4+ T cells in vitro. To the 
best of our knowledge, this is the first study to demonstrate that M. kansasii suppresses 
lymphocyte proliferation and modulates cytokine expression from CD4+ T cells through 
suppression of Th1 and Th17 cell responses, and promotion of “inappropriate” Th2 cell 
responses. 
 
This PhD study has demonstrated that water distribution systems are the potential sources of 
M. kansasii and other mycobacterial infections for the miners in the Vaal River gold-mining 
region and that subtype I is the predominant clinical isolate of M. kansasii subtype in this 
region. In contrast to the clonal population structure of subtype I isolates within individual 
geographical regions of other parts of the world, DNA fingerprinting of subtype I isolates in 
this region were found to be genetically diverse. It also showed that probably two other 
subtypes of M. kansasii not detected in other regions of the world are present in the South 
African environment and that the major differences between subtype I and the other subtypes 
lie in genes encoding cell membrane proteins, some of which are virulence factors. It goes on 
to demonstrate that one of the major pathogenic mechanisms for M. kansasii is through the 
suppression of human lymphocyte activity. To our knowledge this the first study to 
demonstrate that water distribution systems in South Africa are possible sources of M. 
kansasii infection and to employ molecular tools to identify different genotypes of this 
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pathogen, to identify unique or divergent genes in subtype I, and to demonstrate that 
immunosuppression is one of the pathogenic mechanisms employed by M. kansasii. 
 
7.2 Future Work 
Following the investigations described in this thesis, several lines of research should be 
pursued. With the potential for M. kansasii infections resulting from water distribution 
systems, it would be important to examine factors that influence the survival and growth of M. 
kansasii in these systems. This can be achieved by examining the role of factors such as 
nutrient levels, pipe materials and disinfection on the survival of M. kansasii in model 
drinking water distribution system biofilms. This would help in providing useful information 
on the survival of the organism and the basis for identifying means of control of infections.  
 
It would also be of interest to develop an infection model to demonstrate the transmission of 
M. kansasii from water to humans. Aerosolisation of water mycobacteria under conditions 
designed to mimic activities of a person taking a shower or swimming can be tested with the 
aid of a loaded six-stage Andersen Cascade Sampler (Andersen, 1958) and a suitable murine 
infection model. This would aid in establishing that water is a definitive source of M. kansasii 
infection in the Vaal River gold-mining region.  
 
Further studies on the distribution of M. kansasii strains from other parts of South Africa 
should be performed to give an accurate picture of the M. kansasii strains circulating in the 
country. This should include both environmental and clinical isolates of M. kansasii. 
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It would also be of interest to perform functional analysis on genes identified by HMDA, 
especially those predicted to encode virulence factors. This can be investigated by first 
deleting the genes identified, followed by assessing changes in the resulting mutant 
phenotypes in a macrophage or mouse model (Pelicic et al, 1997; Silver et al, 1998). This 
would provide insights into important aspects of host-pathogen interactions, and pave a way 
for the development of diagnostic tests and therapeutic against M. kansasii disease. 
 
The identification of major components of SCAF responsible for the observed suppressive 
and immunomodulative effects and the unravelling of the molecular mechanism for these 
effects would be of paramount importance. A good approach of achieving this would be to 
isolate and identify the lipids in SCAF using methods such as Gas Chromatography-Mass 
Spectroscopy (GC-MS) (Slayden and Barry, 2001). The effects of the isolated lipids can then 
be confirmed by testing in an LT assay, by cytokine analysis and by microarray analysis (Smit 
van Dixhoorn et al, 2008). This is vital in the facilitation of the development of a vaccine 
against M. kansasii or other NTM disease. 
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Appendix II: Identification of NTMs from water and biofilm samples obtained from the Vaal 
River gold-mining region and the Secunda coal-mining complex water distribution systems 
 
 
                               Analysis Results 
         
Region Sample ID Sample Site Description     Raw Sample Culture     Species 
         
          ZN   MK PCR  ZN MK PCR  Isolated 
VMR NCHSH  Biofilm Change house showerhead     -          -             +       +     M. kansasii 
 LRR  Biofilm Hostel showerhead      -          -             +       +       M. kansasii 
 LRRSH-1 Biofilm Hostel showerhead      -          -             +       +     M. kansasii 
WSQR  Biofilm Hostel showerhead      -          -             +       +     M. kansasii 
 KPUGW-I Biofilm Mine underground pipe     -          -             +       +       M. kansasii 
 NRR  Biofilm Hostel tap      -          -             +       -       M. avium 
WVHXD  Biofilm Hospital X-ray Dept tap     -          -             +       -       M. avium 
 LRK  Biofilm Hostel kitchen tap      -          -             +       -       M. avium 
 NRK  Biofilm Hostel kitchen tap      -          -             +       -     M. avium 
SMC BCHSH  Biofilm Change house showerhead     -          -             +       -     M. avium 
BCH  Biofilm Change house showerhead     -          -             +       -     M. avium 
MCHSH  Biofilm Change house showerhead     -          -             +       -     M. intracellulare 
VMR WVHDW Water Hospital ward tap      - -            +       -       M. fortuitum 
 KRKW  Water Hostel kitchen tap      - -            +       -            M. fortuitum 
 NRT14  Water Hostel tap      - -            +       -       M. fortuitum 
KTR  Biofilm Taxi rank public tap      - -            +       -       M. fortuitum 
 IRK  Biofilm Hostel kitchen tap      - -            +       -       M. fortuitum 
 NHT-1  Biofilm Hostel tap       - -            +       -       M. fortuitum 
 NFT22  Water Hostel tap      - -            +       -       M. fortuitum 
NKT  Water Hostel kitchen tap      - -            +       -      M. peregrinum 
KRK  Biofilm Hostel kitchen tap      - -            +       -       M. peregrinum 
SMC  BHBTW  Biofilm Hostel tap      - -            +       -       M. peregrinum 
MCH-2  Biofilm Change house showerhead     - -            +       -       M. peregrinum 
MCHTW-1 Biofilm Change house tap      - -            +       -       M. peregrinum 
BCHTW  Biofilm Hostel showerhead      - -            +       -       M. chelonae 
SSC  Biofilm Office kitchen tap      - -            +       -       M. chelonae 
MCH-1  Biofilm Change house showerhead     -           -            +       -     M. chelonae 
BHBSW  Biofilm Hostel showerhead      -           -            +       -     M. chelonae 
VMR MFW  Biofilm Hostel tap      - -            +       -       M. chelonae 
LCH  Biofilm Change house showerhead     - -            +       -       M. chelonae 
KFW  Biofilm Hostel tap      - -            +       -       M. chelonae 
KRWCH  Biofilm Hostel showerhead      - -            +       -     M. parascrofulaceum         
UMQ  Biofilm Hostel tap      - -            +       -       M. gordonae 
SWSH  Biofilm Hospital ward showerhead     - -            +       -       M. gordonae 
HKT  Biofilm Hostel kitchen tap      - -            +       -       M. gordonae 
ESQK  Water Hostel kitchen tap      - -            +       -       M. gordonae 
KRCP  Biofilm Hostel tap      - -            +       -       M. gordonae 
NCH-1  Water Change house showerhead     - -            +       -       M. gordonae 
KKT  Biofilm Hostel kitchen tap      - -            +       -       M. gordonae 
LRRT  Biofilm Hostel tap      - -            +       -       M. gordonae 
LRRSH-2 Biofilm Hostel showerhead      - -            +       -       M. gordonae 
NCH-2  Biofilm Change house tap      - -            +       -       M. gordonae 
NHT-1  Biofilm Hostel tap      - -            +       -       M. gordonae 
MQB7  Biofilm Hostel tap      - -            +       -       M. gordonae 
 
  
 Continued on next page 
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Appendix II continued from previous page 
 
 
SMC  BHBTS  Biofilm Hostel tap      - -            +       -       M. gordonae  
MCHTW-2 Water Change house tap      - -            +       -       M. gordonae  
BHB  Biofilm Hostel tap      - -            +       -       M. gordonae  
BHK  Biofilm Hostel tap      - -            +       -       M. gordonae  
BHKW  Biofilm Hostel kitchen tap      - -            +       -      M. gordonae 
 C5WTS  Biofilm Mine surface tap      - -            +       -       M. gordonae 
SP6PS  Biofilm Mine waste pipe      - -            +       -       M. tuscae 
VMR NHT-2  Biofilm Hostel tap      - -            +       -       M. goodii 
NDH  Water Dining hall tap      - -            +       -       M. montefiorense 
UTS  Biofilm Township public tap     - -            +       -       M. setense 
KRSH  Biofilm Hostel showerhead      - -            +       -     M. abscessus 
 
ZN, Ziehl-Neelsen; SMC, Secunda Coal-Mining Complex; VMR, Vaal River Gold Mining Region; MK PCR, M. kansasii-specific PCR
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Appendix III:  PRA patterns of representative clinical and environmental isolates of M. 
kansasii. 
 
 
 
                                          BstEII-digested                                    HaeIII-digested                             
  
                               M         1         2        3         4          5         6       M       1          2        3         4        5          6         M 
 
 
 
 
NB: Numbers above the lanes represent isolates and M denotes the molecular weight 
marker. Lane M, 50bp DNA marker (Fermentas Life Sciences, Glen Burnie, MD, USA); 
lane 1, subtype 1 (clinical isolate, MK087); lanes 2 and 3, unique isolate 2 (clinical 
isolates MK044 and MK136; not previously reported, probably new subtype); lane 4, 
subtype IV (environmental isolate LRR); lane 5 and 6, subtype I (environmental isolates 
KPUGW and WSQR). bp, base pair. 
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Appendix IV:  Identification by DNA sequencing of two representative M. kansasii 
clinical isolates not showing the typical M. kansasii PRA patterns (unique isolates 1 and 2, 
Chapter 4) 
 
Two genes, secA1 and gyrB, and the spacer sequence, 16S-23S rRNA ITS region, were 
targeted for DNA sequencing to confirm the identity of the clinical isolates with unique 
PRA patterns. Both isolates were confirmed to be M. kansasii as shown below. 
 
1. Unique Isolate 1 (MK057) 
a) secA1 gene sequencing  
 
gi|57340229|gb|AY724717.1|  Mycobacterium kansasii strain ATCC 12478 preprotein translocase  
SecA1 (secA1) gene, partial cds 
Length=700; Score = 1231 bits (640), Expect = 0.0; Identities = 640/640 (100%), Gaps = 
0/640 (0%); Strand=Plus/Plus 
 
Query  1    GGCCTACAACGCCGACATCACCTACGGCACCAACAACGAGTTCGGCTTCGACTACCTGCG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GGCCTACAACGCCGACATCACCTACGGCACCAACAACGAGTTCGGCTTCGACTACCTGCG  120 
 
Query  61   CGACAACATGGCGCACTCGCTCGACGACCTGGTGCAGCGCGGGCACGACTTCGCCATCGT  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  CGACAACATGGCGCACTCGCTCGACGACCTGGTGCAGCGCGGGCACGACTTCGCCATCGT  180 
 
Query  121  CGACGAGGTCGACTCCATCCTGATCGACGAGGCCCGCACCCCGCTGATCATCTCCGGCCC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGACGAGGTCGACTCCATCCTGATCGACGAGGCCCGCACCCCGCTGATCATCTCCGGCCC  240 
 
Query  181  CGCCGACGGCGCCTCCAACTGGTACGTCGAGTTCGCCCGGCTGGCGCCGCTGATGGAAAA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CGCCGACGGCGCCTCCAACTGGTACGTCGAGTTCGCCCGGCTGGCGCCGCTGATGGAAAA  300 
 
Query  241  GGACACCCACTACGAGGTAGACCTGCGTAAACGCACCGTCGGCGTGCACGAGAAGGGCGT  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GGACACCCACTACGAGGTAGACCTGCGTAAACGCACCGTCGGCGTGCACGAGAAGGGCGT  360 
 
Query  301  GGAGTTCGTCGAAGACCAGCTCGGTATCGACAACCTCTACGAGGCCGCCAACTCGCCGCT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  GGAGTTCGTCGAAGACCAGCTCGGTATCGACAACCTCTACGAGGCCGCCAACTCGCCGCT  420 
 
Query  361  GGTCAGCTACCTCAACAATGCGCTGAAGGCCAAGGAGCTGTTCAACCGCGACAAGGACTA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GGTCAGCTACCTCAACAATGCGCTGAAGGCCAAGGAGCTGTTCAACCGCGACAAGGACTA  480 
 
Query  421  CATCGTCCGCGACGGCGAGGTGCTCATCGTCGACGAGTTCACCGGTCGGGTGCTCTACGG  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  CATCGTCCGCGACGGCGAGGTGCTCATCGTCGACGAGTTCACCGGTCGGGTGCTCTACGG  540 
 
Query  481  GCGCCGCTACAACGAGGGCATGCACCAGGCCATCGAGGCCAAGGAGCACGTCGAGATCAA  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  GCGCCGCTACAACGAGGGCATGCACCAGGCCATCGAGGCCAAGGAGCACGTCGAGATCAA  600 
 
Query  541  GGCCGAGAACCAGACGCTGGCCACCATCACGCTGCAGAACTACTTCCGGCTCTACGACAA  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  GGCCGAGAACCAGACGCTGGCCACCATCACGCTGCAGAACTACTTCCGGCTCTACGACAA  660 
 
Query  601  GCTCGCCGGCATGACCGGCACCGCCCAGACCGAGGCGGCC  640 
            |||||||||||||||||||||||||||||||||||||||| 
Sbjct  661  GCTCGCCGGCATGACCGGCACCGCCCAGACCGAGGCGGCC  700 
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b) gyrB gene sequencing 
 
gi|6729314|dbj|AB014307.1|  Mycobacterium kansasii gyrB gene for DNA gyrase B subunit, partial cds, strain KPM 1988-1 
Length=1257; Score = 1297 bits (702), Expect = 0.0; Identities = 702/702 (100%), Gaps = 
0/702 (0%); Strand=Plus/Plus 
 
Query  2    TTACGAGAAATCCGAGCCGATGGGACTCAAGCAAGGCGCGCCGACTAAGAAGACCGGCAC  61 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  117  TTACGAGAAATCCGAGCCGATGGGACTCAAGCAAGGCGCGCCGACTAAGAAGACCGGCAC  176 
 
Query  62   GACGGTGCGGTTCTGGGCCGATCCCAATGTTTTTGAGACCACCGAGTACGACTTCGAAAC  121 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  177  GACGGTGCGGTTCTGGGCCGATCCCAATGTTTTTGAGACCACCGAGTACGACTTCGAAAC  236 
 
Query  122  CGTCGCACGACGGTTGCAGGAGATGGCGTTTCTCAACAAGGGGCTCACCATCAATCTGAC  181 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  237  CGTCGCACGACGGTTGCAGGAGATGGCGTTTCTCAACAAGGGGCTCACCATCAATCTGAC  296 
 
Query  182  CGATCAGCGGGTGACCCAGGACGAGGTCGTCGACGAGGTGGTCAGCGACGTCGCCGAGGC  241 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  297  CGATCAGCGGGTGACCCAGGACGAGGTCGTCGACGAGGTGGTCAGCGACGTCGCCGAGGC  356 
 
Query  242  CCCAAAGTCGGCCAGCGAGAAGGCGGCCGAATCCGCCGCCCCGCACAAGGTCAAGAAGCG  301 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  357  CCCAAAGTCGGCCAGCGAGAAGGCGGCCGAATCCGCCGCCCCGCACAAGGTCAAGAAGCG  416 
 
Query  302  TACCTTCCACTATCCCGGGGGTCTGGTTGACTTCGTCAAGCACATCAACCGGACCAAGAA  361 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  417  TACCTTCCACTATCCCGGGGGTCTGGTTGACTTCGTCAAGCACATCAACCGGACCAAGAA  476 
 
Query  362  CGCCATCCACAGCAGCATCGTCGACTTCTCCGGTAAGGGACCCGGCCACGAAGTGGAGAT  421 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  477  CGCCATCCACAGCAGCATCGTCGACTTCTCCGGTAAGGGACCCGGCCACGAAGTGGAGAT  536 
 
Query  422  CGCGATGCAGTGGAATGCCGGCTATTCGGAGTCGGTGCATACCTTCGCCAACACCATCAA  481 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  537  CGCGATGCAGTGGAATGCCGGCTATTCGGAGTCGGTGCATACCTTCGCCAACACCATCAA  596 
 
Query  482  CACCCACGAGGGTGGGACCCACGAAGAGGGGTTCCGCAGCGCGCTGACCTCGGTGGTGAA  541 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  597  CACCCACGAGGGTGGGACCCACGAAGAGGGGTTCCGCAGCGCGCTGACCTCGGTGGTGAA  656 
 
Query  542  CAAGTACGCCAAGGACCGCAAACTGCTCAAGGAAAAGGACCCCAACCTCACCGGCGACGA  601 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  657  CAAGTACGCCAAGGACCGCAAACTGCTCAAGGAAAAGGACCCCAACCTCACCGGCGACGA  716 
 
Query  602  CATCCGGGAAGGGTTGGCCGCGGTGATTTCGGTCAAGGTCAGCGAGCCGCAGTTCGAGGG  661 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  717  CATCCGGGAAGGGTTGGCCGCGGTGATTTCGGTCAAGGTCAGCGAGCCGCAGTTCGAGGG  776 
 
Query  662  CCAGACCAAGACGAAACTGGGCAACACCGAGGTGAAGTCGTT  703 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  777  CCAGACCAAGACGAAACTGGGCAACACCGAGGTGAAGTCGTT  818 
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c) 16S-23S rRNA ITS region sequencing 
 
gi|146218732|emb|AM709725.1|  Mycobacterium kansasii partial 16S rRNA gene, partial 23S 
rRNA gene and ITS1, isolate K7377-03 
Length=404; Score = 582 bits (315), Expect = 3e-163; Identities = 315/315 (100%), Gaps = 
0/315 (0%); Strand=Plus/Plus 
 
Query  1    GCATCCCAACAAGTGGGGTGCAAGCCGTGAGGGGTTCTCGTCTGTAGTGGACGAAAGCCG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  81   GCATCCCAACAAGTGGGGTGCAAGCCGTGAGGGGTTCTCGTCTGTAGTGGACGAAAGCCG  140 
 
Query  61   GGTGCACGACAACAAGCAAAGCCAGACACACTATTGGGTCCTGAGGCAACACTCGGGCTC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  141  GGTGCACGACAACAAGCAAAGCCAGACACACTATTGGGTCCTGAGGCAACACTCGGGCTC  200 
 
Query  121  TGTTCGAGAGTTGTCCCACCATCTTGGTGGTGGGGTGTGGTGTTTGAGAATTGGATAGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  201  TGTTCGAGAGTTGTCCCACCATCTTGGTGGTGGGGTGTGGTGTTTGAGAATTGGATAGTG  260 
 
Query  181  GTTGCGAGCATCAAATGGATGCGTTGCCCTACGGGTAGCGTGTTCTTTTGTGCAATTTTA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  261  GTTGCGAGCATCAAATGGATGCGTTGCCCTACGGGTAGCGTGTTCTTTTGTGCAATTTTA  320 
 
Query  241  TTCTTTGGTTTTTGTGTTTGTAAGTGTCTAAGGGCGCATGGTGGATGCCTTGGCATCGAG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321  TTCTTTGGTTTTTGTGTTTGTAAGTGTCTAAGGGCGCATGGTGGATGCCTTGGCATCGAG  380 
 
Query  301  AGCCGATGAAGGACG  315 
            ||||||||||||||| 
Sbjct  381  AGCCGATGAAGGACG  395 
 
 
 
2. Unique isolate 2 (MK136) 
a) secA1 gene sequencing 
 
gi|57340229|gb|AY724717.1|  Mycobacterium kansasii strain ATCC 12478 preprotein translocase  
SecA1 (secA1) gene, partial cds 
Length=700; Score =  599 bits (324),  Expect = 3e-168; Identities = 324/324 (100%), Gaps = 
0/324 (0%); Strand=Plus/Plus 
 
Query  1    CAGCGCCGGGTGGCCTACAACGCCGACATCACCTACGGCACCAACAACGAGTTCGGCTTC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  50   CAGCGCCGGGTGGCCTACAACGCCGACATCACCTACGGCACCAACAACGAGTTCGGCTTC  109 
 
Query  61   GACTACCTGCGCGACAACATGGCGCACTCGCTCGACGACCTGGTGCAGCGCGGGCACGAC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  110  GACTACCTGCGCGACAACATGGCGCACTCGCTCGACGACCTGGTGCAGCGCGGGCACGAC  169 
 
Query  121  TTCGCCATCGTCGACGAGGTCGACTCCATCCTGATCGACGAGGCCCGCACCCCGCTGATC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  170  TTCGCCATCGTCGACGAGGTCGACTCCATCCTGATCGACGAGGCCCGCACCCCGCTGATC  229 
 
Query  181  ATCTCCGGCCCCGCCGACGGCGCCTCCAACTGGTACGTCGAGTTCGCCCGGCTGGCGCCG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  230  ATCTCCGGCCCCGCCGACGGCGCCTCCAACTGGTACGTCGAGTTCGCCCGGCTGGCGCCG  289 
 
Query  241  CTGATGGAAAAGGACACCCACTACGAGGTAGACCTGCGTAAACGCACCGTCGGCGTGCAC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  290  CTGATGGAAAAGGACACCCACTACGAGGTAGACCTGCGTAAACGCACCGTCGGCGTGCAC  349 
 
Query  301  GAGAAGGGCGTGGAGTTCGTCGAA  324 
            |||||||||||||||||||||||| 
Sbjct  350  GAGAAGGGCGTGGAGTTCGTCGAA  373 
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b) gyrB gene sequencing 
 
gi|6729314|dbj|AB014307.1|  Mycobacterium kansasii gyrB gene for DNA gyrase B subunit, 
partial cds, strain KPM 1988-1 
Length=1257; Score = 1604 bits (868), Expect = 0.0; Identities = 870/871 (99%), Gaps = 
0/871 (0%); Strand=Plus/Plus 
 
Query  2    ACGCACTGTCCACCCGGCTGGAGGTGGAGATCAAGCGCGACGGCCATGAGTGGTCGCAGG  61 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  56   ACGCACTGTCCACCCGGCTGGAGGTGGAGATCAAGCGCGACGGCCATGAGTGGTCGCAGG  115 
 
Query  62   TTTACGAGAAATCCGAGCCGATGGGACTCAAGCAAGGCGCGCCGACTAAGAAGACCGGCA  121 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  116  TTTACGAGAAATCCGAGCCGATGGGACTCAAGCAAGGCGCGCCGACTAAGAAGACCGGCA  175 
 
Query  122  CGACGGTGCGGTTCTGGGCCGATCCCAATGTTTTTGAGACCACCGAGTACGACTTCGAAA  181 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  176  CGACGGTGCGGTTCTGGGCCGATCCCAATGTTTTTGAGACCACCGAGTACGACTTCGAAA  235 
 
Query  182  CCGTCGCACGACGGTTGCAGGAGATGGCGTTTCTCAACAAGGGGCTCACCATCAATCTGA  241 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  236  CCGTCGCACGACGGTTGCAGGAGATGGCGTTTCTCAACAAGGGGCTCACCATCAATCTGA  295 
 
Query  242  CCGATCAGCGGGTGACCCAGGACGAGGTCGTCGACGAGGTGGTCAGCGACGTCGCCGAGG  301 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  296  CCGATCAGCGGGTGACCCAGGACGAGGTCGTCGACGAGGTGGTCAGCGACGTCGCCGAGG  355 
 
Query  302  CCCCAAAGTCGGCCAGCGAGAAGGCGGCCGAATCCGCCGCCCCGCACAAGGTCAAGAAGC  361 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  356  CCCCAAAGTCGGCCAGCGAGAAGGCGGCCGAATCCGCCGCCCCGCACAAGGTCAAGAAGC  415 
 
Query  362  GTACCTTCCACTATCCCGGGGGTCTGGTTGACTTCGTCAAGCACATCAACCGGACCAAGA  421 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  416  GTACCTTCCACTATCCCGGGGGTCTGGTTGACTTCGTCAAGCACATCAACCGGACCAAGA  475 
 
Query  422  ACGCCATCCACAGCAGCATCGTCGACTTCTCCGGTAAGGGACCCGGCCACGAAGTGGAGA  481 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  476  ACGCCATCCACAGCAGCATCGTCGACTTCTCCGGTAAGGGACCCGGCCACGAAGTGGAGA  535 
 
Query  482  TCGCGATGCAGTGGAATGCCGGCTATTCGGAGTCGGTGCATACCTTCGCCAACACCATCA  541 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  536  TCGCGATGCAGTGGAATGCCGGCTATTCGGAGTCGGTGCATACCTTCGCCAACACCATCA  595 
 
Query  542  ACACCCACGAGGGTGGGACCCACGAAGAGGGGTTCCGCAGCGCGCTGACCTCGGTGGTGA  601 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  596  ACACCCACGAGGGTGGGACCCACGAAGAGGGGTTCCGCAGCGCGCTGACCTCGGTGGTGA  655 
 
Query  602  ACAAGTACGCCAAGGACCGCAAACTGGTCAAGGAAAAGGACCCCAACCTCACCGGCGACG  661 
            |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  656  ACAAGTACGCCAAGGACCGCAAACTGCTCAAGGAAAAGGACCCCAACCTCACCGGCGACG  715 
 
Query  662  ACATCCGGGAAGGGTTGGCCGCGGTGATTTCGGTCAAGGTCAGCGAGCCGCAGTTCGAGG  721 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  716  ACATCCGGGAAGGGTTGGCCGCGGTGATTTCGGTCAAGGTCAGCGAGCCGCAGTTCGAGG  775 
 
Query  722  GCCAGACCAAGACGAAACTGGGCAACACCGAGGTGAAGTCGTTCGTGCAGAAGGTGTGCA  781 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  776  GCCAGACCAAGACGAAACTGGGCAACACCGAGGTGAAGTCGTTCGTGCAGAAGGTGTGCA  835 
 
Query  782  ACGAACAGCTCACCCATTGGTTCGAGGCCAACCCCGCTGACGCTAAAACCGTTGTCAACA  841 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  836  ACGAACAGCTCACCCATTGGTTCGAGGCCAACCCCGCTGACGCTAAAACCGTTGTCAACA  895 
 
Query  842  AGGCGGTTTCATCGGCGCAAGCACGCATTGC  872 
            ||||||||||||||||||||||||||||||| 
Sbjct  896  AGGCGGTTTCATCGGCGCAAGCACGCATTGC  926 
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c) 16S-23S rRNA ITS region sequencing  
 
gi|146218732|emb|AM709725.1|  Mycobacterium kansasii partial 16S rRNA gene, partial 23S 
rRNA gene and ITS1, isolate K7377-03 
Length=404; Score = 628 bits (340), Expect = 4e-177; Identities = 340/340 (100%), Gaps = 
0/340 (0%); Strand=Plus/Plus 
 
Query  1    CTCCTTTCTAAGGAGCACCACGAAAAGCATCCCAACAAGTGGGGTGCAAGCCGTGAGGGG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  55   CTCCTTTCTAAGGAGCACCACGAAAAGCATCCCAACAAGTGGGGTGCAAGCCGTGAGGGG  114 
 
Query  61   TTCTCGTCTGTAGTGGACGAAAGCCGGGTGCACGACAACAAGCAAAGCCAGACACACTAT  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  115  TTCTCGTCTGTAGTGGACGAAAGCCGGGTGCACGACAACAAGCAAAGCCAGACACACTAT  174 
 
Query  121  TGGGTCCTGAGGCAACACTCGGGCTCTGTTCGAGAGTTGTCCCACCATCTTGGTGGTGGG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  175  TGGGTCCTGAGGCAACACTCGGGCTCTGTTCGAGAGTTGTCCCACCATCTTGGTGGTGGG  234 
 
Query  181  GTGTGGTGTTTGAGAATTGGATAGTGGTTGCGAGCATCAAATGGATGCGTTGCCCTACGG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  235  GTGTGGTGTTTGAGAATTGGATAGTGGTTGCGAGCATCAAATGGATGCGTTGCCCTACGG  294 
 
Query  241  GTAGCGTGTTCTTTTGTGCAATTTTATTCTTTGGTTTTTGTGTTTGTAAGTGTCTAAGGG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295  GTAGCGTGTTCTTTTGTGCAATTTTATTCTTTGGTTTTTGTGTTTGTAAGTGTCTAAGGG  354 
 
Query  301  CGCATGGTGGATGCCTTGGCATCGAGAGCCGATGAAGGAC  340 
            |||||||||||||||||||||||||||||||||||||||| 
Sbjct  355  CGCATGGTGGATGCCTTGGCATCGAGAGCCGATGAAGGAC  394 
161 
 
Appendix V: Macrorestriction analysis, using PFGE, of M. kansasii genomic DNA after 
XbaI digestion. 
 
 
 
 
 
 
 
 
 
NB: Numbers above the lanes represent isolates and M denotes the molecular weight 
marker, PFG MidRange II (NEB). bp, base pair 
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Appendix VI: Culture Media and Reagents 
 
A. Culture media 
 
Luria-Bertani (LB) broth 
10g tryptone powder 
5g yeast extract 
10g sodium chloride 
Up to 1000ml distilled water; autoclave 
 
Luria-Bertani (LB) agar 
10g tryptone powder 
5g yeast extract 
10g sodium chloride 
15g agar power 
Up to 1000ml with distilled water, autoclave 
 
SOC medium (100ml) 
2g Tryptone 
0.5g Yeast extract 
1ml 1M Sodium chloride 
0.25ml 1M Potassium chloride 
1ml 2M Magnesium chloride, filter sterilised 
1ml 2M Glucose, filter sterilised 
Add tryptone, yeast extract, sodium chloride and potassium chloride to 97ml distilled 
water. Stir to dissolve. Autoclave and cool to room temperature. Add 2M magnesium 
chloride and 2M glucose, each to a final concentration of 20mM. Bring to 100ml with 
sterile distilled water. The final pH should be 7.0. 
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Middlebrook 7H9 broth (BD-Difco Laboratories, Sparks, MD, USA) 
4.7g Middlebrook 7H9 broth base 
2ml glycerol 
0.05% Tween  
Up to 900ml distilled water  
100ml OADC supplement added after autoclaving 
 
Middlebrook 7H10 (BD-Difco Laboratories, Sparks, MD, USA) 
19g Middlebrook 7H10 agar powder 
2ml glycerol  
Up to 900ml distilled water  
100ml OADC supplement added after autoclaving 
 
Dubos medium (BD-Difco Laboratories, Sparks, MD, USA) 
1.3g Dubos broth base 
30ml glycerol 
70ml distilled water 
(For preparing freeze culture stock: equal volume of medium and culture) 
 
 
B. Reagents 
 
TE-Triton X-100 
100mM Tris, 1mM EDTA, pH 8.0 
1% Triton X-100 
 
ESP solution  
0.5M EDTA, pH 8.0 
1% Lauroyl sarcosine 
Autoclaved and stored at room temperature 
Proteinase K weighed and added at a concentration of 1-2mgml before use 
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TE buffer (pH 8.0) 
10mM Tris HCl, pH 8.0 
1mM EDTA 
TBE (x1) 
89 mM Tris 
89 mM Boric acid 
2mM EDTA 
 
Spheroplasting Buffer (plus Tween 80) – autoclaved 
20mM Citrate phosphate buffer (pH 5.6) 
50mM EDTA 
0.1% Tween 80 
(200mM citrate phosphate buffer stock made by mixing 42ml of citric acid [0.2M], 
followed by 58ml sodium hydrogen phosphate [0.5M]) 
 
Ethidium bromide solution 
10mg/ml in distilled water.  
Stored in a dark bottle at 4oC 
 
Lysis solution  
TE, pH 8.0 
Autoclaved and stored at room temperature 
Lysozyme weighed and added at concentrations of 1-2mg/ml before use 
 
Ringer’s solution 
8.6g sodium chloride 
0.3g potassium chloride 
0.33g calcium chloride 
Up to a 1000ml of distilled water. 
 
5M Sodium chloride 
29.2g Sodium chloride in 100ml distilled water 
Autoclave. 
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CTAB/Sodium chloride 
Dissolve 4.1g sodium chloride in 80ml distilled water. While stirring add 10g CTAB (N-
acetyl-N,N,N,-trimethylammonium bromide). If necessary, heat to 65oC. Adjust volume to 
100ml with distilled water and store at room temperature. 
 
0.5M EDTA 
186.12g EDTA 
Up to 1000 distilled water 
 
IPTG Stock Solution (0.1M) 
1.2g IPTG 
Add water to 50ml final volume. Filter sterilise and store at 4oC. 
 
X-Gal (2ml) 
100mg 5-bromo-4-chloro-3-indolyl--D-galactoside. 
Dissolve in 2ml N,N’-dimethylformamide. Cover with foil and store at -20oC. 
 
Maleic acid buffer (pH 7.5)  
0.1M Maleic acid 
0.15M Sodium chloride 
 
20X SSC Buffer 
3M Sodium chloride 
0.3M Sodium citrate 
 
Pre-hybridization Buffer 
5X SSC buffer 
0.1% N-lauroyl sarcosine 
1% Blocking reagent 
0.02% Sodium dodecyl sulphate 
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